<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Single‐dose intravenous ketorolac for acute postoperative pain in adults - McNicol, ED - 2021 | Cochrane Library</title> <meta content="Single‐dose intravenous ketorolac for acute postoperative pain in adults - McNicol, ED - 2021 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013263.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Single‐dose intravenous ketorolac for acute postoperative pain in adults - McNicol, ED - 2021 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013263.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD013263.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Single‐dose intravenous ketorolac for acute postoperative pain in adults" name="citation_title"/> <meta content="Ewan D McNicol" name="citation_author"/> <meta content="Tufts Medical Center" name="citation_author_institution"/> <meta content="ewan.mcnicol@mcphs.edu" name="citation_author_email"/> <meta content="McKenzie C Ferguson" name="citation_author"/> <meta content="Southern Illinois University Edwardsville" name="citation_author_institution"/> <meta content="Roman Schumann" name="citation_author"/> <meta content="VA Boston Healthcare System" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="5" name="citation_issue"/> <meta content="10.1002/14651858.CD013263.pub2" name="citation_doi"/> <meta content="2021" name="citation_date"/> <meta content="2021/05/17" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013263.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013263.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013263.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Acute Pain [*drug therapy]; Analgesics, Opioid [administration &amp; dosage, adverse effects]; Anti-Inflammatory Agents, Non-Steroidal [*administration &amp; dosage, adverse effects]; Bias; Diclofenac [administration &amp; dosage]; Injections, Intravenous; Isoxazoles [administration &amp; dosage]; Ketorolac [*administration &amp; dosage, adverse effects]; Numbers Needed To Treat; Pain, Postoperative [*drug therapy]; Placebos [therapeutic use]; Randomized Controlled Trials as Topic; Time Factors" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013263.pub2&amp;doi=10.1002/14651858.CD013263.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013263.pub2&amp;doi=10.1002/14651858.CD013263.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013263.pub2&amp;doi=10.1002/14651858.CD013263.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013263.pub2&amp;doi=10.1002/14651858.CD013263.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013263.pub2&amp;doi=10.1002/14651858.CD013263.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013263.pub2&amp;doi=10.1002/14651858.CD013263.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013263.pub2&amp;doi=10.1002/14651858.CD013263.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013263.pub2&amp;doi=10.1002/14651858.CD013263.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013263.pub2&amp;doi=10.1002/14651858.CD013263.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013263.pub2&amp;doi=10.1002/14651858.CD013263.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013263.pub2&amp;doi=10.1002/14651858.CD013263.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013263.pub2&amp;doi=10.1002/14651858.CD013263.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013263.pub2&amp;doi=10.1002/14651858.CD013263.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013263.pub2&amp;doi=10.1002/14651858.CD013263.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013263.pub2&amp;doi=10.1002/14651858.CD013263.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013263.pub2&amp;doi=10.1002/14651858.CD013263.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013263.pub2&amp;doi=10.1002/14651858.CD013263.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013263.pub2&amp;doi=10.1002/14651858.CD013263.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013263.pub2&amp;doi=10.1002/14651858.CD013263.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013263.pub2&amp;doi=10.1002/14651858.CD013263.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013263.pub2&amp;doi=10.1002/14651858.CD013263.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013263.pub2&amp;doi=10.1002/14651858.CD013263.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013263.pub2&amp;doi=10.1002/14651858.CD013263.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="8ranHhTh";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD013263\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD013263\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013263\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013263\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","ko","th","ms","hr","fa","fr"],languageCode:"en",accessStatus:"not-found",doi:"10.1002/14651858.CD013263.pub2",title:"Single\\u2010dose intravenous ketorolac for acute postoperative pain in adults",firstPublishedDate:"May 17, 2021 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Pain, Palliative and Supportive Care Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=8ranHhTh&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013263.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD013263.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD013263.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD013263.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013263.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD013263.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;초록&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;บทคัดย่อ&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;쉬운 말 요약&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;ข้้อสรุปภาษาธรรมดา&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD013263.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD013263.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD013263.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD013263.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>8096 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD013263.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013263.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013263.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013263.pub2/full#CD013263-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013263.pub2/full#CD013263-sec-0123"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013263.pub2/full#CD013263-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013263.pub2/full#CD013263-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013263.pub2/full#CD013263-sec-0017"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013263.pub2/full#CD013263-sec-0018"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013263.pub2/full#CD013263-sec-0043"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013263.pub2/full#CD013263-sec-0115"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013263.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013263.pub2/appendices#CD013263-sec-0135"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013263.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013263.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/table_n/CD013263StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/table_n/CD013263StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013263.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013263.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013263.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD013263.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD013263.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD013263.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2021 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Single‐dose intravenous ketorolac for acute postoperative pain in adults</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013263.pub2/information#CD013263-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Ewan D McNicol</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013263.pub2/information#CD013263-cr-0005">McKenzie C Ferguson</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013263.pub2/information#CD013263-cr-0006">Roman Schumann</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/information/en#CD013263-sec-0140">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 17 May 2021 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD013263.pub2">https://doi.org/10.1002/14651858.CD013263.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD013263-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD013263-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD013263-abs-0015">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD013263-abs-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD013263-abs-0013">Français</a> </li> <li class="section-language"> <a class="" href="full/ko#CD013263-abs-0005">한국어</a> </li> <li class="section-language"> <a class="" href="full/th#CD013263-abs-0007">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD013263-abs-0003">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD013263-abs-0001" lang="en"> <section id="CD013263-sec-0001"> <h3 class="title" id="CD013263-sec-0001">Background</h3> <p>Postoperative pain is common and may be severe. Postoperative administration of non‐steroidal anti‐inflammatory drugs (NSAIDs) reduces patient opioid requirements and, in turn, may reduce the incidence and severity of opioid‐induced adverse events (AEs). </p> </section> <section id="CD013263-sec-0002"> <h3 class="title" id="CD013263-sec-0002">Objectives</h3> <p>To assess the analgesic efficacy and adverse effects of single‐dose intravenous ketorolac, compared with placebo or an active comparator, for moderate to severe postoperative pain in adults. </p> </section> <section id="CD013263-sec-0003"> <h3 class="title" id="CD013263-sec-0003">Search methods</h3> <p>We searched the following databases without language restrictions: CENTRAL, MEDLINE, Embase and LILACS on 20 April 2020. We checked clinical trials registers and reference lists of retrieved articles for additional studies. </p> </section> <section id="CD013263-sec-0004"> <h3 class="title" id="CD013263-sec-0004">Selection criteria</h3> <p>Randomized double‐blind trials that compared a single postoperative dose of intravenous ketorolac with placebo or another active treatment, for treating acute postoperative pain in adults following any surgery. </p> </section> <section id="CD013263-sec-0005"> <h3 class="title" id="CD013263-sec-0005">Data collection and analysis</h3> <p>We used standard methodological procedures expected by Cochrane. <br/>Our primary outcome was the number of participants in each arm achieving at least 50% pain relief over a four‐ and six‐hour period.<br/>Our secondary outcomes were time to and number of participants using rescue medication; withdrawals due to lack of efficacy, adverse events (AEs), and for any other cause; and number of participants experiencing any AE, serious AEs (SAEs), and NSAID‐related or opioid‐related AEs.<br/>For subgroup analysis, we planned to analyze different doses of parenteral ketorolac separately and to analyze results based on the type of surgery performed.<br/>We assessed the certainty of evidence using GRADE. </p> </section> <section id="CD013263-sec-0006"> <h3 class="title" id="CD013263-sec-0006">Main results</h3> <p>We included 12 studies, involving 1905 participants undergoing various surgeries (pelvic/abdominal, dental, and orthopedic), with 17 to 83 participants receiving intravenous ketorolac in each study. Mean study population ages ranged from 22.5 years to 67.4 years. Most studies administered a dose of ketorolac of 30 mg; one study assessed 15 mg, and another administered 60 mg. </p> <p>Most studies had an unclear risk of bias for some domains, particularly allocation concealment and blinding, and a high risk of bias due to small sample size. The overall certainty of evidence for each outcome ranged from very low to moderate. Reasons for downgrading certainty included serious study limitations, inconsistency and imprecision. </p> <p><b>Ketorolac versus placebo</b> </p> <p>Very low‐certainty evidence from eight studies (658 participants) suggests that ketorolac results in a large increase in the number of participants achieving at least 50% pain relief over four hours compared to placebo, but the evidence is very uncertain (risk ratio (RR) 2.81, 95% confidence interval (CI) 1.80 to 4.37). The number needed to treat for one additional participant to benefit (NNTB) was 2.4 (95% CI 1.8 to 3.7). Low‐certainty evidence from 10 studies (914 participants) demonstrates that ketorolac may result in a large increase in the number of participants achieving at least 50% pain relief over six hours compared to placebo (RR 3.26, 95% CI 1.93 to 5.51). The NNTB was 2.5 (95% CI 1.9 to 3.7). </p> <p>Among secondary outcomes, for time to rescue medication, moderate‐certainty evidence comparing intravenous ketorolac versus placebo demonstrated a mean median of 271 minutes for ketorolac versus 104 minutes for placebo (6 studies, 633 participants). For the number of participants using rescue medication, very low‐certainty evidence from five studies (417 participants) compared ketorolac with placebo. The RR was 0.60 (95% CI 0.36 to 1.00), that is, it did not demonstrate a difference between groups. </p> <p>Ketorolac probably results in a slight increase in total adverse event rates compared with placebo (74% versus 65%; 8 studies, 810 participants; RR 1.09, 95% CI 1.00 to 1.19; number needed to treat for an additional harmful event (NNTH) 16.7, 95% CI 8.3 to infinite, moderate‐certainty evidence). Serious AEs were rare. Low‐certainty evidence from eight studies (703 participants) did not demonstrate a difference in rates between ketorolac and placebo (RR 0.62, 95% CI 0.13 to 3.03). </p> <p><b>Ketorolac versus NSAIDs </b><br/>Ketorolac was compared to parecoxib in four studies and diclofenac in two studies. For our primary outcome, over both four and six hours there was no evidence of a difference between intravenous ketorolac and another NSAID (low‐certainty and moderate‐certainty evidence, respectively). Over four hours, four studies (337 participants) produced an RR of 1.04 (95% CI 0.89 to 1.21) and over six hours, six studies (603 participants) produced an RR of 1.06 (95% CI 0.95 to 1.19). </p> <p>For time to rescue medication, low‐certainty evidence from four studies (427 participants) suggested that participants receiving ketorolac waited an extra 35 minutes (mean median 331 minutes versus 296 minutes). For the number of participants using rescue medication, very low‐certainty evidence from three studies (260 participants) compared ketorolac with another NSAID. The RR was 0.90 (95% CI 0.58 to 1.40), that is, there may be little or no difference between groups.   </p> <p>Ketorolac probably results in a slight increase in total adverse event rates compared with another NSAID (76% versus 68%, 5 studies, 516 participants; RR 1.11, 95% CI 1.00 to 1.23; NNTH 12.5, 95% CI 6.7 to infinite, moderate‐certainty evidence). Serious AEs were rare. Low‐certainty evidence from five studies (530 participants) did not demonstrate a difference in rates between ketorolac and another NSAID (RR 3.18, 95% CI 0.13 to 76.99). Only one of the five studies reported a single serious AE. </p> </section> <section id="CD013263-sec-0007"> <h3 class="title" id="CD013263-sec-0007">Authors' conclusions</h3> <p>The amount and certainty of evidence for the use of intravenous ketorolac as a treatment for postoperative pain varies across efficacy and safety outcomes and amongst comparators, from very low to moderate. The available evidence indicates that postoperative intravenous ketorolac administration may offer substantial pain relief for most patients, but further research may impact this estimate. Adverse events appear to occur at a slightly higher rate in comparison to placebo and to other NSAIDs. Insufficient information is available to assess whether intravenous ketorolac has a different rate of gastrointestinal or surgical‐site bleeding, renal dysfunction, or cardiovascular events versus other NSAIDs. There was a lack of studies in cardiovascular surgeries and in elderly populations who may be at increased risk for adverse events. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD013263-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD013263-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD013263-abs-0016">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD013263-abs-0012">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD013263-abs-0014">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD013263-abs-0010">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ko#CD013263-abs-0006">한국어</a> </li> <li class="section-language"> <a class="" href="full/ms#CD013263-abs-0009">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/th#CD013263-abs-0008">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD013263-abs-0004">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD013263-abs-0002" lang="en"> <h3>What are the benefits and risks of a single injection of ketorolac (an anti‐inflammation medicine) for relieving short‐term pain after surgery in adults? </h3> <p><b>Key messages</b> </p> <p>· Ketorolac may reduce short‐term pain after surgery by 50% (half) or more in more people than a placebo (dummy treatment).<br/>· There may be little to no difference between ketorolac and other anti‐inflammation medicines in the number of people whose pain is reduced by half or more.<br/>· Ketorolac probably causes slightly more unwanted effects than placebo and other anti‐inflammation medicines; more evidence is required to establish if it causes serious unwanted effects. </p> <p><b>Treating short‐term pain after surgery</b> </p> <p>It is common for people to feel pain in the short term (within six hours) after surgery. Often, medicines called non‐steroidal anti‐inflammatory drugs (NSAIDs) are given to relieve this pain. </p> <p>NSAIDS work by stopping the body’s production of chemicals that cause inflammation and pain. A potential advantage of using NSAIDs is that they may limit the need for stronger pain‐relief medicine such as opioids. Opioids can cause unwanted (adverse) events such as nausea and vomiting, constipation, breathing problems and allergic reactions. People may become addicted to opioids if they take a lot of them. </p> <p>NSAIDs can also cause unwanted effects. These include bleeding at the site of the surgical wound, and potential injury to the kidneys and gut. It is therefore important to weigh the benefits and risks of NSAIDs when considering using them to reduce pain shortly after surgery. </p> <p><b>What did we want to find out?</b> </p> <p>We wanted to find out about the benefits and risks of using a specific NSAID, ketorolac, for relief of short‐term pain after surgery. Ketorolac can be given as an injection, which may be useful when patients cannot take medicines by mouth. </p> <p><b>What did we do?</b> </p> <p>We searched for studies that involved adults (aged over 18) and compared a single injection of ketorolac against: </p> <p>· a placebo (dummy treatment); or<br/>· another treatment. </p> <p>We compared and summarized the results of the studies and rated our confidence in the evidence, based on factors such as study methods and sizes. </p> <p><b>What did we find?</b> </p> <p>We found 12 studies that involved 1905 people in total. The studies investigated the treatment of pain after surgery on the abdomen, pelvis, teeth, bones, joints and muscles. Most studies (10) treated people with a dose of 30 milligrams of ketorolac. They compared ketorolac against: </p> <p>· a placebo;<br/>· another NSAID; or<br/>· an opioid. </p> <p>Here we present the findings from comparisons between ketorolac and placebo or other NSAIDs. </p> <p><i>Pain reduction</i> </p> <p>The evidence suggests that:</p> <p>· around three times more people may have their pain reduced by 50% (half) or more within six hours of surgery when treated with ketorolac rather than placebo; and<br/>· there could be little to no difference between ketorolac and other NSAIDS in the number of people with pain reduced by 50% or more within four or six hours of surgery. </p> <p><i>Need for extra pain medicines (rescue medication)</i> </p> <p>Ketorolac could delay the need for rescue medication compared to placebo or other NSAIDs. The evidence is not robust enough to show if fewer people need rescue medicine when treated with ketorolac. </p> <p><i>Adverse effects</i> </p> <p>Ketorolac probably causes slightly more adverse effects than placebo and other NSAIDS. Serious adverse effects (such as blood collecting in the muscles around the abdomen, causing severe pain) were rare in the studies we found; the evidence suggested there may be little to no difference in the number of serious adverse events between ketorolac and placebo or other NSAIDS. </p> <p><b>What are the limitations of the evidence?</b> </p> <p>Studies were small, and most may have been conducted in ways that could introduce errors into their results. This limited our confidence in the evidence. </p> <p><b>How up to date is this evidence?</b> </p> <p>The evidence is up to date to April 2020.</p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD013263-sec-0123" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD013263-sec-0123"></div> <h3 class="title" id="CD013263-sec-0124">Implications for practice</h3> <section id="CD013263-sec-0124"> <section id="CD013263-sec-0125"> <h5 class="title">For adults with moderate‐to‐severe postoperative pain</h5> <p>The amount and quality of evidence for the use of IV ketorolac for treating postoperative pain varies from very low to moderate for efficacy outcomes and is generally low for safety outcomes. The evidence we have indicates that postoperative administration of IV ketorolac may offer good pain relief for most patients, but further research may impact this estimate. Adverse events appear to occur at a slightly higher rate versus placebo and other non‐steroidal anti‐inflammatory drugs (NSAIDs), but at a similar rate to opioids, but information from randomized trials is insufficient to assess whether ketorolac has a different rate of gastrointestinal or operative‐site bleeding, renal dysfunction, or cardiovascular events when compared with other NSAIDs, or if it reduces opioid‐related adverse events. </p> </section> <section id="CD013263-sec-0126"> <h5 class="title">For clinicians</h5> <p>The amount and quality of evidence for the use of IV ketorolac for treating postoperative pain varies from very low to moderate for efficacy outcomes and is generally low for safety outcomes. The evidence we have indicates that postoperative administration of IV ketorolac offers good pain relief for most patients, but further research may impact this estimate. Adverse events appear to occur at a slightly higher rate versus placebo and other NSAIDs, but at a similar rate to opioids, but information from randomized trials is insufficient to assess whether ketorolac has a different rate of gastrointestinal or operative‐site bleeding, renal dysfunction, or cardiovascular events when compared with other NSAIDs, or if it reduces opioid‐related adverse events. </p> </section> <section id="CD013263-sec-0127"> <h5 class="title">For policymakers</h5> <p>The amount and quality of evidence for the use of IV ketorolac for treating postoperative pain varies from very low to moderate for efficacy outcomes, and policymakers should exercise caution when recommending its use in postoperative guidelines. The evidence we have indicates that postoperative administration of IV ketorolac offers good pain relief for most patients, but further research may impact this estimate. Adverse events appear to occur at a slightly higher rate versus placebo and other NSAIDs, but at a similar rate to opioids, but information from randomized trials is insufficient to assess whether ketorolac has a different rate of gastrointestinal or operative‐site bleeding, renal dysfunction, or cardiovascular events when compared with other NSAIDs, or if it reduces opioid‐related adverse events. </p> </section> <section id="CD013263-sec-0128"> <h5 class="title">For funders of the intervention</h5> <p>The amount and quality of evidence for the use of IV ketorolac for treating postoperative pain varies from very low to moderate for efficacy outcomes and is generally low for safety outcomes. The evidence we have indicates that postoperative administration of IV ketorolac offers good pain relief for most patients, but further research may impact this estimate. Adverse events appear to occur at a slightly higher rate versus placebo and other NSAIDs, but at a similar rate to opioids, but information from randomized trials is insufficient to assess whether ketorolac has a different rate of gastrointestinal or operative‐site bleeding, renal dysfunction, or cardiovascular events when compared with other NSAIDs, or if it reduces opioid‐related adverse events. At this time, parenteral ketorolac is available as a generic product, whereas the other widely‐available parenteral NSAIDs, ibuprofen and diclofenac, are generally only available as brand‐name products. We did not aim to determine whether potential cost savings of generic ketorolac are offset by possible differences in safety or efficacy when parenteral ibuprofen or diclofenac are used instead. </p> </section> </section> <h3 class="title" id="CD013263-sec-0129">Implications for research</h3> <section id="CD013263-sec-0129"> <section id="CD013263-sec-0130"> <h5 class="title">General</h5> <p>While more studies are required to be able to more accurately estimate the efficacy and safety of parenteral ketorolac, there is a lack of studies specifically in cardiovascular surgeries and in elderly populations. </p> </section> <section id="CD013263-sec-0131"> <h5 class="title">Design</h5> <p>The studies included in our review were designed to detect differences in efficacy between interventions. However, further studies that compare different doses of ketorolac may establish whether doses lower than those currently used are equally effective, particularly in elderly patients, where data from non‐randomized studies demonstrate higher adverse event rates. Studies should be large enough to produce precise estimates of effect in order to meaningfully reduce uncertainty. Serious adverse events and adverse events associated with NSAIDs were rare or very rare. There are several epidemiological studies that may more accurately determine the adverse profile of ketorolac, particularly for renal dysfunction, bleeding, cardiovascular events and delay of bone‐healing postoperatively. </p> </section> <section id="CD013263-sec-0132"> <h5 class="title">Outcomes</h5> <p>Endpoints and the pain scoring scales used to assess them in these studies have been extensively validated. Most studies assessed pain relief after administration of each intervention, an outcome shown to be clinically important to patients. Studies conducting cost‐benefit analyses may determine whether the reduced cost of parenteral ketorolac versus brand‐name parenteral diclofenac and ibuprofen is offset by increased adverse event rates and subsequently increased overall costs of care. </p> </section> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD013263-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD013263-sec-0008"></div> <div class="table" id="CD013263-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Intravenous ketorolac compared to placebo for adults with acute postoperative pain</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Intravenous ketorolac compared to placebo for adults with acute postoperative pain</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> adults (mean study ages 23 to 67 years) with acute postoperative pain after abdominal/pelvic, dental or orthopedic surgeries<br/><b>Settings:</b> hospital or community<br/><b>Intervention:</b> intravenous ketorolac (30 mg or 60 mg)<br/><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Probable outcome with:</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect and NNTB or NNTH (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>No of Participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Placebo</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Ketorolac</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants with at least 50% pain relief over 4 hours</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>192 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>586 per 1000</b><br/>(463 to 741) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 2.81</b><br/>(1.80 to 4.37) </p> <p><b>NNTB</b> 2.4 (1.8 to 3.7) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>658<br/>(8 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low</b><sup>a,b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants with at least 50% pain relief over 6 hours</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>231 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>592 per 1000</b><br/>(497 to 705) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 3.26</b><br/>(1.93 to 5.51) </p> <p><b>NNTB</b> 2.5 (1.9 to 3.7) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>914<br/>(10 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Median time to use of rescue medication</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>104 minutes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>271 minutes</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not applicable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>633<br/>(6 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>moderate</b><sup>a,d,e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants using rescue medication over 4 or 6 hours post‐interventions</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>830 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>531 per 1000</b><br/>(456 to 606) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.60</b> <br/>(0.36 to 1.00) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>417<br/>(5 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low</b><sup>a,b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants reporting any adverse event</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>647 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>705 per 1000</b><br/>(647 to 770) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.09</b> <br/>(1.00 to 1.19) </p> <p><b>NNTH</b> 16.7 (8.3 to infinite) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>810<br/>(8 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>moderate</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants experiencing a serious adverse event</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>11 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>7 per 1000</b><br/>(1 to 33) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.62</b> <br/>(0.13 to 3.03) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>703<br/>(8 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>a,f</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Studies underpowered to detect these events</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>CI:</b> confidence interval; <b>NNTB:</b> number needed to treat for an additional beneficial outcome; <b>NNTH:</b> number needed to treat for an additional harmful outcome; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""></td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded once for serious study limitations due to unclear risk of bias in several domains.<br/><sup>b</sup>Downgraded once for inconsistency due to unexplained heterogeneity (I<sup>2</sup> &gt; 50%).<br/><sup>c</sup>Downgraded once for imprecision due to total number of events &lt; 300.<br/><sup>d</sup>Downgraded once for imprecision due to being unable to estimate confidence intervals because of reporting of median data.<br/><sup>e</sup>Upgraded once for large magnitude of effect: time to rescue &gt; 3 times longer in ketorolac group.<br/><sup>f</sup>Downgraded once for imprecision due to very low event rate. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD013263-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Intravenous ketorolac compared to another NSAID for adults with acute postoperative pain</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Intravenous ketorolac compared to another NSAID for adults with acute postoperative pain</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> adults (mean study ages 23 to 67 years) with acute postoperative pain after abdominal/pelvic, dental or orthopedic surgeries<br/><b>Settings:</b> hospital or community<br/><b>Intervention:</b> intravenous ketorolac (30 mg)<br/><b>Comparison:</b> another NSAID (parecoxib or diclofenac) </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Probable outcome with:</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect and NNTB or NNTH (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>No of Participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Other NSAID</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Ketorolac</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants with at least 50% pain relief over 4 hours</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>630 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>656 per 1000</b><br/>(561 to 763) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.04</b> <br/>(0.89 to 1.21) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>337<br/>(4 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants with at least 50% pain relief over 6 hours</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>626 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>663 per 1000</b><br/>(595 to 745) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.06</b> <br/>(0.95 to 1.19) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>603<br/>(6 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>moderate</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Median time to use of rescue medication</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>296 minutes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>331 minutes</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not applicable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>427<br/>(4 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>a,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants using rescue medication over 4 or 6 hours post interventions</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>515 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>474 per 1000</b><br/>(381 to 582) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.90</b> <br/>(0.58 to 1.40) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>260<br/>(3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low</b><sup>a,b,d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants reporting any adverse event</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>683 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>759 per 1000</b> <br/>(683 to 841) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.11</b> <br/>(1.00 to 1.23) </p> <p><b>NNTH</b> 12.5 (6.7 to infinite) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>516<br/>(5 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>moderate</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants experiencing a serious adverse event</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b><br/>(0 to 0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 3.18</b> <br/>(0.13 to 76.99) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>530<br/>(5 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>a,e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Studies underpowered to detect these events.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>CI:</b> confidence interval; <b>NNTB:</b> number needed to treat for an additional beneficial outcome; <b>NNTH:</b> number needed to treat for an additional harmful outcome; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded once for serious study limitations due to unclear risk of bias in several domains.<br/><sup>b</sup>Downgraded once for imprecision due to total number of events &lt; 300.<br/><sup>c</sup>Downgraded once for imprecision due to being unable to estimate confidence intervals because of reporting of median data.<br/><sup>d</sup>Downgraded once for inconsistency due to unexplained heterogeneity (I<sup>2</sup> &gt; 50%).<br/><sup>e</sup>Downgraded once for imprecision due to very low event rate. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD013263-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD013263-sec-0009"></div> <p>The methodology and several sections of the text in this review are derived from a series of reviews published in the Cochrane Library that assess single or combined analgesic agents for postoperative pain, and from suggested wording from the Pain, Palliative and Supportive Care Cochrane Review Group (PaPaS CRG) (<a href="./references#CD013263-bbs2-0121" title="DerryS , CooperTE , PhillipsT . Single fixed-dose oral dexketoprofen plus tramadol for acute postoperative pain in adults. Cochrane Database of Systematic Reviews2016, Issue 9. Art. No: CD012232. [DOI: 10.1002/14651858.CD012232.pub2]">Derry 2016</a>). </p> <section id="CD013263-sec-0010"> <h3 class="title" id="CD013263-sec-0010">Description of the condition</h3> <p>Evidence indicates that around 80% of people experience postoperative pain and that 75% of people report pain of moderate or greater severity (<a href="./references#CD013263-bbs2-0126" title="GanTJ , HabibAS , MillerTE , WhiteW , ApfelbaumJL . Incidence, patient satisfaction, and perceptions of post-surgical pain: results from a US national survey. Current Medical Research and Opinion2014;30(1):149-60.">Gan 2014</a>). Surgeries of the upper and lower extremities, thoracic, abdominal, and back/spinal column surgeries have been associated with higher levels of pain (<a href="./references#CD013263-bbs2-0165" title="SommerM , De RijkeJM , Van KleefM , KesselsAG , PetersML , GeurtsJW , et al. The prevalence of postoperative pain in a sample of 1490 surgical inpatients. European Journal of Anaesthesiology2008;25(4):267-74.">Sommer 2008</a>). Many people receive suboptimal perioperative analgesia, which affects quality of life, functioning, and time to recovery, and places them at risk for developing acute postsurgical complications and persistent postsurgical pain (<a href="./references#CD013263-bbs2-0109" title="ChouR , GordonDB , De Leon-CasasolaOA , RosenbergJM , BicklerS , BrennanT , et al. Management of postoperative pain: a clinical practice guideline from the American Pain Society, the American Society of Regional Anesthesia and Pain Medicine, and the American Society of Anesthesiologists' Committee on Regional Anesthesia, Executive Committee, and Administrative Council. Journal of Pain2016;17(2):131-57. [PMID: 26827847]">Chou 2016</a>; <a href="./references#CD013263-bbs2-0126" title="GanTJ , HabibAS , MillerTE , WhiteW , ApfelbaumJL . Incidence, patient satisfaction, and perceptions of post-surgical pain: results from a US national survey. Current Medical Research and Opinion2014;30(1):149-60.">Gan 2014</a>). Populations at increased risk for inadequate treatment of perioperative pain include children, minorities, the elderly, and those with substance‐use disorders (<a href="./references#CD013263-bbs2-0101" title="AndersonKO , GreenCR , PayneR . Racial and ethnic disparities in pain: causes and consequences of unequal care. Journal of Pain2009;10(12):1187-204.">Anderson 2009</a>; <a href="./references#CD013263-bbs2-0106" title="BrasherC , GafsousB , DugueS , ThiollierA , KinderfJ, NivocheY , et al. Postoperative pain management in children and infants: an update. Pediatric Drugs2014;16(2):129-40. [DOI: 10.1007/s40272-013-0062-0]">Brasher 2014</a>; <a href="./references#CD013263-bbs2-0109" title="ChouR , GordonDB , De Leon-CasasolaOA , RosenbergJM , BicklerS , BrennanT , et al. Management of postoperative pain: a clinical practice guideline from the American Pain Society, the American Society of Regional Anesthesia and Pain Medicine, and the American Society of Anesthesiologists' Committee on Regional Anesthesia, Executive Committee, and Administrative Council. Journal of Pain2016;17(2):131-57. [PMID: 26827847]">Chou 2016</a>). </p> <p>This review was based on a series of reviews published in the Cochrane Library. Cochrane's aim is to increase awareness of the range of analgesics that are potentially available, and present evidence for relative analgesic efficacy through indirect comparisons with placebo, in very similar trials performed in a standard manner, with very similar outcomes, and over the same duration. Such relative analgesic efficacy does not in itself determine choice of drug for any situation or person, but guides policy‐making at the local level. The series covers all analgesics licensed for acute postoperative pain in the UK, and dipyrone, which is commonly used in Spain, Portugal, and Latin‐American countries. The results have been examined in overviews of efficacy and harm (<a href="./references#CD013263-bbs2-0156" title="MooreRA , DerryS , AldingtonD , WiffenPJ . Single dose oral analgesics for acute postoperative pain in adults - an overview of Cochrane reviews. Cochrane Database of Systematic Reviews2015, Issue 9. Art. No: CD008659. [DOI: 10.1002/14651858.CD008659.pub3]">Moore 2015a</a>; <a href="./references#CD013263-bbs2-0157" title="MooreRA , DerryS , AldingtonD , WiffenPJ . Adverse events associated with single dose oral analgesics for acute postoperative pain in adults - an overview of Cochrane reviews. Cochrane Database of Systematic Reviews2015, Issue 10. Art. No: CD011407. [DOI: 10.1002/14651858.CD011407.pub2]">Moore 2015b</a>), and related individual reviews include ibuprofen (<a href="./references#CD013263-bbs2-0117" title="DerryC , DerryS , MooreRA , McQuayHJ . Single dose oral ibuprofen for acute postoperative pain in adults. Cochrane Database of Systematic Reviews2009, Issue 3. Art. No: CD001548. [DOI: 10.1002/14651858.CD001548.pub2] [PMID: 19588326]">Derry 2009</a>), paracetamol (acetaminophen) (<a href="./references#CD013263-bbs2-0167" title="TomsL , McQuayHJ , DerryS , MooreRA . Single dose oral paracetamol (acetaminophen) for postoperative pain in adults. Cochrane Database of Systematic Reviews2008, Issue 4. Art. No: CD004602. [DOI: 10.1002/14651858.CD004602.pub2]">Toms 2008</a>), ketoprofen and dexketoprofen (<a href="./references#CD013263-bbs2-0127" title="GaskellH , DerryS , WiffenPJ , MooreRA . Single dose oral ketoprofen and dexketoprofen for acute postoperative pain in adults. Cochrane Database of Systematic Reviews2017, Issue 5. Art. No: CD007355. [DOI: 10.1002/14651858.CD007355.pub3] [PMID: 19821407]">Gaskell 2017</a>), codeine (<a href="./references#CD013263-bbs2-0118" title="DerryS , MooreRA , McQuayHJ . Single dose oral codeine, as a single agent, for acute postoperative pain in adults. Cochrane Database of Systematic Reviews2010, Issue 4. Art. No: CD008099. [DOI: 10.1002/14651858.CD008099.pub2] [PMID: 20393966]">Derry 2010</a>), and combinations such as ibuprofen plus paracetamol (<a href="./references#CD013263-bbs2-0119" title="DerryCJ , DerryS , MooreRA . Single dose oral ibuprofen plus paracetamol (acetaminophen) for acute postoperative pain. Cochrane Database of Systematic Reviews2013, Issue 6. Art. No: CD010210. [DOI: 10.1002/14651858.CD010210.pub2] [PMID: 23794268]">Derry 2013</a>), ibuprofen plus codeine (<a href="./references#CD013263-bbs2-0120" title="DerryS , KarlinSM , MooreRA . Single dose oral ibuprofen plus codeine for acute postoperative pain in adults. Cochrane Database of Systematic Reviews2015, Issue 2. Art. No: CD010107. [DOI: 10.1002/14651858.CD010107.pub2]">Derry 2015</a>), and paracetamol plus codeine (<a href="./references#CD013263-bbs2-0168" title="TomsL , DerryS , MooreRA , McQuayHJ . Single dose oral paracetamol (acetaminophen) with codeine for postoperative pain in adults. Cochrane Database of Systematic Reviews2009, Issue 1. Art. No: CD001547. [DOI: 10.1002/14651858.CD001547.pub2]">Toms 2009</a>). </p> </section> <section id="CD013263-sec-0011"> <h3 class="title" id="CD013263-sec-0011">Description of the intervention</h3> <section id="CD013263-sec-0012"> <h4 class="title">Acute pain trials</h4> <p>Single‐dose trials in acute pain are commonly short in duration, rarely lasting longer than 12 hours. The numbers of participants are normally small, allowing no reliable conclusions to be drawn about safety. To show that the analgesic is working, it is necessary to compare the drug to a placebo control (<a href="./references#CD013263-bbs2-0144" title="McQuayHJ , MooreRA . Placebo. Postgraduate Medical Journal2005;81(953):155-60. [DOI: 10.1136/pgmj.2004.024737]">McQuay 2005</a>). There are clear ethical considerations in doing this. These ethical considerations are addressed by using acute pain situations where the pain is expected to go away, and by providing additional analgesia, commonly called rescue analgesia, if the pain has not diminished after about one hour. This is reasonable, because not all participants given an analgesic will have significant pain relief. Approximately 18% of participants given placebo will have significant pain relief (<a href="./references#CD013263-bbs2-0153" title="MooreA , McQuayH . Bandolier's Little Book of Making Sense of the Medical Evidence. Oxford: Oxford University Press, 2006. [ISBN: 0-19-856604-2]">Moore 2006</a>), and up to 50% may have inadequate analgesia with active medicines (<a href="./references#CD013263-bbs2-0157" title="MooreRA , DerryS , AldingtonD , WiffenPJ . Adverse events associated with single dose oral analgesics for acute postoperative pain in adults - an overview of Cochrane reviews. Cochrane Database of Systematic Reviews2015, Issue 10. Art. No: CD011407. [DOI: 10.1002/14651858.CD011407.pub2]">Moore 2015b</a>). Hence, the use of additional or rescue analgesia is important for all participants in the trials. </p> <p>Clinical trials measuring the efficacy of analgesics in acute pain have been standardized over many years (<a href="./references#CD013263-bbs2-0145" title="McQuayHJ , DerryS , EcclestonC , WiffenPJ , MooreRA . Evidence for analgesic effect in acute pain – 50 years on. Pain2012;153(7):1364-7. [DOI: 10.1016/j.pain.2012.01.024]">McQuay 2012</a>). Trials have to be randomized and double‐blind. Typically, in the first few hours or days after an operation, people develop pain that is moderate to severe in intensity, and will then be given the test analgesic or placebo. Pain is measured using standard pain intensity scales immediately before the intervention, and then using pain intensity and pain relief scales over the following four to six hours for shorter‐acting drugs, and up to 12 or 24 hours for longer‐acting drugs. Pain relief of half the maximum possible pain relief or better (at least 50% pain relief) is typically regarded as a clinically useful outcome (<a href="./references#CD013263-bbs2-0155" title="MooreRA , StraubeS , PaineJ , DerryS , McQuayHJ . Minimum efficacy criteria for comparisons between treatments using individual patient meta-analysis of acute pain trials: examples of etoricoxib, paracetamol, ibuprofen, and ibuprofen/paracetamol combinations after third molar extraction. Pain2011;152(5):982-9. [DOI: 10.1016/j.pain.2010.11.030]">Moore 2011</a>). For people given rescue medication, it is usual for no additional pain measurements to be made, and for all subsequent measures to be recorded as initial pain intensity or baseline (zero) pain relief (baseline observation carried forward (BOCF)). This process ensures that analgesia from the rescue medication is not wrongly ascribed to the test intervention. In some trials, the last observation is carried forward (LOCF), which gives an inflated response for the test intervention compared to placebo, but the effect has been shown to be negligible over four to six hours (<a href="./references#CD013263-bbs2-0152" title="MooreRA , EdwardsJE , McQuayHJ . Acute pain: individual patient meta-analysis shows the impact of different ways of analysing and presenting results. Pain2005;116(3):322-31. [DOI: 10.1016/j.pain.2005.05.001]">Moore 2005</a>). People usually remain in the hospital or clinic for at least the first six hours following the intervention, with measurements supervised, although they may then be allowed home to make their own measurements in trials of longer duration. Knowing the relative efficacy of different analgesic drugs at various doses can be helpful (<a href="./references#CD013263-bbs2-0156" title="MooreRA , DerryS , AldingtonD , WiffenPJ . Single dose oral analgesics for acute postoperative pain in adults - an overview of Cochrane reviews. Cochrane Database of Systematic Reviews2015, Issue 9. Art. No: CD008659. [DOI: 10.1002/14651858.CD008659.pub3]">Moore 2015a</a>). </p> </section> <section id="CD013263-sec-0013"> <h4 class="title">Recommendations for non‐steroidal anti‐inflammatory drug use in postoperative guidelines</h4> <p>Treatment guidelines for acute pain developed by major professional organizations recommend a multimodal approach to analgesia, which routinely includes administration of both an opioid and one or more non‐opioids, the latter of which frequently includes a non‐steroidal anti‐inflammatory drug (NSAID) or acetaminophen or both (<a href="./references#CD013263-bbs2-0109" title="ChouR , GordonDB , De Leon-CasasolaOA , RosenbergJM , BicklerS , BrennanT , et al. Management of postoperative pain: a clinical practice guideline from the American Pain Society, the American Society of Regional Anesthesia and Pain Medicine, and the American Society of Anesthesiologists' Committee on Regional Anesthesia, Executive Committee, and Administrative Council. Journal of Pain2016;17(2):131-57. [PMID: 26827847]">Chou 2016</a>; <a href="./references#CD013263-bbs2-0161" title="SchugSA , PalmerGM , ScottDA , AlcockM , HalliwellR , MottJF . APM:SE Working Group of the Australian and New Zealand College of Anaesthetists and Faculty of Pain Medicine, AcutePain Management: Scientific Evidence. 5th edition. Melbourne: ANZCA &amp; FPM, 2020.">Schug 2020</a>). Postoperative administration of NSAIDs has been shown to reduce patient requirements for opioids and, in turn, to reduce the incidence and severity of opioid‐induced adverse events (AEs); however, NSAIDs do not typically offer adequate relief of severe pain when administered as a sole analgesic agent (<a href="./references#CD013263-bbs2-0107" title="CepedaMS , CarrDB , MirandaN , DiazA , SilvaC , MoralesO . Comparison of morphine, ketorolac, and their combination for postoperative pain. Results from a large, randomized, double-blind trial. Anesthesiology2005;103(6):1225-32. [PMID: 16306736]">Cepeda 2005</a>). </p> </section> <section id="CD013263-sec-0014"> <h4 class="title">Parenteral ketorolac</h4> <p>Parenteral analgesics may be required postoperatively if people are unable to tolerate oral medications. Until 2009, the only NSAID approved for intravenous (IV) administration for postoperative pain in the USA and many other countries was ketorolac. Ketorolac, an acetic acid derivative, can be administered by mouth, intranasally, or parenterally as either an IV or intramuscular (IM) injection (<a href="./references#CD013263-bbs2-0139" title="Wolters Kluwer Clinical Drug Information, IncLexicomp Online, Pediatric and Neonatal Lexi-Drugs Online. Hudson (OH): Wolters Kluwer Clinical Drug Information, Inc, 2013.">Lexicomp 2018</a>). The IM route is not preferred, as drug absorption may be unreliable and the injection itself may be painful (<a href="./references#CD013263-bbs2-0161" title="SchugSA , PalmerGM , ScottDA , AlcockM , HalliwellR , MottJF . APM:SE Working Group of the Australian and New Zealand College of Anaesthetists and Faculty of Pain Medicine, AcutePain Management: Scientific Evidence. 5th edition. Melbourne: ANZCA &amp; FPM, 2020.">Schug 2020</a>). It is a potent analgesic but has only moderate anti‐inflammatory properties (<a href="./references#CD013263-bbs2-0131" title="GrosserT , SmythE , FitzGeraldG . Pharmacotherapy of inflammation, fever, pain, and gout. In: BruntonLL , Hilal-DandanR , KnollmannBC , editors(s). Goodman &amp; Gilman's: The Pharmacological Basis of Therapeutics. 13th edition. New York (NY): McGraw-Hill, 2018.">Grosser 2018</a>). It has a rapid onset (30 to 60 minutes) and short duration of action (half‐life of four to six hours). Typical IV doses are 15 mg or 30 mg every six hours, with 15 mg recommended in people over the age of 65 years. While oral bioavailability is estimated at 100%, oral administration in the postoperative setting is generally reserved for continuation of therapy initiated with IM or IV ketorolac. Recommended maximum duration of therapy varies by country, but a combined therapy duration (oral and parenteral) of five days should not be exceeded (<a href="./references#CD013263-bbs2-0139" title="Wolters Kluwer Clinical Drug Information, IncLexicomp Online, Pediatric and Neonatal Lexi-Drugs Online. Hudson (OH): Wolters Kluwer Clinical Drug Information, Inc, 2013.">Lexicomp 2018</a>). </p> <p>Parenteral ketorolac has efficacy in reducing pain and opioid requirements (<a href="./references#CD013263-bbs2-0107" title="CepedaMS , CarrDB , MirandaN , DiazA , SilvaC , MoralesO . Comparison of morphine, ketorolac, and their combination for postoperative pain. Results from a large, randomized, double-blind trial. Anesthesiology2005;103(6):1225-32. [PMID: 16306736]">Cepeda 2005</a>). Common AEs of systemic administration include somnolence, dizziness, headache, gastrointestinal (GI) pain, dyspepsia, nausea, and pain at the site of injection (<a href="./references#CD013263-bbs2-0131" title="GrosserT , SmythE , FitzGeraldG . Pharmacotherapy of inflammation, fever, pain, and gout. In: BruntonLL , Hilal-DandanR , KnollmannBC , editors(s). Goodman &amp; Gilman's: The Pharmacological Basis of Therapeutics. 13th edition. New York (NY): McGraw-Hill, 2018.">Grosser 2018</a>). Its acute safety profile includes increased risk of GI and operative‐site bleeding and renal events, particularly with use beyond five days and in at‐risk populations (such as older people) (<a href="./references#CD013263-bbs2-0122" title="FeldmanHI , KinmanJL , BerlinJA , HennessyS , KimmelSE , FarrarJ , et al. Parenteral ketorolac: the risk for acute renal failure. Annals of Internal Medicine1997;126(3):193-9.">Feldman 1997</a>; <a href="./references#CD013263-bbs2-0166" title="StromBL , BerlinJA , KinmanJL , SpitzPW , HennessyS , FeldmanH , et al. Parenteral ketorolac and risk of gastrointestinal and operative site bleeding: a postmarketing surveillance study. JAMA1996;275(5):376-82.">Strom 1996</a>). Although clinical evidence is lacking, concern for altered bone and ligament healing may also cause providers to avoid the use of ketorolac postoperatively (<a href="./references#CD013263-bbs2-0135" title="HarderAT , AnYH . The mechanisms of the inhibitory effects of nonsteroidal anti-inflammatory drugs on bone healing: a concise review. Journal of Clinical Pharmacology2003;43(8):807-15. [PMID: 12953337]">Harder 2003</a>; <a href="./references#CD013263-bbs2-0141" title="Marquez-LaraA , HutchinsonID , Nuñez F Jr, SmithTL , MillerAN . Nonsteroidal anti-inflammatory drugs and bone-healing: a systematic review of research quality. JBJS Reviews2016;4(3 e4):1-14. [PMID: 27500434]">Marquez‐Lara 2016</a>). </p> </section> </section> <section id="CD013263-sec-0015"> <h3 class="title" id="CD013263-sec-0015">How the intervention might work</h3> <p>NSAIDs inhibit cyclo‐oxygenase (COX) isoenzymes, thereby reducing the formation of prostaglandins that are responsible for pain and inflammation at a site of injury or disease (<a href="./references#CD013263-bbs2-0124" title="FitzGeraldGA , PatronoC . The coxibs, selective inhibitors of cyclooxygenase-2. New England Journal of Medicine2001;345(6):433-42. [DOI: 10.1056/NEJM200108093450607]">FitzGerald 2001</a>). In addition to their peripheral effects, NSAIDs act in the spinal cord and central nervous system (CNS) to reduce pain even when inflammation is not present. They also act on inflammatory pathways other than those involving COX. Inhibition of COX may also play a role in the AE profile of NSAIDs. NSAIDs account for more reports of drug toxicity than any other agents (<a href="./references#CD013263-bbs2-0136" title="HawkeyCJ . Cyclooxygenase inhibition: between the devil and the deep blue sea. Gut2002;50 Suppl 3:iii25-30. [PMID: 11953329]">Hawkey 2002</a>). Risk factors for toxicity include dose, duration of therapy, patient age, and pre‐existing renal impairment. At least two forms of COX are expressed in tissues: COX‐1 is responsible for the production of prostaglandins that play a predominately protective role in the GI tract, vascular system, and kidneys, and for the production of thromboxane A2, responsible for platelet aggregation and vasoconstriction (<a href="./references#CD013263-bbs2-0125" title="FitzGeraldGA . Coxibs and cardiovascular disease. New England Journal of Medicine2004;351(17):1709-11. [PMID: 15470192]">FitzGerald 2004</a>). COX‐2 is expressed constitutively in the vasculature, CNS, and kidneys, but in other organs it is induced after trauma (including surgery) and inflammation. Inhibition of the production of protective prostaglandins and thromboxane A2 may lead to GI, hematological, cardiovascular, and renal AEs. Postoperative patients are at greater risk of developing NSAID‐induced acute kidney injury as they may be volume‐depleted, as are older people, who rely on prostaglandins to maintain renal function. NSAIDs that selectively inhibit the COX‐1 isoenzyme, such as ketorolac, may increase the incidence of GI bleeding and interfere more with platelet aggregation in comparison to NSAIDs that are selective for COX‐2 or that have a balanced COX‐1/COX‐2 profile (<a href="./references#CD013263-bbs2-0124" title="FitzGeraldGA , PatronoC . The coxibs, selective inhibitors of cyclooxygenase-2. New England Journal of Medicine2001;345(6):433-42. [DOI: 10.1056/NEJM200108093450607]">FitzGerald 2001</a>; <a href="./references#CD013263-bbs2-0125" title="FitzGeraldGA . Coxibs and cardiovascular disease. New England Journal of Medicine2004;351(17):1709-11. [PMID: 15470192]">FitzGerald 2004</a>). Conversely, NSAIDs that are selective for COX‐2 may confer an increased risk of cardiovascular events versus COX‐1 selective agents. NSAIDs may also occasionally produce liver damage, particularly with long‐term use (<a href="./references#CD013263-bbs2-0102" title="American Pain Society (APS). Principles of Analgesic Use in the Treatment of Acute Pain and Cancer Pain. 6th edition. Glenview (IL): APS, 2008.">APS 2008</a>). </p> </section> <section id="CD013263-sec-0016"> <h3 class="title" id="CD013263-sec-0016">Why it is important to do this review</h3> <p>Increasing concerns about the risks of excessive opioid use in the postoperative setting, and in particular the risk of people developing opioid use disorder, has led to greater emphasis on the importance of multimodal strategies that reduce opioid requirements (<a href="./references#CD013263-bbs2-0109" title="ChouR , GordonDB , De Leon-CasasolaOA , RosenbergJM , BicklerS , BrennanT , et al. Management of postoperative pain: a clinical practice guideline from the American Pain Society, the American Society of Regional Anesthesia and Pain Medicine, and the American Society of Anesthesiologists' Committee on Regional Anesthesia, Executive Committee, and Administrative Council. Journal of Pain2016;17(2):131-57. [PMID: 26827847]">Chou 2016</a>). NSAIDs are considered an integral part of a multimodal analgesic regimen, despite their unfavorable safety profile. </p> <p>The approval of parenteral formulations of ibuprofen and diclofenac has expanded the menu of NSAIDs for treating postoperative pain in people who require IV analgesia (<a href="./references#CD013263-bbs2-0105" title="BookstaverPB , MillerAD , RudisillCN , NorrisLB . Intravenous ibuprofen: the first injectable product for the treatment of pain and fever. Journal of Pain Research2010;3:67-79. [PMID: 21197311]">Bookstaver 2010</a>; <a href="./references#CD013263-bbs2-0114" title="DanielsSE , GanTJ , HamiltonDA , SinglaN , LacouturePG , JohnsonO , et al. A pooled analysis evaluating renal safety in placebo-and active comparator-controlled phase III trials of multiple-dose injectable HPβCD-diclofenac in subjects with acute postoperative pain. Pain Medicine2016;17(12):2378-88. [PMID: 28025372]">Daniels 2016</a>; <a href="./references#CD013263-bbs2-0163" title="ScottLJ . Intravenous ibuprofen: in adults for pain and fever. Drugs2012;72(8):1099-109. [PMID: 22621696]">Scott 2012</a>). Both NSAIDs are the subject of separate Cochrane Reviews (<a href="./references#CD013263-bbs2-0123" title="FergusonMC , McNicolED , SchumannR . Single-dose intravenous ibuprofen for acute postoperative pain in adults. Cochrane Database of Systematic Reviews2019, Issue 2. Art. No: CD013264. [DOI: 10.1002/14651858.CD013264]">Ferguson 2018</a>; <a href="./references#CD013263-bbs2-0143" title="McNicolED , FergusonMC , SchumannR . Single-dose intravenous diclofenac for acute postoperative pain in adults. Cochrane Database of Systematic Reviews2018, Issue 8. Art. No: CD012498. [DOI: 10.1002/14651858.CD012498]">McNicol 2018</a>). Because of their balanced COX‐1/COX‐2 profile, they may be safer (although more expensive) options than ketorolac in this setting. It is therefore important to assess the risk:benefit profile of these individual agents. </p> <p>The target audiences for this review include: perioperative caregivers who make decisions about postoperative pain management; and affected patients who wish to find information about the effectiveness and risks of a specific postoperative pain medication. We anticipate that the information from our review will be disseminated through respective publishing journals and medical literature databases. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD013263-sec-0017" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD013263-sec-0017"></div> <p>To assess the analgesic efficacy and adverse effects of single‐dose intravenous ketorolac, compared with placebo or an active comparator, for moderate to severe postoperative pain in adults. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD013263-sec-0018" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD013263-sec-0018"></div> <section id="CD013263-sec-0019"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD013263-sec-0020"> <h4 class="title">Types of studies</h4> <p>We included randomized controlled trials (RCTs), with at least 10 participants randomly allocated to each treatment group. We only include trials that conducted a double‐blind assessment of participant outcomes. We include multiple‐dose studies if appropriate data from the first dose were available, and cross‐over studies provided that data from the first phase were presented separately or could be obtained. </p> <p>We exclude:</p> <p> <ul id="CD013263-list-0001"> <li> <p>non‐randomized studies;</p> </li> <li> <p>review articles, case reports, and clinical observations;</p> </li> <li> <p>studies of experimental pain;</p> </li> <li> <p>studies of less than four hours' duration or studies that did not present data over four‐ to six‐hours post‐dose; </p> </li> <li> <p>studies where ketorolac was administered preoperatively or intraoperatively;</p> </li> <li> <p>studies where pain was not participant‐reported.</p> </li> </ul> </p> <p>For postpartum pain, we include studies if the pain investigated was due to episiotomy or caesarean section irrespective of the presence of uterine cramps; we exclude studies investigating pain due to uterine cramps alone. </p> <p>We required full journal publication, with the exception of online clinical trial results, summaries of otherwise unpublished clinical trials, and abstracts with sufficient information to assess eligibility and sufficient data for analysis. For an abstract with insufficient data, we assumed that if the study was valid, the investigators would publish its data in full within three years. If not, we excluded without attempting to contact authors. </p> </section> <section id="CD013263-sec-0021"> <h4 class="title">Types of participants</h4> <p>We included studies of adults (aged 18 years and above) with established postoperative pain of moderate‐to‐severe intensity following day surgery or inpatient surgery. For studies using a visual analogue scale (VAS) (see Glossary: <a href="./appendices#CD013263-sec-0136">Appendix 1</a>), we considered that pain intensity of more than 30 mm equates to pain of at least moderate intensity (<a href="./references#CD013263-bbs2-0110" title="CollinsSL , MooreRA , McQuayHJ . The visual analogue pain intensity scale: what is moderate pain in millimetres?Pain1997;72(1-2):95-7. [DOI: 10.1016/S0304-3959(97)00005-5]">Collins 1997</a>). We excluded studies that included participants with mild pain, unless they presented data for those with moderate‐to‐severe pain separately. </p> </section> <section id="CD013263-sec-0022"> <h4 class="title">Types of interventions</h4> <p>We included trials that delivered ketorolac, administered as a single IV dose, for the relief of acute postoperative pain, and compared to placebo or any active comparator. </p> </section> <section id="CD013263-sec-0023"> <h4 class="title">Types of outcome measures</h4> <section id="CD013263-sec-0024"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD013263-list-0002"> <li> <p>Number of participants achieving at least 50% pain relief over a four‐hour period and over a six‐hour period. </p> </li> </ul> </p> </section> <section id="CD013263-sec-0025"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD013263-list-0003"> <li> <p>Median or mean time to use of rescue medication.</p> </li> <li> <p>Number of participants using rescue medication over a four‐ or six‐hour period.</p> </li> <li> <p>Withdrawals due to lack of efficacy, AEs, and for any cause.</p> </li> <li> <p>Participants reporting or experiencing any AE.</p> </li> <li> <p>Participants experiencing any serious adverse event (SAE). SAEs typically include any untoward medical occurrence or effect that at any dose results in death, is life‐threatening, requires hospitalization or prolongation of existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly or birth defect, is an 'important medical event' that may jeopardize the patient, or may require an intervention to prevent one of the above characteristics or consequences. </p> </li> <li> <p>Specific AEs associated with parenteral NSAIDs, that is, renal dysfunction, cardiovascular events, GI or operative site bleeding, and thrombophlebitis. </p> </li> <li> <p>Specific AEs associated with opioids. A reduction in opioid requirements with an effective analgesic may, in turn, reduce the incidence of opioid‐induced AEs. We assessed the following opioid‐related AEs: nausea, vomiting, nausea and vomiting, pruritus, respiratory depression, sedation, urinary retention, and allergic reaction/rashes. </p> </li> </ul> </p> </section> </section> </section> <section id="CD013263-sec-0026"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD013263-sec-0027"> <h4 class="title">Electronic searches</h4> <p>We searched the following databases without language restrictions or restrictions on the time period covered. </p> <p> <ul id="CD013263-list-0004"> <li> <p>The Cochrane Central Register of Controlled Trials (CENTRAL), Issue 4 of 12, 2020, in the Cochrane Library. </p> </li> <li> <p>MEDLINE (via Ovid) 1946 to April 17th 2020.</p> </li> <li> <p>Embase (via Ovid) 1980 to 2020 week 16.</p> </li> <li> <p>LILACS (Bireme) to April 2020.</p> </li> </ul> </p> <p>We used medical subject headings (MeSH) or equivalent and text word terms. We tailored searches to individual databases. The search strategies used can be found in <a href="./appendices#CD013263-sec-0137">Appendix 2</a>. </p> </section> <section id="CD013263-sec-0028"> <h4 class="title">Searching other resources</h4> <p>We searched <a href="http://www.clinicaltrials.gov" target="_blank">www.clinicaltrials.gov</a> and the World Health Organization International Clinical Trials Registry Platform (ICTRP) (<a href="http://apps.who.int/trialsearch/" target="_blank">apps.who.int/trialsearch/</a>) for ongoing trials. In addition, we checked reference lists of reviews and retrieved articles for additional studies, and we performed citation searches on key articles. We contacted experts in the field for unpublished and ongoing trials. We contacted study authors for additional information where necessary. If a published protocol was not available, we did not contact study authors if the outcomes listed in their Methods section were those that we would expect from similar studies and if these outcomes were reported in full in the Results section. </p> </section> </section> <section id="CD013263-sec-0029"> <h3 class="title" id="CD013263-sec-0029">Data collection and analysis</h3> <section id="CD013263-sec-0030"> <h4 class="title">Selection of studies</h4> <p>Two review authors (a combination of EM, MF, and RS) independently determined eligibility by reading the abstract of each study identified by the search. Independent review authors eliminated studies that clearly did not satisfy inclusion criteria, and obtained full copies of the remaining studies. Two review authors (a combination of EM, MF, and RS) independently read and selected studies, and, in the event of disagreement, the third review author adjudicated. We did not anonymize the studies before assessment. </p> <p>We include a PRISMA flow chart in the full review, which shows the status of identified studies (<a href="./references#CD013263-bbs2-0146" title="MoherD , LiberatiA , TetzlaffJ , AltmanDG , the PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLOS Medicine2009;6(7):e1000097.">Moher 2009</a>), as recommended in Section 11.2.1 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD013263-bbs2-0162" title="SchünemannHJ , HigginsJP , VistGE , GlasziouP , AklEA , SkoetzN , et al. Chapter 14: Completing ‘Summary of findings’ tables and grading the certainty of the evidence. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.2 (updated February 2021). The Cochrane Collaboration, 2021. Available from www.training.cochrane.org/handbook.">Schünemann 2021</a>). We included studies in the review irrespective of whether measured outcome data were reported in a 'usable' way. </p> </section> <section id="CD013263-sec-0031"> <h4 class="title">Data extraction and management</h4> <p>Two review authors (a combination of EM, MF, and RS) independently extracted data using a previously‐piloted standard form and checked for agreement before entry into Review Manager 5 (<a href="./references#CD013263-bbs2-0158" title="The Nordic Cochrane Centre, The Cochrane CollaborationReview Manager. Version 5.4.1. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2020.">Review Manager 2020</a>). In the event of disagreement, the third review author adjudicated. We extracted the following information: </p> <p> <ul id="CD013263-list-0005"> <li> <p>study methods;</p> </li> <li> <p>study population;</p> </li> <li> <p>interventions;</p> </li> <li> <p>pain intensity scale used and baseline pain intensity;</p> </li> <li> <p>outcomes of interest. We extracted efficacy outcomes for the six hours post‐administration of interventions. We extracted safety outcomes for the duration of the study. </p> </li> </ul> </p> <p>We collated multiple reports of the same study, so that each study, rather than each report, was the unit of interest in the review. We collected information about the included studies in sufficient detail to complete a 'Characteristics of included studies' table. </p> </section> <section id="CD013263-sec-0032"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (a combination of EM, MF, and RS) independently assessed risks of bias for each study, using the criteria outlined in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (Chapter 8, <a href="./references#CD013263-bbs2-0137" title="HigginsJP , AltmanDG , SterneJA . Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1/.">Higgins 2011</a>), and, in the event of disagreement, the third review author adjudicated. We completed a risk of bias table for each included study using the risk of bias tool in Review Manager 5 (<a href="./references#CD013263-bbs2-0158" title="The Nordic Cochrane Centre, The Cochrane CollaborationReview Manager. Version 5.4.1. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2020.">Review Manager 2020</a>). </p> <p>We assessed the following for each study.</p> <p> <ul id="CD013263-list-0006"> <li> <p>Random sequence generation (checking for possible selection bias). We assessed the method used to generate the allocation sequence as: low risk of bias (any truly random process, e.g. random‐number table; computer random‐number generator); unclear risk of bias (method used to generate sequence not clearly stated). We excluded studies using a non‐random process (e.g. odd or even date of birth; hospital or clinic record number). </p> </li> <li> <p>Allocation concealment (checking for possible selection bias). The method used to conceal allocation to interventions prior to assignment determines whether intervention allocation could have been foreseen in advance of or during recruitment, or changed after assignment. We assessed the methods as: low risk of bias (e.g. telephone or central randomization; consecutively‐numbered sealed opaque envelopes); unclear risk of bias (method not clearly stated). We excluded studies that did not conceal allocation (e.g. open list). </p> </li> <li> <p>Blinding of participants and personnel (checking for possible performance bias). We assessed the methods used to blind study participants and personnel from knowledge of which intervention a participant received. We assessed methods as: low risk of bias (study stated that it was blinded and described the method used to achieve blinding, such as identical tablets matched in appearance or smell, or a double‐dummy technique); unclear risk of bias (study stated that it was blinded but did not provide an adequate description of how it was achieved). We excluded studies that were not double‐blind. </p> </li> <li> <p>Blinding of outcome assessment (checking for possible detection bias). In this review, pain‐related outcomes were self‐assessed, so that the same considerations apply to detection bias as performance bias. </p> </li> <li> <p>Incomplete outcome data (checking for possible attrition bias due to the amount, nature, and handling of incomplete outcome data). We assessed the methods used to deal with incomplete data as: low risk (fewer than 10% of participants did not complete the study or the study used intention‐to‐treat (ITT) analysis and imputed missing data using BOCF, or both); unclear risk of bias (used ITT analysis and imputed missing data using LOCF or did not describe methods of imputation); high risk of bias (used only 'completer' analysis). </p> </li> <li> <p>Selective reporting (checking for reporting bias). We assessed whether primary and secondary outcome measures were prespecified and whether these were consistent with those reported. We assessed reporting of results as having low risk of bias (e.g. the study protocol was available and all the study's prespecified outcomes of interest in the review were reported in the prespecified way; the study protocol was not available but it was clear that published reports included all expected outcomes, including those that were prespecified); high risk of bias (e.g. not all of the study's prespecified primary outcomes were reported; one or more primary outcomes were reported using measurements, analysis methods or subsets of data that were not prespecified); or unclear risk of bias (information insufficient to permit judgment of 'low risk' or 'high risk'). </p> </li> <li> <p>Size of study (checking for possible biases confounded by small size). We assessed studies as being at low risk of bias (200 participants or more per treatment arm); unclear risk of bias (50 to 199 participants per treatment arm); high risk of bias (fewer than 50 participants per treatment arm). </p> </li> </ul> </p> </section> <section id="CD013263-sec-0033"> <h4 class="title">Measures of treatment effect</h4> <p>We used the risk ratio (RR) to establish statistical difference, and the number needed to treat for an additional beneficial outcome (NNTB) with 95% confidence intervals (CIs), and pooled percentages as absolute measures of effect. </p> <p>We used the following terms to describe adverse outcomes in terms of harm or prevention of harm. </p> <p> <ul id="CD013263-list-0007"> <li> <p>When fewer adverse outcomes occurred with treatment than with control (placebo or active), we used the term 'number needed to treat to prevent one additional harmful event' (NNTp). </p> </li> <li> <p>When more adverse outcomes occurred with treatment compared with control (placebo or active), we used the term 'number needed for one additional harmful event' (NNTH). </p> </li> </ul> </p> </section> <section id="CD013263-sec-0034"> <h4 class="title">Unit of analysis issues</h4> <p>We accepted only randomization of individual participants. If two or more active treatment arms were compared with a placebo arm within the same meta‐analysis, we avoided double‐counting of participants in the placebo arm by splitting the total number between the active arms. If we identified multiple‐dose studies, we used data for the most commonly‐used dose only; and for cross‐over studies, we used only data from the first treatment phase. </p> </section> <section id="CD013263-sec-0035"> <h4 class="title">Dealing with missing data</h4> <p>One issue with missing data in these studies was from imputation using LOCF when a participant requests rescue medication. It has been shown that this does not affect results for up to six hours after taking study medication (<a href="./references#CD013263-bbs2-0152" title="MooreRA , EdwardsJE , McQuayHJ . Acute pain: individual patient meta-analysis shows the impact of different ways of analysing and presenting results. Pain2005;116(3):322-31. [DOI: 10.1016/j.pain.2005.05.001]">Moore 2005</a>). Where large amounts of data were missing, we reported this in our review and assessed such results with caution. We consulted the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD013263-bbs2-0115" title="DeeksJJ , HigginsJP , Altman DG (editors). Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.2 (updated February 2021). The Cochrane Collaboration, 2021. Available from www.training.cochrane.org/handbook.">Deeks 2021</a>) for guidance. Where papers reported results using more than one method of imputation, we analyzed data using the primary method reported and performed sensitivity analysis by entering data from secondary methods. We also attempted to assess differences between intervention groups in reasons for missing data and how these differences might bias results. </p> </section> <section id="CD013263-sec-0036"> <h4 class="title">Assessment of heterogeneity</h4> <p>We assessed statistical heterogeneity by visually examining forest plots and quantified it using the I<sup>2</sup> statistic. The I<sup>2</sup> statistic is a reliable and robust test to quantify heterogeneity, since it does not depend on the number of trials or on the between‐study variance. The I<sup>2</sup> statistic measures the extent of inconsistency among studies' results, and can be interpreted as the proportion of total variation in study estimates that is due to heterogeneity rather than sampling error. An I<sup>2</sup> value of greater than 50% is considered to indicate substantial heterogeneity (<a href="./references#CD013263-bbs2-0115" title="DeeksJJ , HigginsJP , Altman DG (editors). Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.2 (updated February 2021). The Cochrane Collaboration, 2021. Available from www.training.cochrane.org/handbook.">Deeks 2021</a>). If heterogeneity was high (I<sup>2</sup> greater than 50%), we looked for possible causes including the influence of small studies. </p> </section> <section id="CD013263-sec-0037"> <h4 class="title">Assessment of reporting biases</h4> <p>To assess the impact of reporting bias, we considered the number of additional participants needed in studies with zero effect (relative benefit of one) required to change the number needed to treat (NNT) for all statistically significant outcomes to an unacceptably high level (in this case the arbitrary NNT of 10) (<a href="./references#CD013263-bbs2-0154" title="MooreRA , BardenJ , DerryS , McQuayHJ . Managing potential publication bias. In: McQuayHJ , KalsoE , MooreRA , editors(s). Systematic Reviews in Pain Research: Methodology Refined. Seattle (WA): IASP Press, 2008:15-24. [978-0-931092-69-5]">Moore 2008</a>). Where this number was fewer than 400 (equivalent to four studies with 100 participants per comparison, or 50 participants per group), we considered the results to be susceptible to publication bias and therefore unreliable (low‐certainty evidence). </p> <p>We also attempted to mitigate the potential for publication bias by searching clinical trial websites, and by contacting the manufacturers of parenteral ketorolac for an internal reference list of completed studies (see <a href="#CD013263-sec-0028">Searching other resources</a>). </p> </section> <section id="CD013263-sec-0038"> <h4 class="title">Data synthesis</h4> <p>For efficacy analyses, we used the number of participants in each treatment group who were randomized, received medication, and provided at least one post‐baseline assessment. For safety analyses, we used the number of participants randomized to each treatment group who took the study medication. </p> <p>For the primary outcome (number of participants achieving at least 50% pain relief over a four‐ to six‐hour period), if numbers were not reported directly, we converted the mean total pain relief (TOTPAR), or summed pain intensity difference (SPID), VAS TOTPAR, or VAS SPID (see Glossary: <a href="./appendices#CD013263-sec-0136">Appendix 1</a>) values for the active and placebo groups in each study to a percentage of maximum TOTPAR or a percentage of maximum SPID by division into the calculated maximum value (<a href="./references#CD013263-bbs2-0113" title="CooperSA . Single-dose analgesic studies: the upside and downside of assay sensitivity. In: MaxMB , PortenoyRK , LaskaEM , editors(s). The Design of Analgesic Clinical Trials. Advances in Pain Research and Therapy. Vol. 18. New York (NY): Raven Press, 1991:117-24.">Cooper 1991</a>). We then calculated the proportion of participants in each treatment group who achieved at least 50% maximum TOTPAR using verified equations (<a href="./references#CD013263-bbs2-0147" title="MooreA , McQuayH , GavaghanD . Deriving dichotomous outcome measures from continuous data in randomised controlled trials of analgesics. Pain1996;66(2-3):229-37. [DOI: 10.1016/0304-3959(96)03032-1]">Moore 1996</a>; <a href="./references#CD013263-bbs2-0148" title="MooreA , McQuayH , GavaghanD . Deriving dichotomous outcome measures from continuous data in randomised controlled trials of analgesics: verification from independent data. Pain1997;69(1-2):127-30. [DOI: 10.1016/S0304-3959(96)03251-4]">Moore 1997a</a>; <a href="./references#CD013263-bbs2-0149" title="MooreA , MooreO , McQuayH , GavaghanD . Deriving dichotomous outcome measures from continuous data in randomised controlled trials of analgesics: use of pain intensity and visual analogue scales. Pain1997;69(3):311-5. [DOI: 10.1016/S0304-3959(96)03306-4]">Moore 1997b</a>), and converted these proportions into the number of participants achieving at least 50% maximum TOTPAR by multiplying by the total number of participants in the treatment group. We used this information on the number of participants with at least 50% maximum TOTPAR for active and placebo groups to calculate RR and NNT. </p> <p>We accepted the following pain measures for the calculation of TOTPAR or SPID (in order of priority: see <a href="./appendices#CD013263-sec-0136">Appendix 1</a>): </p> <p> <ul id="CD013263-list-0008"> <li> <p>5‐point categorical pain relief scales with comparable wording to 'none', 'slight', 'moderate', 'good', and 'complete'; </p> </li> <li> <p>4‐point categorical pain intensity scales with comparable wording to 'none', 'mild', 'moderate', and 'severe'; </p> </li> <li> <p>VAS for pain relief;</p> </li> <li> <p>VAS for pain intensity.</p> </li> </ul> </p> <p>If none of these measures were available, we planned to use the number of participants reporting 'very good or excellent' on a 5‐point categorical global scale with the wording 'poor', 'fair', 'good', 'very good', and 'excellent' for the number of participants achieving at least 50% pain relief (<a href="./references#CD013263-bbs2-0111" title="CollinsSL , EdwardsJ , MooreRA , SmithLA , McQuayHJ . Seeking a simple measure of analgesia for mega-trials: is a single global assessment good enough?Pain2001;91(1-2):189-94. [DOI: 10.1016/S0304-3959(00)00435-8]">Collins 2001</a>). </p> <p>For dichotomous outcomes, we calculated RR estimates with 95% CIs using the Mantel‐Haenszel method in Review Manager 5 and RevMan Web (<a href="./references#CD013263-bbs2-0158" title="The Nordic Cochrane Centre, The Cochrane CollaborationReview Manager. Version 5.4.1. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2020.">Review Manager 2020</a>; <a href="./references#CD013263-bbs2-0159" title="The Cochrane CollaborationReview Manager Web (RevMan Web). Version 2.2.1. The Cochrane Collaboration, 2021. Available at revman.cochrane.org.">RevMan Web 2021</a>). We calculated NNTB and NNTH with 95% CIs using the pooled number of events and the method of Cook and Sackett (<a href="./references#CD013263-bbs2-0112" title="CookRJ , SackettDL . The number needed to treat: a clinically useful measure of treatment effect. BMJ1995;310(6977):452-4. [DOI: 10.1136/bmj.310.6977.452]">Cook 1995</a>). We assumed a statistically significant difference from control when the 95% CI of the RR did not include the number one. </p> <p>For the continuous outcome of time to rescue medication, we intended to pool mean scores using the inverse variance method in Review Manager 5 and RevMan Web (<a href="./references#CD013263-bbs2-0158" title="The Nordic Cochrane Centre, The Cochrane CollaborationReview Manager. Version 5.4.1. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2020.">Review Manager 2020</a>; <a href="./references#CD013263-bbs2-0159" title="The Cochrane CollaborationReview Manager Web (RevMan Web). Version 2.2.1. The Cochrane Collaboration, 2021. Available at revman.cochrane.org.">RevMan Web 2021</a>). However, the data were only available as medians in the relevant studies, so instead we calculated the mean of these medians and presented the analysis as such. </p> <p>We used a fixed‐effect model for all initial meta‐analyses. If a meta‐analysis had an I<sup>2</sup> score of greater than 50%, we reanalyzed data using a random‐effects model and presented the analysis using this model  (<a href="./references#CD013263-bbs2-0115" title="DeeksJJ , HigginsJP , Altman DG (editors). Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.2 (updated February 2021). The Cochrane Collaboration, 2021. Available from www.training.cochrane.org/handbook.">Deeks 2021</a>, see <a href="#CD013263-sec-0040">Sensitivity analysis</a>). </p> </section> <section id="CD013263-sec-0039"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We analyzed different doses (15 mg, 30 mg, and 60 mg) separately, if there were sufficient data. We also planned to analyze different surgeries if there were sufficient data, as postoperative pain levels and analgesic efficacy may differ (<a href="./references#CD013263-bbs2-0165" title="SommerM , De RijkeJM , Van KleefM , KesselsAG , PetersML , GeurtsJW , et al. The prevalence of postoperative pain in a sample of 1490 surgical inpatients. European Journal of Anaesthesiology2008;25(4):267-74.">Sommer 2008</a>). We planned to use the Z test to explore whether there were differences between subgroups (<a href="./references#CD013263-bbs2-0169" title="TramèrMR , ReynoldsDJ , MooreRA , McQuayHJ . Impact of covert duplicate results on meta-analysis: a case study. BMJ1997;315(7109):635-40. [DOI: 10.1136/bmj.315.7109.635]">Tramèr 1997</a>), if appropriate. </p> </section> <section id="CD013263-sec-0040"> <h4 class="title">Sensitivity analysis</h4> <p>For meta‐analyses with an I<sup>2</sup> score greater than 50%, we reanalyzed data using a random‐effects model. We preferentially present the data for these re‐analyses within the <a href="#CD013263-sec-0057">Effects of interventions</a> section rather than presenting them initially as fixed‐effect analyses. </p> </section> <section id="CD013263-sec-0041"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>Two review authors (EM, MF) independently rated the certainty of the evidence for each outcome. We used the GRADE system to rank the certainty of the evidence using GRADEprofiler Guideline Development Tool software (<a href="./references#CD013263-bbs2-0130" title="McMaster University (developed by Evidence Prime)GRADEpro Guideline Development Tool. Hamilton (ON): McMaster University (developed by Evidence Prime), 2015. Available from www.gradepro.org.">GRADEpro GDT 2015</a>), and the guidelines provided in the <i>Cochrane</i> <i>Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD013263-bbs2-0162" title="SchünemannHJ , HigginsJP , VistGE , GlasziouP , AklEA , SkoetzN , et al. Chapter 14: Completing ‘Summary of findings’ tables and grading the certainty of the evidence. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.2 (updated February 2021). The Cochrane Collaboration, 2021. Available from www.training.cochrane.org/handbook.">Schünemann 2021</a>). We reported our judgment on the certainty of evidence in the summary of findings tables. </p> <p>The GRADE approach uses five considerations (study limitations, consistency of effect, imprecision, indirectness, and publication bias) to assess the certainty of the body of evidence for each outcome. The GRADE system uses the following criteria for assigning grade of evidence. </p> <p> <ul id="CD013263-list-0009"> <li> <p>High: we are very confident that the true effect lies close to that of the estimate of the effect. </p> </li> <li> <p>Moderate: we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of effect, but there is a possibility that it is substantially different. </p> </li> <li> <p>Low: our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect. </p> </li> <li> <p>Very low: we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </li> </ul> </p> <p>The GRADE system uses the following criteria for assigning a certainty level to a body of evidence (<a href="./references#CD013263-bbs2-0162" title="SchünemannHJ , HigginsJP , VistGE , GlasziouP , AklEA , SkoetzN , et al. Chapter 14: Completing ‘Summary of findings’ tables and grading the certainty of the evidence. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.2 (updated February 2021). The Cochrane Collaboration, 2021. Available from www.training.cochrane.org/handbook.">Schünemann 2021</a>). </p> <p> <ul id="CD013263-list-0010"> <li> <p>High: randomized trials; or double upgraded observational studies.</p> </li> <li> <p>Moderate: downgraded randomized trials; or upgraded observational studies.</p> </li> <li> <p>Low: double‐downgraded randomized trials; or observational studies.</p> </li> <li> <p>Very low: triple‐downgraded randomized trials; or downgraded observational studies; or case series/case reports. </p> </li> </ul> </p> <p>Factors that may decrease the certainty level of a body of evidence are:</p> <p> <ul id="CD013263-list-0011"> <li> <p>limitations in the design and implementation of available studies suggesting high likelihood of bias; </p> </li> <li> <p>indirectness of evidence (indirect population, intervention, control, outcomes);</p> </li> <li> <p>unexplained heterogeneity or inconsistency of results (including problems with subgroup analyses); </p> </li> <li> <p>imprecision of results (wide CIs);</p> </li> <li> <p>high probability of publication bias.</p> </li> </ul> </p> <p>Factors that may increase the certainty level of a body of evidence are:</p> <p> <ul id="CD013263-list-0012"> <li> <p>large magnitude of effect;</p> </li> <li> <p>all plausible confounding would reduce a demonstrated effect or suggest a spurious effect when results show no effect; </p> </li> <li> <p>dose–response gradient.</p> </li> </ul> </p> <p>We decreased the grade rating by one (–1) or two (–2) (up to a maximum of –3 to 'very low') if we identified: </p> <p> <ul id="CD013263-list-0013"> <li> <p>serious (−1) or very serious (−2) limitation to study certainty;</p> </li> <li> <p>important inconsistency (−1);</p> </li> <li> <p>some (−1) or major (−2) uncertainty about directness;</p> </li> <li> <p>imprecise or sparse data (−1);</p> </li> <li> <p>high probability of reporting bias (−1).</p> </li> </ul> </p> <p>We paid particular attention to:</p> <p> <ul id="CD013263-list-0014"> <li> <p>inconsistency, where point estimates varied widely across studies or CIs of studies showed minimal or no overlap (<a href="./references#CD013263-bbs2-0132" title="GuyattGH , OxmanAD , KunzR , WoodcockJ , BrozekJ , HelfandM , et al. GRADE guidelines: 7. Rating the quality of evidence – inconsistency. Journal of Clinical Epidemiology2011;64(12):1294-302. [DOI: 10.1016/j.jclinepi.2011.03.017]">Guyatt 2011</a>); </p> </li> <li> <p>potential for publication bias, based on the amount of unpublished data required to make the result clinically irrelevant (<a href="./references#CD013263-bbs2-0154" title="MooreRA , BardenJ , DerryS , McQuayHJ . Managing potential publication bias. In: McQuayHJ , KalsoE , MooreRA , editors(s). Systematic Reviews in Pain Research: Methodology Refined. Seattle (WA): IASP Press, 2008:15-24. [978-0-931092-69-5]">Moore 2008</a>). </p> </li> </ul> </p> <p>In addition, there may be circumstances where the overall rating for a particular outcome needs to be adjusted as recommended by GRADE guidelines (<a href="./references#CD013263-bbs2-0133" title="GuyattG , OxmanAD , SultanS , BrozekJ , GlasziouP , Alonso-CoelloP , et al. GRADE guidelines: 11. Making an overall rating of confidence in effect estimates for a single outcome and for all outcomes. Journal of Clinical Epidemiology2013;66(2):151-7. [DOI: 10.1016/j.jclinepi.2012.01.006]">Guyatt 2013a</a>). For example, if there were so few data that the results are highly susceptible to the random play of chance, or if studies used LOCF imputation in circumstances where there were substantial differences in AE withdrawals, one would have no confidence in the result, and would need to downgrade the certainty of the evidence by three levels, to very low certainty. In circumstances where there were no data reported for an outcome, we reported the level of evidence as very low certainty (<a href="./references#CD013263-bbs2-0134" title="GuyattGH , OxmanAD , SantessoN , HelfandM , VistG , KunzR , et al. GRADE guidelines: 12. Preparing summary of findings tables – binary outcomes. Journal of Clinical Epidemiology2013;66(2):158-72. [DOI: 10.1016/j.jclinepi.2012.01.012]">Guyatt 2013b</a>). </p> <section id="CD013263-sec-0042"> <h5 class="title">Summary of findings tables</h5> <p>We include two summary of findings tables to present the main findings for comparisons with placebo and with an active comparator (another NSAID), in a transparent and simple tabular format. In particular, we included key information about the certainty of the evidence (using GRADE), the magnitude of effect of the interventions examined, and the sum of available data on the following outcomes: </p> <p> <ul id="CD013263-list-0015"> <li> <p>number of participants achieving at least 50% pain relief over a four‐hour period and over a six‐hour period; </p> </li> <li> <p>median or mean time to use of rescue medication;</p> </li> <li> <p>number of participants using rescue medication over a four‐ or six‐hour period;</p> </li> <li> <p>participants reporting any AE;</p> </li> <li> <p>participants experiencing any SAE.</p> </li> </ul> </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD013263-sec-0043" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD013263-sec-0043"></div> <section id="CD013263-sec-0044"> <h3 class="title">Description of studies</h3> <p>See <a href="./references#CD013263-sec-0146" title="">Characteristics of included studies</a>; <a href="./references#CD013263-sec-0147" title="">Characteristics of excluded studies</a>; Characteristics of studies awaiting classification; and <a href="./references#CD013263-sec-0148" title="">Characteristics of ongoing studies</a> tables. </p> <section id="CD013263-sec-0045"> <h4 class="title">Results of the search</h4> <p>Our literature search yielded 1499 references from CENTRAL, 1011 references from MEDLINE, 1528 references from Embase, and 6 from LILACS (a total of 2484 after de‐duplication). We reviewed the abstracts associated with these references and identified 100 potentially relevant studies, determining that the remaining references clearly did not meet our inclusion criteria. After full‐text review, we excluded 81 studies that did not meet our inclusion criteria. Our search of clinical trial websites yielded 70 ongoing or completed trials from <a href="http://ClinicalTrials.gov" target="_blank">ClinicalTrials.gov</a> and 531 studies from the WHO ICTRP. From these, we found no studies in addition to those already identified from our database searches (<a href="#CD013263-fig-0001">Figure 1</a>). </p> <div class="figure" id="CD013263-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD013263-fig-0001" src="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/image_n/nCD013263-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD013263-sec-0046"> <h4 class="title">Included studies</h4> <p>Twelve studies fulfilled our inclusion criteria (<a href="./references#CD013263-bbs2-0001" title="BalestrieriP , SimmonsG , HillD , BrownJ , JacksonA , Brull SJ , et al. The effect of intravenous ketorolac given intraoperatively versus postoperatively on outcome from gynecologic abdominal surgery. Journal of Clinical Anesthesia1997;9(5):358-64. ">Balestrieri 1997</a>; <a href="./references#CD013263-bbs2-0002" title="BartonS , LangelandF , SnabesM , LeComteD , KussM , DhaddaS , et al. Efficacy and safety of intravenous parecoxib sodium in relieving acute postoperative pain following gynecologic laparotomy surgery. Anesthesiology2002;97(2):306-14. ">Barton 2002</a>; <a href="./references#CD013263-bbs2-0003" title="BikhaziG , SnabesM , BajwaZ , DavisD , LeComteD , TraylorL , et al. A clinical trial demonstrates the analgesic activity of intravenous parecoxib sodium compared with ketorolac or morphine after gynecologic surgery with laparotomy. American Journal of Obstetrics and Gynecology2004;191(4):1183-91. ">Bikhazi 2004</a>; <a href="./references#CD013263-bbs2-0004" title="ChristensenK , DanielsS , BandyD , ErnstC , HamiltonD , MermelsteinF , et al. A double-blind placebo-controlled comparison of a novel formulation of intravenous diclofenac and ketorolac for postoperative third molar extraction pain. Anesthesia Progress2011;58(2):73-81. ">Christensen 2011</a>; <a href="./references#CD013263-bbs2-0005" title="GanT , DanielsS , SinglaN , HamiltonD , CarrD . A novel injectable formulation of diclofenac compared with intravenous ketorolac or placebo for acute moderate-to-severe pain after abdominal or pelvic surgery: a multicenter, double-blind, randomized, multiple-dose study. Anesthesia and Analgesia2012;115(5):1212-20. ">Gan 2012</a>; <a href="./references#CD013263-bbs2-0006" title="GonzalezC , MartinezJ , EsparzaV , MorenoL , CarreonJ . Comparison of intravenous ketorolac and butorphanol on ventilatory function and analgesia of pain after surgery. Proceedings of the Western Pharmacology Society1994;37:147-8. ">Gonzalez 1994</a>; <a href="./references#CD013263-bbs2-0007" title="MehlischD , DesjardinsP , DanielsS , HubbardR . Single doses of parecoxib sodium intravenously are as effective as ketorolac in reducing pain after oral surgery. Journal of Oral and Maxillofacial Surgery2003;61(9):1030-7. ">Mehlisch 2003</a>; <a href="./references#CD013263-bbs2-0008" title="MoodieJ , BisleyE , HuangS , PickthornK , BellG . A single-center, randomized, double-blind, active, and placebo-controlled study of KAI-1678, a novel PKC-epsilon inhibitor, in the treatment of acute postoperative orthopedic pain. Pain Medicine2013;14(6):916-24. ">Moodie 2013</a>; <a href="./references#CD013263-bbs2-0009" title="ParkeT , MillettS , OldS , GoodwinA , RiceA . Ketorolac for early postoperative analgesia. Journal of Clinical Anesthesia1995;7(6):465-9. ">Parke 1995</a>; <a href="./references#CD013263-bbs2-0010" title="RasmussenG , StecknerK , HogueC , TorriS , HubbardR . Intravenous parecoxib sodium for acute pain after orthopedic knee surgery. American Journal of Orthopedics2002;31(6):336-43. ">Rasmussen 2002</a>; <a href="./references#CD013263-bbs2-0011" title="RomundstadL , BreivikH , NiemiG , HelleA , StubhaugA . Methylprednisolone intravenously 1 day after surgery has sustained analgesic and opioid-sparing effects. Acta Anaesthesiologica Scandinavica2004;48(10):1223-31. ">Romundstad 2004</a>; <a href="./references#CD013263-bbs2-0012" title="ZhouT , TangJ , WhiteP . Propacetamol versus ketorolac for treatment of acute postoperative pain after total hip or knee replacement. Anesthesia and Analgesia2001;92(6):1569-75. ">Zhou 2001</a>). All but one study (<a href="./references#CD013263-bbs2-0006" title="GonzalezC , MartinezJ , EsparzaV , MorenoL , CarreonJ . Comparison of intravenous ketorolac and butorphanol on ventilatory function and analgesia of pain after surgery. Proceedings of the Western Pharmacology Society1994;37:147-8. ">Gonzalez 1994</a>) compared ketorolac with placebo. Six studies used another NSAID arm (<a href="./references#CD013263-bbs2-0002" title="BartonS , LangelandF , SnabesM , LeComteD , KussM , DhaddaS , et al. Efficacy and safety of intravenous parecoxib sodium in relieving acute postoperative pain following gynecologic laparotomy surgery. Anesthesiology2002;97(2):306-14. ">Barton 2002</a>; <a href="./references#CD013263-bbs2-0003" title="BikhaziG , SnabesM , BajwaZ , DavisD , LeComteD , TraylorL , et al. A clinical trial demonstrates the analgesic activity of intravenous parecoxib sodium compared with ketorolac or morphine after gynecologic surgery with laparotomy. American Journal of Obstetrics and Gynecology2004;191(4):1183-91. ">Bikhazi 2004</a>; <a href="./references#CD013263-bbs2-0004" title="ChristensenK , DanielsS , BandyD , ErnstC , HamiltonD , MermelsteinF , et al. A double-blind placebo-controlled comparison of a novel formulation of intravenous diclofenac and ketorolac for postoperative third molar extraction pain. Anesthesia Progress2011;58(2):73-81. ">Christensen 2011</a>; <a href="./references#CD013263-bbs2-0005" title="GanT , DanielsS , SinglaN , HamiltonD , CarrD . A novel injectable formulation of diclofenac compared with intravenous ketorolac or placebo for acute moderate-to-severe pain after abdominal or pelvic surgery: a multicenter, double-blind, randomized, multiple-dose study. Anesthesia and Analgesia2012;115(5):1212-20. ">Gan 2012</a>; <a href="./references#CD013263-bbs2-0007" title="MehlischD , DesjardinsP , DanielsS , HubbardR . Single doses of parecoxib sodium intravenously are as effective as ketorolac in reducing pain after oral surgery. Journal of Oral and Maxillofacial Surgery2003;61(9):1030-7. ">Mehlisch 2003</a>; <a href="./references#CD013263-bbs2-0010" title="RasmussenG , StecknerK , HogueC , TorriS , HubbardR . Intravenous parecoxib sodium for acute pain after orthopedic knee surgery. American Journal of Orthopedics2002;31(6):336-43. ">Rasmussen 2002</a>) and four included an opioid arm (<a href="./references#CD013263-bbs2-0002" title="BartonS , LangelandF , SnabesM , LeComteD , KussM , DhaddaS , et al. Efficacy and safety of intravenous parecoxib sodium in relieving acute postoperative pain following gynecologic laparotomy surgery. Anesthesiology2002;97(2):306-14. ">Barton 2002</a>; <a href="./references#CD013263-bbs2-0003" title="BikhaziG , SnabesM , BajwaZ , DavisD , LeComteD , TraylorL , et al. A clinical trial demonstrates the analgesic activity of intravenous parecoxib sodium compared with ketorolac or morphine after gynecologic surgery with laparotomy. American Journal of Obstetrics and Gynecology2004;191(4):1183-91. ">Bikhazi 2004</a>; <a href="./references#CD013263-bbs2-0006" title="GonzalezC , MartinezJ , EsparzaV , MorenoL , CarreonJ . Comparison of intravenous ketorolac and butorphanol on ventilatory function and analgesia of pain after surgery. Proceedings of the Western Pharmacology Society1994;37:147-8. ">Gonzalez 1994</a>; <a href="./references#CD013263-bbs2-0010" title="RasmussenG , StecknerK , HogueC , TorriS , HubbardR . Intravenous parecoxib sodium for acute pain after orthopedic knee surgery. American Journal of Orthopedics2002;31(6):336-43. ">Rasmussen 2002</a>). </p> <p>Eight trials were conducted in the USA (<a href="./references#CD013263-bbs2-0001" title="BalestrieriP , SimmonsG , HillD , BrownJ , JacksonA , Brull SJ , et al. The effect of intravenous ketorolac given intraoperatively versus postoperatively on outcome from gynecologic abdominal surgery. Journal of Clinical Anesthesia1997;9(5):358-64. ">Balestrieri 1997</a>; <a href="./references#CD013263-bbs2-0002" title="BartonS , LangelandF , SnabesM , LeComteD , KussM , DhaddaS , et al. Efficacy and safety of intravenous parecoxib sodium in relieving acute postoperative pain following gynecologic laparotomy surgery. Anesthesiology2002;97(2):306-14. ">Barton 2002</a>; <a href="./references#CD013263-bbs2-0003" title="BikhaziG , SnabesM , BajwaZ , DavisD , LeComteD , TraylorL , et al. A clinical trial demonstrates the analgesic activity of intravenous parecoxib sodium compared with ketorolac or morphine after gynecologic surgery with laparotomy. American Journal of Obstetrics and Gynecology2004;191(4):1183-91. ">Bikhazi 2004</a>; <a href="./references#CD013263-bbs2-0004" title="ChristensenK , DanielsS , BandyD , ErnstC , HamiltonD , MermelsteinF , et al. A double-blind placebo-controlled comparison of a novel formulation of intravenous diclofenac and ketorolac for postoperative third molar extraction pain. Anesthesia Progress2011;58(2):73-81. ">Christensen 2011</a>; <a href="./references#CD013263-bbs2-0005" title="GanT , DanielsS , SinglaN , HamiltonD , CarrD . A novel injectable formulation of diclofenac compared with intravenous ketorolac or placebo for acute moderate-to-severe pain after abdominal or pelvic surgery: a multicenter, double-blind, randomized, multiple-dose study. Anesthesia and Analgesia2012;115(5):1212-20. ">Gan 2012</a>; <a href="./references#CD013263-bbs2-0007" title="MehlischD , DesjardinsP , DanielsS , HubbardR . Single doses of parecoxib sodium intravenously are as effective as ketorolac in reducing pain after oral surgery. Journal of Oral and Maxillofacial Surgery2003;61(9):1030-7. ">Mehlisch 2003</a>; <a href="./references#CD013263-bbs2-0010" title="RasmussenG , StecknerK , HogueC , TorriS , HubbardR . Intravenous parecoxib sodium for acute pain after orthopedic knee surgery. American Journal of Orthopedics2002;31(6):336-43. ">Rasmussen 2002</a>; <a href="./references#CD013263-bbs2-0012" title="ZhouT , TangJ , WhiteP . Propacetamol versus ketorolac for treatment of acute postoperative pain after total hip or knee replacement. Anesthesia and Analgesia2001;92(6):1569-75. ">Zhou 2001</a>), one in Mexico (<a href="./references#CD013263-bbs2-0006" title="GonzalezC , MartinezJ , EsparzaV , MorenoL , CarreonJ . Comparison of intravenous ketorolac and butorphanol on ventilatory function and analgesia of pain after surgery. Proceedings of the Western Pharmacology Society1994;37:147-8. ">Gonzalez 1994</a>), one in New Zealand (<a href="./references#CD013263-bbs2-0008" title="MoodieJ , BisleyE , HuangS , PickthornK , BellG . A single-center, randomized, double-blind, active, and placebo-controlled study of KAI-1678, a novel PKC-epsilon inhibitor, in the treatment of acute postoperative orthopedic pain. Pain Medicine2013;14(6):916-24. ">Moodie 2013</a>), one in England (<a href="./references#CD013263-bbs2-0009" title="ParkeT , MillettS , OldS , GoodwinA , RiceA . Ketorolac for early postoperative analgesia. Journal of Clinical Anesthesia1995;7(6):465-9. ">Parke 1995</a>) and one in Norway (<a href="./references#CD013263-bbs2-0011" title="RomundstadL , BreivikH , NiemiG , HelleA , StubhaugA . Methylprednisolone intravenously 1 day after surgery has sustained analgesic and opioid-sparing effects. Acta Anaesthesiologica Scandinavica2004;48(10):1223-31. ">Romundstad 2004</a>). Total enrollment ranged from 53 to 353 participants, with the number of participants in each study receiving ketorolac ranging from 17 to 83, placebo 25 to 82, another NSAID 29 to 255 and an opioid 40 to 60. Where reported, mean study population ages ranged from 22.5 years (<a href="./references#CD013263-bbs2-0007" title="MehlischD , DesjardinsP , DanielsS , HubbardR . Single doses of parecoxib sodium intravenously are as effective as ketorolac in reducing pain after oral surgery. Journal of Oral and Maxillofacial Surgery2003;61(9):1030-7. ">Mehlisch 2003</a>), to 67.4 years, (<a href="./references#CD013263-bbs2-0010" title="RasmussenG , StecknerK , HogueC , TorriS , HubbardR . Intravenous parecoxib sodium for acute pain after orthopedic knee surgery. American Journal of Orthopedics2002;31(6):336-43. ">Rasmussen 2002</a>), with most studies having mean ages between 40 and 45 years. The ages of participants generally reflected the type of surgical procedure; for example <a href="./references#CD013263-bbs2-0007" title="MehlischD , DesjardinsP , DanielsS , HubbardR . Single doses of parecoxib sodium intravenously are as effective as ketorolac in reducing pain after oral surgery. Journal of Oral and Maxillofacial Surgery2003;61(9):1030-7. ">Mehlisch 2003</a> using a dental model enrolled younger participants, whereas orthopedic procedures enrolled older participants. Two studies enrolled participants undergoing dental surgery (third molar extraction; <a href="./references#CD013263-bbs2-0004" title="ChristensenK , DanielsS , BandyD , ErnstC , HamiltonD , MermelsteinF , et al. A double-blind placebo-controlled comparison of a novel formulation of intravenous diclofenac and ketorolac for postoperative third molar extraction pain. Anesthesia Progress2011;58(2):73-81. ">Christensen 2011</a>; <a href="./references#CD013263-bbs2-0007" title="MehlischD , DesjardinsP , DanielsS , HubbardR . Single doses of parecoxib sodium intravenously are as effective as ketorolac in reducing pain after oral surgery. Journal of Oral and Maxillofacial Surgery2003;61(9):1030-7. ">Mehlisch 2003</a>); five studies enrolled participants undergoing abdominal/pelvic surgeries (<a href="./references#CD013263-bbs2-0001" title="BalestrieriP , SimmonsG , HillD , BrownJ , JacksonA , Brull SJ , et al. The effect of intravenous ketorolac given intraoperatively versus postoperatively on outcome from gynecologic abdominal surgery. Journal of Clinical Anesthesia1997;9(5):358-64. ">Balestrieri 1997</a>; <a href="./references#CD013263-bbs2-0002" title="BartonS , LangelandF , SnabesM , LeComteD , KussM , DhaddaS , et al. Efficacy and safety of intravenous parecoxib sodium in relieving acute postoperative pain following gynecologic laparotomy surgery. Anesthesiology2002;97(2):306-14. ">Barton 2002</a>; <a href="./references#CD013263-bbs2-0003" title="BikhaziG , SnabesM , BajwaZ , DavisD , LeComteD , TraylorL , et al. A clinical trial demonstrates the analgesic activity of intravenous parecoxib sodium compared with ketorolac or morphine after gynecologic surgery with laparotomy. American Journal of Obstetrics and Gynecology2004;191(4):1183-91. ">Bikhazi 2004</a>; <a href="./references#CD013263-bbs2-0005" title="GanT , DanielsS , SinglaN , HamiltonD , CarrD . A novel injectable formulation of diclofenac compared with intravenous ketorolac or placebo for acute moderate-to-severe pain after abdominal or pelvic surgery: a multicenter, double-blind, randomized, multiple-dose study. Anesthesia and Analgesia2012;115(5):1212-20. ">Gan 2012</a>; <a href="./references#CD013263-bbs2-0006" title="GonzalezC , MartinezJ , EsparzaV , MorenoL , CarreonJ . Comparison of intravenous ketorolac and butorphanol on ventilatory function and analgesia of pain after surgery. Proceedings of the Western Pharmacology Society1994;37:147-8. ">Gonzalez 1994</a>); and five studies assessed participants undergoing orthopedic procedures (<a href="./references#CD013263-bbs2-0008" title="MoodieJ , BisleyE , HuangS , PickthornK , BellG . A single-center, randomized, double-blind, active, and placebo-controlled study of KAI-1678, a novel PKC-epsilon inhibitor, in the treatment of acute postoperative orthopedic pain. Pain Medicine2013;14(6):916-24. ">Moodie 2013</a>; <a href="./references#CD013263-bbs2-0009" title="ParkeT , MillettS , OldS , GoodwinA , RiceA . Ketorolac for early postoperative analgesia. Journal of Clinical Anesthesia1995;7(6):465-9. ">Parke 1995</a>; <a href="./references#CD013263-bbs2-0010" title="RasmussenG , StecknerK , HogueC , TorriS , HubbardR . Intravenous parecoxib sodium for acute pain after orthopedic knee surgery. American Journal of Orthopedics2002;31(6):336-43. ">Rasmussen 2002</a>; <a href="./references#CD013263-bbs2-0011" title="RomundstadL , BreivikH , NiemiG , HelleA , StubhaugA . Methylprednisolone intravenously 1 day after surgery has sustained analgesic and opioid-sparing effects. Acta Anaesthesiologica Scandinavica2004;48(10):1223-31. ">Romundstad 2004</a>; <a href="./references#CD013263-bbs2-0012" title="ZhouT , TangJ , WhiteP . Propacetamol versus ketorolac for treatment of acute postoperative pain after total hip or knee replacement. Anesthesia and Analgesia2001;92(6):1569-75. ">Zhou 2001</a>).<br/>Nine studies were funded in part or entirely by the manufacturers of one of the interventions; one study was funded by a grant (<a href="./references#CD013263-bbs2-0012" title="ZhouT , TangJ , WhiteP . Propacetamol versus ketorolac for treatment of acute postoperative pain after total hip or knee replacement. Anesthesia and Analgesia2001;92(6):1569-75. ">Zhou 2001</a>). Two studies did not report funding (<a href="./references#CD013263-bbs2-0006" title="GonzalezC , MartinezJ , EsparzaV , MorenoL , CarreonJ . Comparison of intravenous ketorolac and butorphanol on ventilatory function and analgesia of pain after surgery. Proceedings of the Western Pharmacology Society1994;37:147-8. ">Gonzalez 1994</a>; <a href="./references#CD013263-bbs2-0011" title="RomundstadL , BreivikH , NiemiG , HelleA , StubhaugA . Methylprednisolone intravenously 1 day after surgery has sustained analgesic and opioid-sparing effects. Acta Anaesthesiologica Scandinavica2004;48(10):1223-31. ">Romundstad 2004</a>).<br/>Study designs were similar: participants received one of the assigned interventions after reporting moderate‐to‐severe pain postoperatively, and outcomes such as pain relief, pain intensity difference, or time to use of rescue medication were assessed. The exception was <a href="./references#CD013263-bbs2-0001" title="BalestrieriP , SimmonsG , HillD , BrownJ , JacksonA , Brull SJ , et al. The effect of intravenous ketorolac given intraoperatively versus postoperatively on outcome from gynecologic abdominal surgery. Journal of Clinical Anesthesia1997;9(5):358-64. ">Balestrieri 1997</a>, where participants were scheduled to receive interventions regardless of report of postoperative pain. In this study participants in both groups had mean categorical pain intensity of 2.3 at baseline (2 = moderate). </p> <p>In most studies the dose of ketorolac administered was 30 mg. <a href="./references#CD013263-bbs2-0001" title="BalestrieriP , SimmonsG , HillD , BrownJ , JacksonA , Brull SJ , et al. The effect of intravenous ketorolac given intraoperatively versus postoperatively on outcome from gynecologic abdominal surgery. Journal of Clinical Anesthesia1997;9(5):358-64. ">Balestrieri 1997</a> administered 60 mg and <a href="./references#CD013263-bbs2-0012" title="ZhouT , TangJ , WhiteP . Propacetamol versus ketorolac for treatment of acute postoperative pain after total hip or knee replacement. Anesthesia and Analgesia2001;92(6):1569-75. ">Zhou 2001</a> administered both 15 and 30 mg doses. </p> <section id="CD013263-sec-0047"> <h5 class="title">Ongoing studies</h5> <p>Seven trials were ongoing at the time of completion of our review. One study published its protocol in a medical journal (<a href="./references#CD013263-bbs2-0094" title="ClausC , LytleE , TongD , SiglerD , LagoD , BahouraM , et al. The effect of ketorolac on posterior thoracolumbar spinal fusions: a prospective double-blinded randomised placebo-controlled trial protocol. BMJ Open2019;9(1):e025855. ">Claus 2019</a>). The other studies are available on clinical trial websites (<a href="./references#CD013263-bbs2-0095" title="Irct201607271674N. Treatment of postoperative pain with intravenous ketorolac in mandibular fracture surgery. www.who.int/trialsearch/Trial2.aspx?TrialID=IRCT201607271674N13 (first received 6 August 2016). ">Irct201607271674N 2016</a>; <a href="./references#CD013263-bbs2-0096" title="Irct2017041033350N. Effect of ketorolac and paracetamol on pain control after hernia surgery. www.who.int/trialsearch/Trial2.aspx?TrialID=IRCT2017041033350N1 (first received 4 May 2017). ">Irct2017041033350N 2017</a>; <a href="./references#CD013263-bbs2-0097" title="Irct20171003036530N. Comparison the effect of IV ibuprofen and IV ketorolac on post operation pain. www.who.int/trialsearch/Trial2.aspx?TrialID=IRCT20171003036530N2 (first received 3 September 2018). ">Irct20171003036530N 2018</a>; <a href="./references#CD013263-bbs2-0098" title="Irct20180909040979N. Comparison of the effect of intravenous ketorolac and paracetamol on pain. www.who.int/trialsearch/Trial2.aspx?TrialID=IRCT20180909040979N4 (first received 12 September 2019). ">Irct20180909040979N 2019</a>; <a href="./references#CD013263-bbs2-0099" title="NCT02700451. Post-op acetaminophen vs NSAID use on lumbar spinal fusion outcomes. clinicaltrials.gov/show/nct02700451 (first posted 7 March 2016). ">NCT02700451</a>; <a href="./references#CD013263-bbs2-0100" title="NCT03823534. Post-op pain control for prophylactic intramedullary nailing. clinicaltrials.gov/show/NCT03823534 (first posted 30 January 2019). ">NCT03823534</a>). <a href="./references#CD013263-bbs2-0094" title="ClausC , LytleE , TongD , SiglerD , LagoD , BahouraM , et al. The effect of ketorolac on posterior thoracolumbar spinal fusions: a prospective double-blinded randomised placebo-controlled trial protocol. BMJ Open2019;9(1):e025855. ">Claus 2019</a> is primarily a safety trial. Its primary outcome is to demonstrate that the use of ketorolac does not decrease thoracolumbar spinal fusion rates postoperatively. It intends to enroll at least 300 participants in each arm (ketorolac or placebo). The remaining six are efficacy studies with targeted enrollments ranging from 60 to 300 participants and primary outcomes assessing pain intensity and opioid use. Ketorolac doses range from 15 mg in participants over 65 years to 30 mg in younger participants. In addition to orthopedic and abdominal populations (<a href="./references#CD013263-bbs2-0095" title="Irct201607271674N. Treatment of postoperative pain with intravenous ketorolac in mandibular fracture surgery. www.who.int/trialsearch/Trial2.aspx?TrialID=IRCT201607271674N13 (first received 6 August 2016). ">Irct201607271674N 2016</a>; <a href="./references#CD013263-bbs2-0096" title="Irct2017041033350N. Effect of ketorolac and paracetamol on pain control after hernia surgery. www.who.int/trialsearch/Trial2.aspx?TrialID=IRCT2017041033350N1 (first received 4 May 2017). ">Irct2017041033350N 2017</a>; <a href="./references#CD013263-bbs2-0097" title="Irct20171003036530N. Comparison the effect of IV ibuprofen and IV ketorolac on post operation pain. www.who.int/trialsearch/Trial2.aspx?TrialID=IRCT20171003036530N2 (first received 3 September 2018). ">Irct20171003036530N 2018</a>; <a href="./references#CD013263-bbs2-0099" title="NCT02700451. Post-op acetaminophen vs NSAID use on lumbar spinal fusion outcomes. clinicaltrials.gov/show/nct02700451 (first posted 7 March 2016). ">NCT02700451</a>; <a href="./references#CD013263-bbs2-0100" title="NCT03823534. Post-op pain control for prophylactic intramedullary nailing. clinicaltrials.gov/show/NCT03823534 (first posted 30 January 2019). ">NCT03823534</a>), pain after coronary artery bypass graft (<a href="./references#CD013263-bbs2-0098" title="Irct20180909040979N. Comparison of the effect of intravenous ketorolac and paracetamol on pain. www.who.int/trialsearch/Trial2.aspx?TrialID=IRCT20180909040979N4 (first received 12 September 2019). ">Irct20180909040979N 2019</a>) will also be assessed. </p> </section> </section> <section id="CD013263-sec-0048"> <h4 class="title">Excluded studies</h4> <p>Eighty‐one studies did not meet all of our inclusion criteria (<a href="#CD013263-fig-0001">Figure 1</a>). Common reasons included multiple‐dose studies that did not present data from the first dose separately, studies where we could not establish that all participants had moderate‐to‐severe pain at baseline, and studies with ineligible route or timing of administration. We excluded two trials posted on clinical trial websites as they had started enrolling participants more than five years ago, but had still not posted results (<a href="./references#CD013263-bbs2-0049" title="nct00293631. Study of lornoxicam or ketorolac or placebo for post-operative pain after bunionectomy. clinicaltrials.gov/show/nct00293631 (first posted February 17, 2006). ">NCT00293631</a>; <a href="./references#CD013263-bbs2-0051" title="nct00845754. Post-operative treatment with ketorolac after abdominal myomectomy. clinicaltrials.gov/show/nct00845754 (first posted February 18, 2009). ">NCT00845754</a>). We excluded two studies as the corresponding publication was not available from any source (<a href="./references#CD013263-bbs2-0020" title="BrownC , WildV , BynumL . Comparison of intravenous ketorolac tromethamine and morphine sulfate in postoperative pain. International Journal of Clinical Pharmacology and Therapeutics1988;43(2):142. ">Brown 1988</a>; <a href="./references#CD013263-bbs2-0037" title="HegazyE , El-HadyN , AbdallahM . Comparative study of postoperative analgesic effects of parecoxib versus ketorolac and placebo in cervical disc surgery. Egyptian Journal of Anaesthesia2003;19(2):179-82. ">Hegazy 2003</a>). </p> </section> </section> <section id="CD013263-sec-0049"> <h3 class="title">Risk of bias in included studies</h3> <p>Our findings are summarized in <a href="#CD013263-fig-0002">Figure 2</a> and <a href="#CD013263-fig-0003">Figure 3</a>. </p> <div class="figure" id="CD013263-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD013263-fig-0002" src="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/image_n/nCD013263-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD013263-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD013263-fig-0003" src="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/image_n/nCD013263-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD013263-sec-0050"> <h4 class="title">Allocation</h4> <section id="CD013263-sec-0051"> <h5 class="title">Random sequence generation</h5> <p>All studies reported that they were randomized, and all but two described adequate methods of randomization, that is by computer‐generated numbers or a table of random numbers. <a href="./references#CD013263-bbs2-0006" title="GonzalezC , MartinezJ , EsparzaV , MorenoL , CarreonJ . Comparison of intravenous ketorolac and butorphanol on ventilatory function and analgesia of pain after surgery. Proceedings of the Western Pharmacology Society1994;37:147-8. ">Gonzalez 1994</a> and <a href="./references#CD013263-bbs2-0007" title="MehlischD , DesjardinsP , DanielsS , HubbardR . Single doses of parecoxib sodium intravenously are as effective as ketorolac in reducing pain after oral surgery. Journal of Oral and Maxillofacial Surgery2003;61(9):1030-7. ">Mehlisch 2003</a> offered no description of how randomization was performed. </p> </section> <section id="CD013263-sec-0052"> <h5 class="title">Allocation concealment</h5> <p>Only one study described adequate allocation concealment (<a href="./references#CD013263-bbs2-0011" title="RomundstadL , BreivikH , NiemiG , HelleA , StubhaugA . Methylprednisolone intravenously 1 day after surgery has sustained analgesic and opioid-sparing effects. Acta Anaesthesiologica Scandinavica2004;48(10):1223-31. ">Romundstad 2004</a>). Participants in this study were assigned according to information in opaque envelopes marked with consecutive patient numbers only. In the remaining articles, allocation concealment was not mentioned. </p> </section> </section> <section id="CD013263-sec-0053"> <h4 class="title">Blinding</h4> <p>Four studies described adequate methods of blinding both investigators and participants (<a href="./references#CD013263-bbs2-0004" title="ChristensenK , DanielsS , BandyD , ErnstC , HamiltonD , MermelsteinF , et al. A double-blind placebo-controlled comparison of a novel formulation of intravenous diclofenac and ketorolac for postoperative third molar extraction pain. Anesthesia Progress2011;58(2):73-81. ">Christensen 2011</a>; <a href="./references#CD013263-bbs2-0008" title="MoodieJ , BisleyE , HuangS , PickthornK , BellG . A single-center, randomized, double-blind, active, and placebo-controlled study of KAI-1678, a novel PKC-epsilon inhibitor, in the treatment of acute postoperative orthopedic pain. Pain Medicine2013;14(6):916-24. ">Moodie 2013</a>; <a href="./references#CD013263-bbs2-0009" title="ParkeT , MillettS , OldS , GoodwinA , RiceA . Ketorolac for early postoperative analgesia. Journal of Clinical Anesthesia1995;7(6):465-9. ">Parke 1995</a>; <a href="./references#CD013263-bbs2-0012" title="ZhouT , TangJ , WhiteP . Propacetamol versus ketorolac for treatment of acute postoperative pain after total hip or knee replacement. Anesthesia and Analgesia2001;92(6):1569-75. ">Zhou 2001</a>). Although none of the articles explicitly stated that the interventions were indistinguishable from each other, methods used to ensure blinding were described in sufficient detail (e.g. double‐dummy technique) for us to believe that neither the investigator nor the study participant would have been able to discriminate interventions based on their appearance. We assessed the remaining studies as having an unclear risk of bias, either because they did not describe methods of blinding in any way, because their descriptions were inadequate for us to determine whether investigators or participants would have been able to distinguish interventions, or because they only described how participants were blinded. One study (<a href="./references#CD013263-bbs2-0011" title="RomundstadL , BreivikH , NiemiG , HelleA , StubhaugA . Methylprednisolone intravenously 1 day after surgery has sustained analgesic and opioid-sparing effects. Acta Anaesthesiologica Scandinavica2004;48(10):1223-31. ">Romundstad 2004</a>) appeared to have used adequate methods to blind participants and investigators, but most were able to guess if they had received or administered, respectively, an active or placebo intervention. </p> </section> <section id="CD013263-sec-0054"> <h4 class="title">Incomplete outcome data</h4> <p>We assessed six studies as having a low risk (<a href="./references#CD013263-bbs2-0003" title="BikhaziG , SnabesM , BajwaZ , DavisD , LeComteD , TraylorL , et al. A clinical trial demonstrates the analgesic activity of intravenous parecoxib sodium compared with ketorolac or morphine after gynecologic surgery with laparotomy. American Journal of Obstetrics and Gynecology2004;191(4):1183-91. ">Bikhazi 2004</a>; <a href="./references#CD013263-bbs2-0005" title="GanT , DanielsS , SinglaN , HamiltonD , CarrD . A novel injectable formulation of diclofenac compared with intravenous ketorolac or placebo for acute moderate-to-severe pain after abdominal or pelvic surgery: a multicenter, double-blind, randomized, multiple-dose study. Anesthesia and Analgesia2012;115(5):1212-20. ">Gan 2012</a>; <a href="./references#CD013263-bbs2-0007" title="MehlischD , DesjardinsP , DanielsS , HubbardR . Single doses of parecoxib sodium intravenously are as effective as ketorolac in reducing pain after oral surgery. Journal of Oral and Maxillofacial Surgery2003;61(9):1030-7. ">Mehlisch 2003</a>; <a href="./references#CD013263-bbs2-0008" title="MoodieJ , BisleyE , HuangS , PickthornK , BellG . A single-center, randomized, double-blind, active, and placebo-controlled study of KAI-1678, a novel PKC-epsilon inhibitor, in the treatment of acute postoperative orthopedic pain. Pain Medicine2013;14(6):916-24. ">Moodie 2013</a>; <a href="./references#CD013263-bbs2-0009" title="ParkeT , MillettS , OldS , GoodwinA , RiceA . Ketorolac for early postoperative analgesia. Journal of Clinical Anesthesia1995;7(6):465-9. ">Parke 1995</a>; <a href="./references#CD013263-bbs2-0011" title="RomundstadL , BreivikH , NiemiG , HelleA , StubhaugA . Methylprednisolone intravenously 1 day after surgery has sustained analgesic and opioid-sparing effects. Acta Anaesthesiologica Scandinavica2004;48(10):1223-31. ">Romundstad 2004</a>), and the remaining six studies as having an unclear risk of attrition bias. For the former, ITT analyses were used or all participants completed the study, or both. Missing data were appropriately imputed. For the latter, this was primarily because they did not describe how missing data were imputed. <a href="./references#CD013263-bbs2-0006" title="GonzalezC , MartinezJ , EsparzaV , MorenoL , CarreonJ . Comparison of intravenous ketorolac and butorphanol on ventilatory function and analgesia of pain after surgery. Proceedings of the Western Pharmacology Society1994;37:147-8. ">Gonzalez 1994</a> did not present AE data separately for each intervention group. Withdrawal rates were generally low across studies. </p> </section> <section id="CD013263-sec-0055"> <h4 class="title">Selective reporting</h4> <p>Seven of the 12 studies had a low risk of reporting bias. While published protocols were generally not available for these studies, all outcomes listed in their Methods section were those that we would expect from similar studies and were reported in full in the Results section. We assessed one study as having a high risk of bias. In <a href="./references#CD013263-bbs2-0008" title="MoodieJ , BisleyE , HuangS , PickthornK , BellG . A single-center, randomized, double-blind, active, and placebo-controlled study of KAI-1678, a novel PKC-epsilon inhibitor, in the treatment of acute postoperative orthopedic pain. Pain Medicine2013;14(6):916-24. ">Moodie 2013</a>, secondary outcomes assessed were inconsistent between the published protocol and study report. We assessed the remaining four studies as having unclear risk of bias, mostly due to incomplete reporting of secondary outcomes, such as only displaying some results graphically. </p> </section> <section id="CD013263-sec-0056"> <h4 class="title">Other potential sources of bias</h4> <p>The major threat to reliability was the small size of the studies. Only three studies enrolled at least 50 participants in each arm and we assessed these as having an unclear risk of bias due to sample size (<a href="./references#CD013263-bbs2-0001" title="BalestrieriP , SimmonsG , HillD , BrownJ , JacksonA , Brull SJ , et al. The effect of intravenous ketorolac given intraoperatively versus postoperatively on outcome from gynecologic abdominal surgery. Journal of Clinical Anesthesia1997;9(5):358-64. ">Balestrieri 1997</a>; <a href="./references#CD013263-bbs2-0005" title="GanT , DanielsS , SinglaN , HamiltonD , CarrD . A novel injectable formulation of diclofenac compared with intravenous ketorolac or placebo for acute moderate-to-severe pain after abdominal or pelvic surgery: a multicenter, double-blind, randomized, multiple-dose study. Anesthesia and Analgesia2012;115(5):1212-20. ">Gan 2012</a>; <a href="./references#CD013263-bbs2-0006" title="GonzalezC , MartinezJ , EsparzaV , MorenoL , CarreonJ . Comparison of intravenous ketorolac and butorphanol on ventilatory function and analgesia of pain after surgery. Proceedings of the Western Pharmacology Society1994;37:147-8. ">Gonzalez 1994</a>). The highest number of participants in a single ketorolac group was 83 in <a href="./references#CD013263-bbs2-0001" title="BalestrieriP , SimmonsG , HillD , BrownJ , JacksonA , Brull SJ , et al. The effect of intravenous ketorolac given intraoperatively versus postoperatively on outcome from gynecologic abdominal surgery. Journal of Clinical Anesthesia1997;9(5):358-64. ">Balestrieri 1997</a>. The remaining studies had fewer than 50 participants in at least one arm of the study, with <a href="./references#CD013263-bbs2-0008" title="MoodieJ , BisleyE , HuangS , PickthornK , BellG . A single-center, randomized, double-blind, active, and placebo-controlled study of KAI-1678, a novel PKC-epsilon inhibitor, in the treatment of acute postoperative orthopedic pain. Pain Medicine2013;14(6):916-24. ">Moodie 2013</a> administering ketorolac to only 17 participants. We assessed these studies as having a high risk of bias. </p> </section> </section> <section id="CD013263-sec-0057"> <h3 class="title" id="CD013263-sec-0057">Effects of interventions</h3> <p>See: <a href="./full#CD013263-tbl-0001"><b>Summary of findings 1</b> Intravenous ketorolac compared to placebo for adults with acute postoperative pain</a>; <a href="./full#CD013263-tbl-0002"><b>Summary of findings 2</b> Intravenous ketorolac compared to another NSAID for adults with acute postoperative pain</a> </p> <p>See <a href="./full#CD013263-tbl-0001">summary of findings Table 1</a> for outcomes for the main comparison, ketorolac versus placebo, and <a href="./full#CD013263-tbl-0002">summary of findings Table 2</a> for the comparison of ketorolac versus another NSAID. All 12 included studies provided usable data for analysis. However, we did not use all data in meta‐analysis, either because there was only one study for a given outcome, or there were too few participants or events for a given outcome. </p> <section id="CD013263-sec-0058"> <h4 class="title">1. Ketorolac versus placebo</h4> <section id="CD013263-sec-0059"> <h5 class="title">Proportion of participants achieving at least 50% postoperative pain relief over a four‐hour period and over a six‐hour period </h5> <p>Only two studies reported numbers of participants achieving this outcome directly, and only over the six‐hour time period (<a href="./references#CD013263-bbs2-0005" title="GanT , DanielsS , SinglaN , HamiltonD , CarrD . A novel injectable formulation of diclofenac compared with intravenous ketorolac or placebo for acute moderate-to-severe pain after abdominal or pelvic surgery: a multicenter, double-blind, randomized, multiple-dose study. Anesthesia and Analgesia2012;115(5):1212-20. ">Gan 2012</a>; <a href="./references#CD013263-bbs2-0011" title="RomundstadL , BreivikH , NiemiG , HelleA , StubhaugA . Methylprednisolone intravenously 1 day after surgery has sustained analgesic and opioid-sparing effects. Acta Anaesthesiologica Scandinavica2004;48(10):1223-31. ">Romundstad 2004</a>). <a href="./references#CD013263-bbs2-0005" title="GanT , DanielsS , SinglaN , HamiltonD , CarrD . A novel injectable formulation of diclofenac compared with intravenous ketorolac or placebo for acute moderate-to-severe pain after abdominal or pelvic surgery: a multicenter, double-blind, randomized, multiple-dose study. Anesthesia and Analgesia2012;115(5):1212-20. ">Gan 2012</a> reported the number of participants achieving at least 30% pain relief; we used this as a surrogate value. For the remaining studies we derived numbers, using the equations described earlier (<a href="#CD013263-sec-0038">Data synthesis</a>) from tables or figures. Eight studies (658 participants) compared ketorolac 30 mg (<a href="./references#CD013263-bbs2-0002" title="BartonS , LangelandF , SnabesM , LeComteD , KussM , DhaddaS , et al. Efficacy and safety of intravenous parecoxib sodium in relieving acute postoperative pain following gynecologic laparotomy surgery. Anesthesiology2002;97(2):306-14. ">Barton 2002</a>; <a href="./references#CD013263-bbs2-0003" title="BikhaziG , SnabesM , BajwaZ , DavisD , LeComteD , TraylorL , et al. A clinical trial demonstrates the analgesic activity of intravenous parecoxib sodium compared with ketorolac or morphine after gynecologic surgery with laparotomy. American Journal of Obstetrics and Gynecology2004;191(4):1183-91. ">Bikhazi 2004</a>; <a href="./references#CD013263-bbs2-0007" title="MehlischD , DesjardinsP , DanielsS , HubbardR . Single doses of parecoxib sodium intravenously are as effective as ketorolac in reducing pain after oral surgery. Journal of Oral and Maxillofacial Surgery2003;61(9):1030-7. ">Mehlisch 2003</a>; <a href="./references#CD013263-bbs2-0008" title="MoodieJ , BisleyE , HuangS , PickthornK , BellG . A single-center, randomized, double-blind, active, and placebo-controlled study of KAI-1678, a novel PKC-epsilon inhibitor, in the treatment of acute postoperative orthopedic pain. Pain Medicine2013;14(6):916-24. ">Moodie 2013</a>; <a href="./references#CD013263-bbs2-0010" title="RasmussenG , StecknerK , HogueC , TorriS , HubbardR . Intravenous parecoxib sodium for acute pain after orthopedic knee surgery. American Journal of Orthopedics2002;31(6):336-43. ">Rasmussen 2002</a>; <a href="./references#CD013263-bbs2-0011" title="RomundstadL , BreivikH , NiemiG , HelleA , StubhaugA . Methylprednisolone intravenously 1 day after surgery has sustained analgesic and opioid-sparing effects. Acta Anaesthesiologica Scandinavica2004;48(10):1223-31. ">Romundstad 2004</a>; <a href="./references#CD013263-bbs2-0012" title="ZhouT , TangJ , WhiteP . Propacetamol versus ketorolac for treatment of acute postoperative pain after total hip or knee replacement. Anesthesia and Analgesia2001;92(6):1569-75. ">Zhou 2001</a>) or 60 mg (<a href="./references#CD013263-bbs2-0001" title="BalestrieriP , SimmonsG , HillD , BrownJ , JacksonA , Brull SJ , et al. The effect of intravenous ketorolac given intraoperatively versus postoperatively on outcome from gynecologic abdominal surgery. Journal of Clinical Anesthesia1997;9(5):358-64. ">Balestrieri 1997</a>) versus placebo over four hours post‐administration of interventions. </p> <p> <ul id="CD013263-list-0016"> <li> <p>The proportion of participants with at least 50% pain relief with ketorolac was 57% (177/309, range 35% to 82%). </p> </li> <li> <p>The proportion of participants with at least 50% pain relief with placebo was 19% (67/349, range 0 to 39%). </p> </li> <li> <p>The relative benefit of treatment compared with placebo was 2.81 (95% confidence interval (CI) 1.80 to 4.37); the number needed to treat for an additional beneficial outcome (NNTB) for one additional participant to benefit compared with placebo was 2.4 (95% CI 1.8 to 3.7) (<a href="./references#CD013263-fig-0004" title="">Analysis 1.1</a>). </p> </li> </ul> </p> <p>Ten studies (914 participants) compared ketorolac 30 mg (<a href="./references#CD013263-bbs2-0002" title="BartonS , LangelandF , SnabesM , LeComteD , KussM , DhaddaS , et al. Efficacy and safety of intravenous parecoxib sodium in relieving acute postoperative pain following gynecologic laparotomy surgery. Anesthesiology2002;97(2):306-14. ">Barton 2002</a>; <a href="./references#CD013263-bbs2-0003" title="BikhaziG , SnabesM , BajwaZ , DavisD , LeComteD , TraylorL , et al. A clinical trial demonstrates the analgesic activity of intravenous parecoxib sodium compared with ketorolac or morphine after gynecologic surgery with laparotomy. American Journal of Obstetrics and Gynecology2004;191(4):1183-91. ">Bikhazi 2004</a>; <a href="./references#CD013263-bbs2-0004" title="ChristensenK , DanielsS , BandyD , ErnstC , HamiltonD , MermelsteinF , et al. A double-blind placebo-controlled comparison of a novel formulation of intravenous diclofenac and ketorolac for postoperative third molar extraction pain. Anesthesia Progress2011;58(2):73-81. ">Christensen 2011</a>; <a href="./references#CD013263-bbs2-0005" title="GanT , DanielsS , SinglaN , HamiltonD , CarrD . A novel injectable formulation of diclofenac compared with intravenous ketorolac or placebo for acute moderate-to-severe pain after abdominal or pelvic surgery: a multicenter, double-blind, randomized, multiple-dose study. Anesthesia and Analgesia2012;115(5):1212-20. ">Gan 2012</a>; <a href="./references#CD013263-bbs2-0007" title="MehlischD , DesjardinsP , DanielsS , HubbardR . Single doses of parecoxib sodium intravenously are as effective as ketorolac in reducing pain after oral surgery. Journal of Oral and Maxillofacial Surgery2003;61(9):1030-7. ">Mehlisch 2003</a>; <a href="./references#CD013263-bbs2-0008" title="MoodieJ , BisleyE , HuangS , PickthornK , BellG . A single-center, randomized, double-blind, active, and placebo-controlled study of KAI-1678, a novel PKC-epsilon inhibitor, in the treatment of acute postoperative orthopedic pain. Pain Medicine2013;14(6):916-24. ">Moodie 2013</a>; <a href="./references#CD013263-bbs2-0010" title="RasmussenG , StecknerK , HogueC , TorriS , HubbardR . Intravenous parecoxib sodium for acute pain after orthopedic knee surgery. American Journal of Orthopedics2002;31(6):336-43. ">Rasmussen 2002</a>; <a href="./references#CD013263-bbs2-0011" title="RomundstadL , BreivikH , NiemiG , HelleA , StubhaugA . Methylprednisolone intravenously 1 day after surgery has sustained analgesic and opioid-sparing effects. Acta Anaesthesiologica Scandinavica2004;48(10):1223-31. ">Romundstad 2004</a>; <a href="./references#CD013263-bbs2-0012" title="ZhouT , TangJ , WhiteP . Propacetamol versus ketorolac for treatment of acute postoperative pain after total hip or knee replacement. Anesthesia and Analgesia2001;92(6):1569-75. ">Zhou 2001</a>), or 60 mg (<a href="./references#CD013263-bbs2-0001" title="BalestrieriP , SimmonsG , HillD , BrownJ , JacksonA , Brull SJ , et al. The effect of intravenous ketorolac given intraoperatively versus postoperatively on outcome from gynecologic abdominal surgery. Journal of Clinical Anesthesia1997;9(5):358-64. ">Balestrieri 1997</a>), versus placebo over six hours post‐administration of interventions. </p> <p> <ul id="CD013263-list-0017"> <li> <p>The proportion of participants with at least 50% pain relief with ketorolac was 61% (266/438, range 36% to 77%). </p> </li> <li> <p>The proportion of participants with at least 50% pain relief with placebo was 23% (110/476, range 0 to 55%). </p> </li> <li> <p>The relative benefit of treatment compared with placebo was 3.26 (95% CI 1.93 to 5.51); the NNTB for one additional participant to benefit compared with placebo was 2.5 (95% CI 1.9 to 3.7) (<a href="./references#CD013263-fig-0005" title="">Analysis 1.2</a>). </p> </li> </ul> </p> <p>We assessed the certainty of evidence for this outcome as very low over four hours, and low over six hours. We downgraded certainty over four hours based on unclear risk of bias for several domains among the included studies (study limitations), unexplained heterogeneity among studies (important inconsistency), and a low total number of participants in the analysis (imprecision). We downgraded certainty over six hours due to unclear risk of bias for several domains among the included studies (study limitations) and unexplained heterogeneity among studies.  </p> </section> <section id="CD013263-sec-0060"> <h5 class="title">Time to use of rescue medication</h5> <p>This outcome examined the time from taking study medication to use of rescue medication. A longer time to use of rescue medication indicates a longer duration of analgesia from the assigned intervention. Not all studies reported relevant data; of those that did, all but one (<a href="./references#CD013263-bbs2-0011" title="RomundstadL , BreivikH , NiemiG , HelleA , StubhaugA . Methylprednisolone intravenously 1 day after surgery has sustained analgesic and opioid-sparing effects. Acta Anaesthesiologica Scandinavica2004;48(10):1223-31. ">Romundstad 2004</a>) reported median times to remedication, rather than means. </p> <p>For the comparison of IV ketorolac versus placebo, the median time to use of rescue medication was 271 minutes for ketorolac and 104 minutes for placebo (6 studies, 633 participants) (<a href="./references#CD013263-bbs2-0001" title="BalestrieriP , SimmonsG , HillD , BrownJ , JacksonA , Brull SJ , et al. The effect of intravenous ketorolac given intraoperatively versus postoperatively on outcome from gynecologic abdominal surgery. Journal of Clinical Anesthesia1997;9(5):358-64. ">Balestrieri 1997</a>; <a href="./references#CD013263-bbs2-0003" title="BikhaziG , SnabesM , BajwaZ , DavisD , LeComteD , TraylorL , et al. A clinical trial demonstrates the analgesic activity of intravenous parecoxib sodium compared with ketorolac or morphine after gynecologic surgery with laparotomy. American Journal of Obstetrics and Gynecology2004;191(4):1183-91. ">Bikhazi 2004</a>; <a href="./references#CD013263-bbs2-0005" title="GanT , DanielsS , SinglaN , HamiltonD , CarrD . A novel injectable formulation of diclofenac compared with intravenous ketorolac or placebo for acute moderate-to-severe pain after abdominal or pelvic surgery: a multicenter, double-blind, randomized, multiple-dose study. Anesthesia and Analgesia2012;115(5):1212-20. ">Gan 2012</a>; <a href="./references#CD013263-bbs2-0007" title="MehlischD , DesjardinsP , DanielsS , HubbardR . Single doses of parecoxib sodium intravenously are as effective as ketorolac in reducing pain after oral surgery. Journal of Oral and Maxillofacial Surgery2003;61(9):1030-7. ">Mehlisch 2003</a>; <a href="./references#CD013263-bbs2-0010" title="RasmussenG , StecknerK , HogueC , TorriS , HubbardR . Intravenous parecoxib sodium for acute pain after orthopedic knee surgery. American Journal of Orthopedics2002;31(6):336-43. ">Rasmussen 2002</a>; <a href="./references#CD013263-bbs2-0012" title="ZhouT , TangJ , WhiteP . Propacetamol versus ketorolac for treatment of acute postoperative pain after total hip or knee replacement. Anesthesia and Analgesia2001;92(6):1569-75. ">Zhou 2001</a>). In almost all of these studies, time to rescue was longer in those participants assigned to ketorolac. We judged the certainty of evidence as moderate, downgrading once for both unclear risk of bias for several domains among the included studies (study limitations) and for imprecision, and upgrading once for large magnitude of effect. </p> </section> <section id="CD013263-sec-0061"> <h5 class="title">Number of participants using rescue medication over a four‐ or six‐hour period</h5> <p>This outcome assessed the need for rescue analgesia in the period immediately after administering the assigned interventions. </p> <p>Five studies (417 participants) included comparisons of ketorolac with placebo (<a href="./references#CD013263-bbs2-0002" title="BartonS , LangelandF , SnabesM , LeComteD , KussM , DhaddaS , et al. Efficacy and safety of intravenous parecoxib sodium in relieving acute postoperative pain following gynecologic laparotomy surgery. Anesthesiology2002;97(2):306-14. ">Barton 2002</a>; <a href="./references#CD013263-bbs2-0003" title="BikhaziG , SnabesM , BajwaZ , DavisD , LeComteD , TraylorL , et al. A clinical trial demonstrates the analgesic activity of intravenous parecoxib sodium compared with ketorolac or morphine after gynecologic surgery with laparotomy. American Journal of Obstetrics and Gynecology2004;191(4):1183-91. ">Bikhazi 2004</a>; <a href="./references#CD013263-bbs2-0004" title="ChristensenK , DanielsS , BandyD , ErnstC , HamiltonD , MermelsteinF , et al. A double-blind placebo-controlled comparison of a novel formulation of intravenous diclofenac and ketorolac for postoperative third molar extraction pain. Anesthesia Progress2011;58(2):73-81. ">Christensen 2011</a>; <a href="./references#CD013263-bbs2-0009" title="ParkeT , MillettS , OldS , GoodwinA , RiceA . Ketorolac for early postoperative analgesia. Journal of Clinical Anesthesia1995;7(6):465-9. ">Parke 1995</a><a href="./references#CD013263-bbs2-0012" title="ZhouT , TangJ , WhiteP . Propacetamol versus ketorolac for treatment of acute postoperative pain after total hip or knee replacement. Anesthesia and Analgesia2001;92(6):1569-75. ">Zhou 2001</a>). </p> <p> <ul id="CD013263-list-0018"> <li> <p>The proportion of participants using rescue medication with ketorolac was 54% (105/194, range 26% to 93%). </p> </li> <li> <p>The proportion of participants using rescue medication with placebo was 83% (185/223, range 73% to 97%). </p> </li> <li> <p>The risk ratio of treatment compared with placebo was 0.60 (95% CI 0.36 to 1.00), that is, there is no evidence of a difference (<a href="./references#CD013263-fig-0006" title="">Analysis 1.3</a>). This meta‐analysis had substantial heterogeneity, as demonstrated by an I<sup>2</sup> score of 95%.  </p> </li> </ul> </p> <p>We judged the certainty of evidence for this outcome as very low, due to downgrading once for each of unclear risk of bias for several domains among the included studies (study limitations), unexplained heterogeneity (I<sup>2</sup> = 95%) and the low total number of events (imprecision). </p> </section> <section id="CD013263-sec-0062"> <h5 class="title">Withdrawals due to adverse events, lack of efficacy, and for any cause</h5> <p>In addition to study limitations, numbers of participants withdrawing were generally low, and reasons for withdrawal were inconsistently reported. We therefore judged the certainty of evidence for these outcomes to be very low. </p> <p> <ul id="CD013263-list-0019"> <li> <p>The proportion of participants withdrawing due to AEs was 2% (11/452) with ketorolac versus 2% (8/493) with placebo (<a href="./references#CD013263-fig-0007" title="">Analysis 1.4</a>: RR 1.31, 95% CI 0.56 to 3.06; 10 studies, 945 participants). </p> </li> <li> <p>The proportion of participants withdrawing due to lack of efficacy was 3% (10/339) with ketorolac versus 3% (12/359) with placebo (<a href="./references#CD013263-fig-0008" title="">Analysis 1.5</a>; RR 0.81, 95% CI 0.36 to 1.78; 7 studies, 698 participants). Most withdrawals occurred in one study (<a href="./references#CD013263-bbs2-0005" title="GanT , DanielsS , SinglaN , HamiltonD , CarrD . A novel injectable formulation of diclofenac compared with intravenous ketorolac or placebo for acute moderate-to-severe pain after abdominal or pelvic surgery: a multicenter, double-blind, randomized, multiple-dose study. Anesthesia and Analgesia2012;115(5):1212-20. ">Gan 2012</a>). </p> </li> <li> <p>The proportion of participants withdrawing for any cause was 6% (19/307) with ketorolac versus 7% (24/327) with placebo (<a href="./references#CD013263-fig-0009" title="">Analysis 1.6</a>; RR 0.80, 95% CI 0.47 to 1.36; 7 studies, 634 participants). Most withdrawals occurred in one study (<a href="./references#CD013263-bbs2-0005" title="GanT , DanielsS , SinglaN , HamiltonD , CarrD . A novel injectable formulation of diclofenac compared with intravenous ketorolac or placebo for acute moderate-to-severe pain after abdominal or pelvic surgery: a multicenter, double-blind, randomized, multiple-dose study. Anesthesia and Analgesia2012;115(5):1212-20. ">Gan 2012</a>), primarily due to participants' requests. </p> </li> </ul> </p> </section> <section id="CD013263-sec-0063"> <h5 class="title">Participants experiencing any adverse event</h5> <p>Not all studies reported the number of participants experiencing any AE. The time over which AEs were measured varied. In one multiple‐dose study (<a href="./references#CD013263-bbs2-0005" title="GanT , DanielsS , SinglaN , HamiltonD , CarrD . A novel injectable formulation of diclofenac compared with intravenous ketorolac or placebo for acute moderate-to-severe pain after abdominal or pelvic surgery: a multicenter, double-blind, randomized, multiple-dose study. Anesthesia and Analgesia2012;115(5):1212-20. ">Gan 2012</a>), AEs were measured through the end of the study (five to nine days after baseline observations). </p> <p>Eight studies (810 participants) included comparisons of ketorolac versus placebo (<a href="./references#CD013263-bbs2-0001" title="BalestrieriP , SimmonsG , HillD , BrownJ , JacksonA , Brull SJ , et al. The effect of intravenous ketorolac given intraoperatively versus postoperatively on outcome from gynecologic abdominal surgery. Journal of Clinical Anesthesia1997;9(5):358-64. ">Balestrieri 1997</a>; <a href="./references#CD013263-bbs2-0002" title="BartonS , LangelandF , SnabesM , LeComteD , KussM , DhaddaS , et al. Efficacy and safety of intravenous parecoxib sodium in relieving acute postoperative pain following gynecologic laparotomy surgery. Anesthesiology2002;97(2):306-14. ">Barton 2002</a>; <a href="./references#CD013263-bbs2-0003" title="BikhaziG , SnabesM , BajwaZ , DavisD , LeComteD , TraylorL , et al. A clinical trial demonstrates the analgesic activity of intravenous parecoxib sodium compared with ketorolac or morphine after gynecologic surgery with laparotomy. American Journal of Obstetrics and Gynecology2004;191(4):1183-91. ">Bikhazi 2004</a>; <a href="./references#CD013263-bbs2-0005" title="GanT , DanielsS , SinglaN , HamiltonD , CarrD . A novel injectable formulation of diclofenac compared with intravenous ketorolac or placebo for acute moderate-to-severe pain after abdominal or pelvic surgery: a multicenter, double-blind, randomized, multiple-dose study. Anesthesia and Analgesia2012;115(5):1212-20. ">Gan 2012</a>; <a href="./references#CD013263-bbs2-0007" title="MehlischD , DesjardinsP , DanielsS , HubbardR . Single doses of parecoxib sodium intravenously are as effective as ketorolac in reducing pain after oral surgery. Journal of Oral and Maxillofacial Surgery2003;61(9):1030-7. ">Mehlisch 2003</a>; <a href="./references#CD013263-bbs2-0008" title="MoodieJ , BisleyE , HuangS , PickthornK , BellG . A single-center, randomized, double-blind, active, and placebo-controlled study of KAI-1678, a novel PKC-epsilon inhibitor, in the treatment of acute postoperative orthopedic pain. Pain Medicine2013;14(6):916-24. ">Moodie 2013</a>; <a href="./references#CD013263-bbs2-0010" title="RasmussenG , StecknerK , HogueC , TorriS , HubbardR . Intravenous parecoxib sodium for acute pain after orthopedic knee surgery. American Journal of Orthopedics2002;31(6):336-43. ">Rasmussen 2002</a>; <a href="./references#CD013263-bbs2-0012" title="ZhouT , TangJ , WhiteP . Propacetamol versus ketorolac for treatment of acute postoperative pain after total hip or knee replacement. Anesthesia and Analgesia2001;92(6):1569-75. ">Zhou 2001</a>). </p> <p> <ul id="CD013263-list-0020"> <li> <p>The proportion of participants reporting an AE with ketorolac was 74% (286/385).</p> </li> <li> <p>The proportion of participants reporting an AE with placebo was 65% (275/425).</p> </li> <li> <p>The risk ratio of treatment compared with placebo was 1.09 (95% CI 1.00 to 1.19); the NNTH was 16.7 (95% CI 8.3 to infinite) (<a href="./references#CD013263-fig-0010" title="">Analysis 1.7</a>). </p> </li> </ul> </p> <p>We assessed the certainty of evidence for comparisons with placebo as moderate, based on unclear risk of bias in several domains for the included studies (study limitations). </p> </section> <section id="CD013263-sec-0064"> <h5 class="title">Participants experiencing any serious adverse event</h5> <p>In those studies that reported them, SAEs were very rare (<a href="./references#CD013263-fig-0011" title="">Analysis 1.8</a>). We assessed the certainty of evidence for this outcome as low, based on the very low event rates (imprecision) and unclear risk of bias for several domains in the included studies (study limitations). Eight studies (703 participants) did not demonstrate a difference in SAE rates between ketorolac and placebo (RR 0.62, 95% CI 0.13 to 3.03) (<a href="./references#CD013263-bbs2-0002" title="BartonS , LangelandF , SnabesM , LeComteD , KussM , DhaddaS , et al. Efficacy and safety of intravenous parecoxib sodium in relieving acute postoperative pain following gynecologic laparotomy surgery. Anesthesiology2002;97(2):306-14. ">Barton 2002</a>; <a href="./references#CD013263-bbs2-0003" title="BikhaziG , SnabesM , BajwaZ , DavisD , LeComteD , TraylorL , et al. A clinical trial demonstrates the analgesic activity of intravenous parecoxib sodium compared with ketorolac or morphine after gynecologic surgery with laparotomy. American Journal of Obstetrics and Gynecology2004;191(4):1183-91. ">Bikhazi 2004</a>; <a href="./references#CD013263-bbs2-0004" title="ChristensenK , DanielsS , BandyD , ErnstC , HamiltonD , MermelsteinF , et al. A double-blind placebo-controlled comparison of a novel formulation of intravenous diclofenac and ketorolac for postoperative third molar extraction pain. Anesthesia Progress2011;58(2):73-81. ">Christensen 2011</a>; <a href="./references#CD013263-bbs2-0005" title="GanT , DanielsS , SinglaN , HamiltonD , CarrD . A novel injectable formulation of diclofenac compared with intravenous ketorolac or placebo for acute moderate-to-severe pain after abdominal or pelvic surgery: a multicenter, double-blind, randomized, multiple-dose study. Anesthesia and Analgesia2012;115(5):1212-20. ">Gan 2012</a>; <a href="./references#CD013263-bbs2-0007" title="MehlischD , DesjardinsP , DanielsS , HubbardR . Single doses of parecoxib sodium intravenously are as effective as ketorolac in reducing pain after oral surgery. Journal of Oral and Maxillofacial Surgery2003;61(9):1030-7. ">Mehlisch 2003</a>; <a href="./references#CD013263-bbs2-0008" title="MoodieJ , BisleyE , HuangS , PickthornK , BellG . A single-center, randomized, double-blind, active, and placebo-controlled study of KAI-1678, a novel PKC-epsilon inhibitor, in the treatment of acute postoperative orthopedic pain. Pain Medicine2013;14(6):916-24. ">Moodie 2013</a>; <a href="./references#CD013263-bbs2-0009" title="ParkeT , MillettS , OldS , GoodwinA , RiceA . Ketorolac for early postoperative analgesia. Journal of Clinical Anesthesia1995;7(6):465-9. ">Parke 1995</a>; <a href="./references#CD013263-bbs2-0011" title="RomundstadL , BreivikH , NiemiG , HelleA , StubhaugA . Methylprednisolone intravenously 1 day after surgery has sustained analgesic and opioid-sparing effects. Acta Anaesthesiologica Scandinavica2004;48(10):1223-31. ">Romundstad 2004</a>). Only one participant administered ketorolac suffered an SAE (<a href="./references#CD013263-bbs2-0005" title="GanT , DanielsS , SinglaN , HamiltonD , CarrD . A novel injectable formulation of diclofenac compared with intravenous ketorolac or placebo for acute moderate-to-severe pain after abdominal or pelvic surgery: a multicenter, double-blind, randomized, multiple-dose study. Anesthesia and Analgesia2012;115(5):1212-20. ">Gan 2012</a>). The participant experienced an abdominal hematoma, which was considered to be possibly treatment‐related. Four participants receiving placebo experienced an SAE: appendicitis, which was assessed as being unrelated to therapy (<a href="./references#CD013263-bbs2-0004" title="ChristensenK , DanielsS , BandyD , ErnstC , HamiltonD , MermelsteinF , et al. A double-blind placebo-controlled comparison of a novel formulation of intravenous diclofenac and ketorolac for postoperative third molar extraction pain. Anesthesia Progress2011;58(2):73-81. ">Christensen 2011</a>); a left knee joint hematoma in one participant; a wound infection in the right hip with cellulitis in one participant (both considered procedure‐related); and thrombus formation in the peroneal vein, which was resolved with thrombolysis therapy (<a href="./references#CD013263-bbs2-0008" title="MoodieJ , BisleyE , HuangS , PickthornK , BellG . A single-center, randomized, double-blind, active, and placebo-controlled study of KAI-1678, a novel PKC-epsilon inhibitor, in the treatment of acute postoperative orthopedic pain. Pain Medicine2013;14(6):916-24. ">Moodie 2013</a>). No participants receiving another NSAID experienced an SAE. Two participants receiving an opioid suffered an SAE: pulmonary emboli and persistent nausea and vomiting, both of which were considered unrelated to treatment. </p> </section> <section id="CD013263-sec-0065"> <h5 class="title">Specific adverse events</h5> <p>Methods of assessment and the reporting of specific AEs were inconsistent across studies, as was the time over which the information was collected. Our AEs of interest were NSAID‐related (renal dysfunction, cardiovascular events, gastrointestinal or operative‐site bleeding, and thrombophlebitis) or opioid‐related (nausea, vomiting, nausea and vomiting, pruritus, respiratory depression, sedation, urinary retention, and allergic reaction/rashes). These AEs occurred infrequently in all groups, with the exception of nausea, vomiting, itching and sedation amongst the opioid‐related AEs. Other than for these four outcomes, there were insufficient data for meta‐analysis. As with our analysis of SAEs, we assessed the certainty of evidence for the four meta‐analyses as low. Where there were so few events or studies that meta‐analysis was precluded, we assessed the certainty of evidence as very low. </p> <section id="CD013263-sec-0066"> <h6 class="title">Renal dysfunction</h6> <p>Only one study reported assessing renal dysfunction (<a href="./references#CD013263-bbs2-0005" title="GanT , DanielsS , SinglaN , HamiltonD , CarrD . A novel injectable formulation of diclofenac compared with intravenous ketorolac or placebo for acute moderate-to-severe pain after abdominal or pelvic surgery: a multicenter, double-blind, randomized, multiple-dose study. Anesthesia and Analgesia2012;115(5):1212-20. ">Gan 2012</a>). No participants in either of the intervention groups experienced this AE. </p> </section> <section id="CD013263-sec-0067"> <h6 class="title">Cardiovascular events</h6> <p>In the two studies that reported cardiovascular events (<a href="./references#CD013263-bbs2-0001" title="BalestrieriP , SimmonsG , HillD , BrownJ , JacksonA , Brull SJ , et al. The effect of intravenous ketorolac given intraoperatively versus postoperatively on outcome from gynecologic abdominal surgery. Journal of Clinical Anesthesia1997;9(5):358-64. ">Balestrieri 1997</a>; <a href="./references#CD013263-bbs2-0005" title="GanT , DanielsS , SinglaN , HamiltonD , CarrD . A novel injectable formulation of diclofenac compared with intravenous ketorolac or placebo for acute moderate-to-severe pain after abdominal or pelvic surgery: a multicenter, double-blind, randomized, multiple-dose study. Anesthesia and Analgesia2012;115(5):1212-20. ">Gan 2012</a>), 13% (21/165) of participants receiving ketorolac experienced an event versus 11% (18/158) of participants receiving placebo. Most of the AEs occurred in <a href="./references#CD013263-bbs2-0001" title="BalestrieriP , SimmonsG , HillD , BrownJ , JacksonA , Brull SJ , et al. The effect of intravenous ketorolac given intraoperatively versus postoperatively on outcome from gynecologic abdominal surgery. Journal of Clinical Anesthesia1997;9(5):358-64. ">Balestrieri 1997</a>. Cardiovascular events in this study were defined as bradycardia, tachycardia, hypotension, and hypertension. In the other study in which cardiovascular events occurred (not defined), none were considered to be treatment‐related (<a href="./references#CD013263-bbs2-0005" title="GanT , DanielsS , SinglaN , HamiltonD , CarrD . A novel injectable formulation of diclofenac compared with intravenous ketorolac or placebo for acute moderate-to-severe pain after abdominal or pelvic surgery: a multicenter, double-blind, randomized, multiple-dose study. Anesthesia and Analgesia2012;115(5):1212-20. ">Gan 2012</a>) (<a href="./references#CD013263-fig-0012" title="">Analysis 1.9</a>). </p> </section> <section id="CD013263-sec-0068"> <h6 class="title">Gastrointestinal bleeding</h6> <p>In the one study that reported gastrointestinal bleeding, 1% of participants (1/82) receiving ketorolac experienced clinically significant bleeding versus none of those receiving placebo (<a href="./references#CD013263-bbs2-0005" title="GanT , DanielsS , SinglaN , HamiltonD , CarrD . A novel injectable formulation of diclofenac compared with intravenous ketorolac or placebo for acute moderate-to-severe pain after abdominal or pelvic surgery: a multicenter, double-blind, randomized, multiple-dose study. Anesthesia and Analgesia2012;115(5):1212-20. ">Gan 2012</a>). </p> </section> <section id="CD013263-sec-0069"> <h6 class="title">Operative‐site bleeding</h6> <p>Two studies reported operative‐site bleeding (<a href="./references#CD013263-bbs2-0005" title="GanT , DanielsS , SinglaN , HamiltonD , CarrD . A novel injectable formulation of diclofenac compared with intravenous ketorolac or placebo for acute moderate-to-severe pain after abdominal or pelvic surgery: a multicenter, double-blind, randomized, multiple-dose study. Anesthesia and Analgesia2012;115(5):1212-20. ">Gan 2012</a>; <a href="./references#CD013263-bbs2-0012" title="ZhouT , TangJ , WhiteP . Propacetamol versus ketorolac for treatment of acute postoperative pain after total hip or knee replacement. Anesthesia and Analgesia2001;92(6):1569-75. ">Zhou 2001</a>). Four per cent (4/110) of those receiving ketorolac experienced this AE versus 1% (1/131) of those receiving placebo (<a href="./references#CD013263-fig-0013" title="">Analysis 1.10</a>).  </p> </section> <section id="CD013263-sec-0070"> <h6 class="title">Thrombophlebitis</h6> <p>Both studies that assessed thrombophlebitis used a six‐point scale (grade 0 = "no reaction" to grade 5 = "thrombosis with overt infection") and defined events as occurring in participants with a score of more than 1 (<a href="./references#CD013263-bbs2-0004" title="ChristensenK , DanielsS , BandyD , ErnstC , HamiltonD , MermelsteinF , et al. A double-blind placebo-controlled comparison of a novel formulation of intravenous diclofenac and ketorolac for postoperative third molar extraction pain. Anesthesia Progress2011;58(2):73-81. ">Christensen 2011</a>; <a href="./references#CD013263-bbs2-0005" title="GanT , DanielsS , SinglaN , HamiltonD , CarrD . A novel injectable formulation of diclofenac compared with intravenous ketorolac or placebo for acute moderate-to-severe pain after abdominal or pelvic surgery: a multicenter, double-blind, randomized, multiple-dose study. Anesthesia and Analgesia2012;115(5):1212-20. ">Gan 2012</a>). No events occurred in <a href="./references#CD013263-bbs2-0004" title="ChristensenK , DanielsS , BandyD , ErnstC , HamiltonD , MermelsteinF , et al. A double-blind placebo-controlled comparison of a novel formulation of intravenous diclofenac and ketorolac for postoperative third molar extraction pain. Anesthesia Progress2011;58(2):73-81. ">Christensen 2011</a>. In <a href="./references#CD013263-bbs2-0005" title="GanT , DanielsS , SinglaN , HamiltonD , CarrD . A novel injectable formulation of diclofenac compared with intravenous ketorolac or placebo for acute moderate-to-severe pain after abdominal or pelvic surgery: a multicenter, double-blind, randomized, multiple-dose study. Anesthesia and Analgesia2012;115(5):1212-20. ">Gan 2012</a> 7% (6/82) receiving ketorolac versus 12% (9/76) receiving placebo were assessed as experiencing this AE (<a href="./references#CD013263-fig-0014" title="">Analysis 1.11</a>). </p> </section> <section id="CD013263-sec-0071"> <h6 class="title">Nausea, vomiting or both</h6> <p>Eight studies (798 participants) compared rates of nausea with ketorolac versus placebo (<a href="./references#CD013263-bbs2-0001" title="BalestrieriP , SimmonsG , HillD , BrownJ , JacksonA , Brull SJ , et al. The effect of intravenous ketorolac given intraoperatively versus postoperatively on outcome from gynecologic abdominal surgery. Journal of Clinical Anesthesia1997;9(5):358-64. ">Balestrieri 1997</a>; <a href="./references#CD013263-bbs2-0002" title="BartonS , LangelandF , SnabesM , LeComteD , KussM , DhaddaS , et al. Efficacy and safety of intravenous parecoxib sodium in relieving acute postoperative pain following gynecologic laparotomy surgery. Anesthesiology2002;97(2):306-14. ">Barton 2002</a>; <a href="./references#CD013263-bbs2-0003" title="BikhaziG , SnabesM , BajwaZ , DavisD , LeComteD , TraylorL , et al. A clinical trial demonstrates the analgesic activity of intravenous parecoxib sodium compared with ketorolac or morphine after gynecologic surgery with laparotomy. American Journal of Obstetrics and Gynecology2004;191(4):1183-91. ">Bikhazi 2004</a>; <a href="./references#CD013263-bbs2-0005" title="GanT , DanielsS , SinglaN , HamiltonD , CarrD . A novel injectable formulation of diclofenac compared with intravenous ketorolac or placebo for acute moderate-to-severe pain after abdominal or pelvic surgery: a multicenter, double-blind, randomized, multiple-dose study. Anesthesia and Analgesia2012;115(5):1212-20. ">Gan 2012</a>; <a href="./references#CD013263-bbs2-0007" title="MehlischD , DesjardinsP , DanielsS , HubbardR . Single doses of parecoxib sodium intravenously are as effective as ketorolac in reducing pain after oral surgery. Journal of Oral and Maxillofacial Surgery2003;61(9):1030-7. ">Mehlisch 2003</a>; <a href="./references#CD013263-bbs2-0009" title="ParkeT , MillettS , OldS , GoodwinA , RiceA . Ketorolac for early postoperative analgesia. Journal of Clinical Anesthesia1995;7(6):465-9. ">Parke 1995</a>; <a href="./references#CD013263-bbs2-0010" title="RasmussenG , StecknerK , HogueC , TorriS , HubbardR . Intravenous parecoxib sodium for acute pain after orthopedic knee surgery. American Journal of Orthopedics2002;31(6):336-43. ">Rasmussen 2002</a>; <a href="./references#CD013263-bbs2-0011" title="RomundstadL , BreivikH , NiemiG , HelleA , StubhaugA . Methylprednisolone intravenously 1 day after surgery has sustained analgesic and opioid-sparing effects. Acta Anaesthesiologica Scandinavica2004;48(10):1223-31. ">Romundstad 2004</a>). </p> <p> <ul id="CD013263-list-0021"> <li> <p>The proportion of participants reporting nausea with ketorolac was 34% (138/402, range 12% to 67%). </p> </li> <li> <p>The proportion of participants reporting nausea with placebo was 39% (154/396, range 16% to 78%). </p> </li> <li> <p>The risk ratio of treatment compared with placebo was 0.88 (95% CI 0.75 to 1.04); there was no evidence of a difference (<a href="./references#CD013263-fig-0015" title="">Analysis 1.12</a>). </p> </li> </ul> </p> <p>Seven studies (724 participants) compared rates of vomiting with ketorolac versus placebo (<a href="./references#CD013263-bbs2-0001" title="BalestrieriP , SimmonsG , HillD , BrownJ , JacksonA , Brull SJ , et al. The effect of intravenous ketorolac given intraoperatively versus postoperatively on outcome from gynecologic abdominal surgery. Journal of Clinical Anesthesia1997;9(5):358-64. ">Balestrieri 1997</a>; <a href="./references#CD013263-bbs2-0002" title="BartonS , LangelandF , SnabesM , LeComteD , KussM , DhaddaS , et al. Efficacy and safety of intravenous parecoxib sodium in relieving acute postoperative pain following gynecologic laparotomy surgery. Anesthesiology2002;97(2):306-14. ">Barton 2002</a>; <a href="./references#CD013263-bbs2-0003" title="BikhaziG , SnabesM , BajwaZ , DavisD , LeComteD , TraylorL , et al. A clinical trial demonstrates the analgesic activity of intravenous parecoxib sodium compared with ketorolac or morphine after gynecologic surgery with laparotomy. American Journal of Obstetrics and Gynecology2004;191(4):1183-91. ">Bikhazi 2004</a>; <a href="./references#CD013263-bbs2-0005" title="GanT , DanielsS , SinglaN , HamiltonD , CarrD . A novel injectable formulation of diclofenac compared with intravenous ketorolac or placebo for acute moderate-to-severe pain after abdominal or pelvic surgery: a multicenter, double-blind, randomized, multiple-dose study. Anesthesia and Analgesia2012;115(5):1212-20. ">Gan 2012</a>; <a href="./references#CD013263-bbs2-0007" title="MehlischD , DesjardinsP , DanielsS , HubbardR . Single doses of parecoxib sodium intravenously are as effective as ketorolac in reducing pain after oral surgery. Journal of Oral and Maxillofacial Surgery2003;61(9):1030-7. ">Mehlisch 2003</a>; <a href="./references#CD013263-bbs2-0010" title="RasmussenG , StecknerK , HogueC , TorriS , HubbardR . Intravenous parecoxib sodium for acute pain after orthopedic knee surgery. American Journal of Orthopedics2002;31(6):336-43. ">Rasmussen 2002</a>; <a href="./references#CD013263-bbs2-0011" title="RomundstadL , BreivikH , NiemiG , HelleA , StubhaugA . Methylprednisolone intravenously 1 day after surgery has sustained analgesic and opioid-sparing effects. Acta Anaesthesiologica Scandinavica2004;48(10):1223-31. ">Romundstad 2004</a>). </p> <p> <ul id="CD013263-list-0022"> <li> <p>The proportion of participants reporting vomiting with ketorolac was 13% (47/365, range 5% to 27%). </p> </li> <li> <p>The proportion of participants reporting vomiting with placebo was 15% (55/359, range 4% to 27%). </p> </li> <li> <p>The risk ratio of treatment compared with placebo was 0.84 (95% CI 0.59 to 1.20); there was no evidence of a difference (<a href="./references#CD013263-fig-0016" title="">Analysis 1.13</a>). </p> </li> </ul> </p> <p>No studies reported nausea and vomiting as a combined outcome.</p> </section> <section id="CD013263-sec-0072"> <h6 class="title">Pruritus</h6> <p>Five studies (574 participants) compared rates of pruritus with ketorolac versus placebo (<a href="./references#CD013263-bbs2-0001" title="BalestrieriP , SimmonsG , HillD , BrownJ , JacksonA , Brull SJ , et al. The effect of intravenous ketorolac given intraoperatively versus postoperatively on outcome from gynecologic abdominal surgery. Journal of Clinical Anesthesia1997;9(5):358-64. ">Balestrieri 1997</a>; <a href="./references#CD013263-bbs2-0002" title="BartonS , LangelandF , SnabesM , LeComteD , KussM , DhaddaS , et al. Efficacy and safety of intravenous parecoxib sodium in relieving acute postoperative pain following gynecologic laparotomy surgery. Anesthesiology2002;97(2):306-14. ">Barton 2002</a>; <a href="./references#CD013263-bbs2-0003" title="BikhaziG , SnabesM , BajwaZ , DavisD , LeComteD , TraylorL , et al. A clinical trial demonstrates the analgesic activity of intravenous parecoxib sodium compared with ketorolac or morphine after gynecologic surgery with laparotomy. American Journal of Obstetrics and Gynecology2004;191(4):1183-91. ">Bikhazi 2004</a>; <a href="./references#CD013263-bbs2-0005" title="GanT , DanielsS , SinglaN , HamiltonD , CarrD . A novel injectable formulation of diclofenac compared with intravenous ketorolac or placebo for acute moderate-to-severe pain after abdominal or pelvic surgery: a multicenter, double-blind, randomized, multiple-dose study. Anesthesia and Analgesia2012;115(5):1212-20. ">Gan 2012</a>; <a href="./references#CD013263-bbs2-0010" title="RasmussenG , StecknerK , HogueC , TorriS , HubbardR . Intravenous parecoxib sodium for acute pain after orthopedic knee surgery. American Journal of Orthopedics2002;31(6):336-43. ">Rasmussen 2002</a>). </p> <p> <ul id="CD013263-list-0023"> <li> <p>The proportion of participants reporting pruritus with ketorolac was 7% (21/290, range 4% to 12%). </p> </li> <li> <p>The proportion of participants reporting pruritus with placebo was 8% (24/284, range 7% to 12%). </p> </li> <li> <p>The risk ratio of treatment compared with placebo was 0.86 (95% CI 0.49 to 1.50); there was no evidence of a difference (<a href="./references#CD013263-fig-0017" title="">Analysis 1.14</a>). </p> </li> </ul> </p> </section> <section id="CD013263-sec-0073"> <h6 class="title">Respiratory depression</h6> <p>Incidence of respiratory depression was only reported in two studies (<a href="./references#CD013263-bbs2-0001" title="BalestrieriP , SimmonsG , HillD , BrownJ , JacksonA , Brull SJ , et al. The effect of intravenous ketorolac given intraoperatively versus postoperatively on outcome from gynecologic abdominal surgery. Journal of Clinical Anesthesia1997;9(5):358-64. ">Balestrieri 1997</a>; <a href="./references#CD013263-bbs2-0010" title="RasmussenG , StecknerK , HogueC , TorriS , HubbardR . Intravenous parecoxib sodium for acute pain after orthopedic knee surgery. American Journal of Orthopedics2002;31(6):336-43. ">Rasmussen 2002</a>). Neither study defined how it was assessed. In combination, four of 125 participants receiving ketorolac and nine of 121 receiving placebo experienced this side effect (<a href="./references#CD013263-fig-0018" title="">Analysis 1.15</a>). </p> </section> <section id="CD013263-sec-0074"> <h6 class="title">Sedation</h6> <p>Six studies (566 participants) compared rates of sedation with ketorolac versus placebo (<a href="./references#CD013263-bbs2-0001" title="BalestrieriP , SimmonsG , HillD , BrownJ , JacksonA , Brull SJ , et al. The effect of intravenous ketorolac given intraoperatively versus postoperatively on outcome from gynecologic abdominal surgery. Journal of Clinical Anesthesia1997;9(5):358-64. ">Balestrieri 1997</a>; <a href="./references#CD013263-bbs2-0002" title="BartonS , LangelandF , SnabesM , LeComteD , KussM , DhaddaS , et al. Efficacy and safety of intravenous parecoxib sodium in relieving acute postoperative pain following gynecologic laparotomy surgery. Anesthesiology2002;97(2):306-14. ">Barton 2002</a>; <a href="./references#CD013263-bbs2-0003" title="BikhaziG , SnabesM , BajwaZ , DavisD , LeComteD , TraylorL , et al. A clinical trial demonstrates the analgesic activity of intravenous parecoxib sodium compared with ketorolac or morphine after gynecologic surgery with laparotomy. American Journal of Obstetrics and Gynecology2004;191(4):1183-91. ">Bikhazi 2004</a>; <a href="./references#CD013263-bbs2-0007" title="MehlischD , DesjardinsP , DanielsS , HubbardR . Single doses of parecoxib sodium intravenously are as effective as ketorolac in reducing pain after oral surgery. Journal of Oral and Maxillofacial Surgery2003;61(9):1030-7. ">Mehlisch 2003</a>; <a href="./references#CD013263-bbs2-0010" title="RasmussenG , StecknerK , HogueC , TorriS , HubbardR . Intravenous parecoxib sodium for acute pain after orthopedic knee surgery. American Journal of Orthopedics2002;31(6):336-43. ">Rasmussen 2002</a>; <a href="./references#CD013263-bbs2-0011" title="RomundstadL , BreivikH , NiemiG , HelleA , StubhaugA . Methylprednisolone intravenously 1 day after surgery has sustained analgesic and opioid-sparing effects. Acta Anaesthesiologica Scandinavica2004;48(10):1223-31. ">Romundstad 2004</a>). </p> <p> <ul id="CD013263-list-0024"> <li> <p>The proportion of participants reporting sedation with ketorolac was 5% (14/283, range 0 to 7%). </p> </li> <li> <p>The proportion of participants reporting sedation with placebo was 10% (30/283, range 0 to 18%). </p> </li> <li> <p>The risk ratio of treatment compared with placebo was 0.47 (95% CI 0.25 to 0.86); the NNTp for one additional participant not to report sedation compared with placebo was 16.7 (95% CI 10 to 100) (<a href="./references#CD013263-fig-0019" title="">Analysis 1.16</a>). </p> </li> </ul> </p> </section> <section id="CD013263-sec-0075"> <h6 class="title">Urinary retention</h6> <p>Only one study reported this safety outcome. <a href="./references#CD013263-bbs2-0003" title="BikhaziG , SnabesM , BajwaZ , DavisD , LeComteD , TraylorL , et al. A clinical trial demonstrates the analgesic activity of intravenous parecoxib sodium compared with ketorolac or morphine after gynecologic surgery with laparotomy. American Journal of Obstetrics and Gynecology2004;191(4):1183-91. ">Bikhazi 2004</a> reported that 2/42 participants receiving ketorolac and 5/45 receiving placebo experienced urinary retention. </p> </section> <section id="CD013263-sec-0076"> <h6 class="title">Allergic reaction/rashes</h6> <p>No study reported this outcome.</p> </section> </section> </section> <section id="CD013263-sec-0077"> <h4 class="title">2. Ketorolac versus another NSAID</h4> <section id="CD013263-sec-0078"> <h5 class="title">Proportion of participants achieving at least 50% postoperative pain relief over a four‐hour period and over a six‐hour period </h5> <p>Four studies provided data for the comparison of IV ketorolac 30 mg versus another NSAID over four hours (<a href="./references#CD013263-bbs2-0002" title="BartonS , LangelandF , SnabesM , LeComteD , KussM , DhaddaS , et al. Efficacy and safety of intravenous parecoxib sodium in relieving acute postoperative pain following gynecologic laparotomy surgery. Anesthesiology2002;97(2):306-14. ">Barton 2002</a>; <a href="./references#CD013263-bbs2-0003" title="BikhaziG , SnabesM , BajwaZ , DavisD , LeComteD , TraylorL , et al. A clinical trial demonstrates the analgesic activity of intravenous parecoxib sodium compared with ketorolac or morphine after gynecologic surgery with laparotomy. American Journal of Obstetrics and Gynecology2004;191(4):1183-91. ">Bikhazi 2004</a>; <a href="./references#CD013263-bbs2-0007" title="MehlischD , DesjardinsP , DanielsS , HubbardR . Single doses of parecoxib sodium intravenously are as effective as ketorolac in reducing pain after oral surgery. Journal of Oral and Maxillofacial Surgery2003;61(9):1030-7. ">Mehlisch 2003</a>; <a href="./references#CD013263-bbs2-0010" title="RasmussenG , StecknerK , HogueC , TorriS , HubbardR . Intravenous parecoxib sodium for acute pain after orthopedic knee surgery. American Journal of Orthopedics2002;31(6):336-43. ">Rasmussen 2002</a>). </p> <p> <ul id="CD013263-list-0025"> <li> <p>The proportion of participants with at least 50% pain relief with ketorolac was 65% (112/172, range 51% to 76%). </p> </li> <li> <p>The proportion of participants with at least 50% pain relief with another NSAID was 63% (104/165, range 55% to 80%). </p> </li> <li> <p>The relative benefit of treatment compared with another NSAID was 1.04 (95% CI 0.89 to 1.21); there was no evidence of a difference (<a href="./references#CD013263-fig-0022" title="">Analysis 2.1</a>). </p> </li> </ul> </p> <p>Six studies (603 participants) compared ketorolac 30 mg, versus another NSAID over six hours (<a href="./references#CD013263-bbs2-0002" title="BartonS , LangelandF , SnabesM , LeComteD , KussM , DhaddaS , et al. Efficacy and safety of intravenous parecoxib sodium in relieving acute postoperative pain following gynecologic laparotomy surgery. Anesthesiology2002;97(2):306-14. ">Barton 2002</a>; <a href="./references#CD013263-bbs2-0003" title="BikhaziG , SnabesM , BajwaZ , DavisD , LeComteD , TraylorL , et al. A clinical trial demonstrates the analgesic activity of intravenous parecoxib sodium compared with ketorolac or morphine after gynecologic surgery with laparotomy. American Journal of Obstetrics and Gynecology2004;191(4):1183-91. ">Bikhazi 2004</a>; <a href="./references#CD013263-bbs2-0004" title="ChristensenK , DanielsS , BandyD , ErnstC , HamiltonD , MermelsteinF , et al. A double-blind placebo-controlled comparison of a novel formulation of intravenous diclofenac and ketorolac for postoperative third molar extraction pain. Anesthesia Progress2011;58(2):73-81. ">Christensen 2011</a>; <a href="./references#CD013263-bbs2-0005" title="GanT , DanielsS , SinglaN , HamiltonD , CarrD . A novel injectable formulation of diclofenac compared with intravenous ketorolac or placebo for acute moderate-to-severe pain after abdominal or pelvic surgery: a multicenter, double-blind, randomized, multiple-dose study. Anesthesia and Analgesia2012;115(5):1212-20. ">Gan 2012</a>; <a href="./references#CD013263-bbs2-0007" title="MehlischD , DesjardinsP , DanielsS , HubbardR . Single doses of parecoxib sodium intravenously are as effective as ketorolac in reducing pain after oral surgery. Journal of Oral and Maxillofacial Surgery2003;61(9):1030-7. ">Mehlisch 2003</a>; <a href="./references#CD013263-bbs2-0010" title="RasmussenG , StecknerK , HogueC , TorriS , HubbardR . Intravenous parecoxib sodium for acute pain after orthopedic knee surgery. American Journal of Orthopedics2002;31(6):336-43. ">Rasmussen 2002</a>). </p> <p> <ul id="CD013263-list-0026"> <li> <p>The proportion of participants with at least 50% pain relief with ketorolac was 66% (199/301, range 46% to 77%). </p> </li> <li> <p>The proportion of participants with at least 50% pain relief with another NSAID was 63% (189/302, range 53% to 76%). </p> </li> <li> <p>The relative benefit of treatment compared with another NSAID was 1.06 (95% CI 0.95 to 1.19); there was no evidence of a difference (<a href="./references#CD013263-fig-0023" title="">Analysis 2.2</a>). </p> </li> </ul> </p> <p>We assessed the certainty of evidence for this outcome as low over four hours and moderate over six hours, based on unclear risk of bias for several domains among the included studies over both time periods (study limitations) and the low total number of events over four hours (imprecision). </p> </section> <section id="CD013263-sec-0079"> <h5 class="title">Time to use of rescue medication</h5> <p>For the comparison of IV ketorolac versus another NSAID, the median time to use of rescue medication was 331 minutes for ketorolac and 296 minutes for another NSAID (4 studies, 427 participants) (<a href="./references#CD013263-bbs2-0003" title="BikhaziG , SnabesM , BajwaZ , DavisD , LeComteD , TraylorL , et al. A clinical trial demonstrates the analgesic activity of intravenous parecoxib sodium compared with ketorolac or morphine after gynecologic surgery with laparotomy. American Journal of Obstetrics and Gynecology2004;191(4):1183-91. ">Bikhazi 2004</a>; <a href="./references#CD013263-bbs2-0005" title="GanT , DanielsS , SinglaN , HamiltonD , CarrD . A novel injectable formulation of diclofenac compared with intravenous ketorolac or placebo for acute moderate-to-severe pain after abdominal or pelvic surgery: a multicenter, double-blind, randomized, multiple-dose study. Anesthesia and Analgesia2012;115(5):1212-20. ">Gan 2012</a>; <a href="./references#CD013263-bbs2-0007" title="MehlischD , DesjardinsP , DanielsS , HubbardR . Single doses of parecoxib sodium intravenously are as effective as ketorolac in reducing pain after oral surgery. Journal of Oral and Maxillofacial Surgery2003;61(9):1030-7. ">Mehlisch 2003</a>; <a href="./references#CD013263-bbs2-0010" title="RasmussenG , StecknerK , HogueC , TorriS , HubbardR . Intravenous parecoxib sodium for acute pain after orthopedic knee surgery. American Journal of Orthopedics2002;31(6):336-43. ">Rasmussen 2002</a>). In none of the studies was there evidence of a difference between ketorolac and another NSAID. We judged the certainty of evidence as low, based on risk of bias in the included studies and imprecision of findings. </p> </section> <section id="CD013263-sec-0080"> <h5 class="title">Number of participants using rescue medication over a four‐ or six‐hour period</h5> <p>Only three studies provided usable data for ketorolac versus another NSAID (parecoxib or diclofenac) (<a href="./references#CD013263-bbs2-0002" title="BartonS , LangelandF , SnabesM , LeComteD , KussM , DhaddaS , et al. Efficacy and safety of intravenous parecoxib sodium in relieving acute postoperative pain following gynecologic laparotomy surgery. Anesthesiology2002;97(2):306-14. ">Barton 2002</a>; <a href="./references#CD013263-bbs2-0003" title="BikhaziG , SnabesM , BajwaZ , DavisD , LeComteD , TraylorL , et al. A clinical trial demonstrates the analgesic activity of intravenous parecoxib sodium compared with ketorolac or morphine after gynecologic surgery with laparotomy. American Journal of Obstetrics and Gynecology2004;191(4):1183-91. ">Bikhazi 2004</a>; <a href="./references#CD013263-bbs2-0004" title="ChristensenK , DanielsS , BandyD , ErnstC , HamiltonD , MermelsteinF , et al. A double-blind placebo-controlled comparison of a novel formulation of intravenous diclofenac and ketorolac for postoperative third molar extraction pain. Anesthesia Progress2011;58(2):73-81. ">Christensen 2011</a>). </p> <p> <ul id="CD013263-list-0027"> <li> <p>The proportion of participants using rescue medication with ketorolac was 48% (63/130).</p> </li> <li> <p>The proportion of participants using rescue medication with another NSAID was 52% (67/130). </p> </li> <li> <p>The risk ratio of ketorolac compared with another NSAID was 0.90 (95% CI 0.58 to 1.40; participants = 260), that is, there is no evidence of a difference (<a href="./references#CD013263-fig-0024" title="">Analysis 2.3</a>). </p> </li> </ul> </p> <p>We judged the certainty of evidence for this outcome as very low, due to unclear risk of bias for several domains among the included studies (study limitations), unexplained heterogeneity (I<sup>2</sup> = 65%) and the low total number of events (imprecision). </p> </section> <section id="CD013263-sec-0081"> <h5 class="title">Withdrawals due to adverse events, lack of efficacy, and for any cause</h5> <p>In addition to study limitations, numbers of participants withdrawing were generally low, and reasons for withdrawal were inconsistently reported. We therefore judged the certainty of evidence for these outcomes to be very low. </p> <p> <ul id="CD013263-list-0028"> <li> <p>The proportion of participants withdrawing due to AEs was 3% (8/262) with ketorolac versus 3% (9/269) with another NSAID (<a href="./references#CD013263-fig-0025" title="">Analysis 2.4</a>; RR 0.87, 95% CI 0.35 to 2.19; 5 studies, 531 participants). </p> </li> <li> <p>The proportion of participants withdrawing due to lack of efficacy was 4% (6/166) with ketorolac versus 5% (8/170) with another NSAID (<a href="./references#CD013263-fig-0026" title="">Analysis 2.5</a>; (RR 0.80, 95% CI 0.29 to 2.19; 3 studies, 336 participants). All of the withdrawals occurred in a single study (<a href="./references#CD013263-bbs2-0005" title="GanT , DanielsS , SinglaN , HamiltonD , CarrD . A novel injectable formulation of diclofenac compared with intravenous ketorolac or placebo for acute moderate-to-severe pain after abdominal or pelvic surgery: a multicenter, double-blind, randomized, multiple-dose study. Anesthesia and Analgesia2012;115(5):1212-20. ">Gan 2012</a>). </p> </li> <li> <p>The proportion of participants withdrawing for any cause was 8% (17/216) with ketorolac versus 11% (25/221) with another NSAID (<a href="./references#CD013263-fig-0027" title="">Analysis 2.6</a>; RR 0.72, 95% CI 0.41 to 1.26; 4 studies, 437 participants). Again, most withdrawals occurred in one study (<a href="./references#CD013263-bbs2-0005" title="GanT , DanielsS , SinglaN , HamiltonD , CarrD . A novel injectable formulation of diclofenac compared with intravenous ketorolac or placebo for acute moderate-to-severe pain after abdominal or pelvic surgery: a multicenter, double-blind, randomized, multiple-dose study. Anesthesia and Analgesia2012;115(5):1212-20. ">Gan 2012</a>), primarily due to participants' requests. </p> </li> </ul> </p> </section> <section id="CD013263-sec-0082"> <h5 class="title">Participants experiencing any adverse event</h5> <p>Five studies reported the number of participants experiencing any AE (<a href="./references#CD013263-bbs2-0002" title="BartonS , LangelandF , SnabesM , LeComteD , KussM , DhaddaS , et al. Efficacy and safety of intravenous parecoxib sodium in relieving acute postoperative pain following gynecologic laparotomy surgery. Anesthesiology2002;97(2):306-14. ">Barton 2002</a>; <a href="./references#CD013263-bbs2-0003" title="BikhaziG , SnabesM , BajwaZ , DavisD , LeComteD , TraylorL , et al. A clinical trial demonstrates the analgesic activity of intravenous parecoxib sodium compared with ketorolac or morphine after gynecologic surgery with laparotomy. American Journal of Obstetrics and Gynecology2004;191(4):1183-91. ">Bikhazi 2004</a>; <a href="./references#CD013263-bbs2-0005" title="GanT , DanielsS , SinglaN , HamiltonD , CarrD . A novel injectable formulation of diclofenac compared with intravenous ketorolac or placebo for acute moderate-to-severe pain after abdominal or pelvic surgery: a multicenter, double-blind, randomized, multiple-dose study. Anesthesia and Analgesia2012;115(5):1212-20. ">Gan 2012</a>; <a href="./references#CD013263-bbs2-0007" title="MehlischD , DesjardinsP , DanielsS , HubbardR . Single doses of parecoxib sodium intravenously are as effective as ketorolac in reducing pain after oral surgery. Journal of Oral and Maxillofacial Surgery2003;61(9):1030-7. ">Mehlisch 2003</a>; <a href="./references#CD013263-bbs2-0010" title="RasmussenG , StecknerK , HogueC , TorriS , HubbardR . Intravenous parecoxib sodium for acute pain after orthopedic knee surgery. American Journal of Orthopedics2002;31(6):336-43. ">Rasmussen 2002</a>). </p> <p> <ul id="CD013263-list-0029"> <li> <p>The proportion of participants reporting an AE with ketorolac was 76% (195/257).</p> </li> <li> <p>The proportion of participants reporting an AE with another NSAID was 68% (177/259).</p> </li> <li> <p>The risk ratio of treatment compared with another NSAID was 1.11 (95% CI 1.00 to 1.23); the NNTH was 12.5 (95% CI 6.7 to infinite) (<a href="./references#CD013263-fig-0028" title="">Analysis 2.7</a>). </p> </li> </ul> </p> <p>We assessed the certainty of evidence for comparisons with another NSAID as moderate, based on unclear risk of bias in several domains for the included studies (study limitations). </p> </section> <section id="CD013263-sec-0083"> <h5 class="title">Participants experiencing any serious adverse event</h5> <p>In those studies that reported them, SAEs were very rare (<a href="./references#CD013263-fig-0029" title="">Analysis 2.8</a>). We assessed the certainty of evidence for this outcome as low, based on the very low event rates and unclear risk of bias for several domains in the included studies. </p> <p>Low‐certainty evidence from five studies (530 participants) did not demonstrate a difference in SAE rates between ketorolac and another NSAID (RR 3.18, 95% CI 0.13 to 76.99) (<a href="./references#CD013263-bbs2-0002" title="BartonS , LangelandF , SnabesM , LeComteD , KussM , DhaddaS , et al. Efficacy and safety of intravenous parecoxib sodium in relieving acute postoperative pain following gynecologic laparotomy surgery. Anesthesiology2002;97(2):306-14. ">Barton 2002</a>; <a href="./references#CD013263-bbs2-0003" title="BikhaziG , SnabesM , BajwaZ , DavisD , LeComteD , TraylorL , et al. A clinical trial demonstrates the analgesic activity of intravenous parecoxib sodium compared with ketorolac or morphine after gynecologic surgery with laparotomy. American Journal of Obstetrics and Gynecology2004;191(4):1183-91. ">Bikhazi 2004</a>; <a href="./references#CD013263-bbs2-0004" title="ChristensenK , DanielsS , BandyD , ErnstC , HamiltonD , MermelsteinF , et al. A double-blind placebo-controlled comparison of a novel formulation of intravenous diclofenac and ketorolac for postoperative third molar extraction pain. Anesthesia Progress2011;58(2):73-81. ">Christensen 2011</a>; <a href="./references#CD013263-bbs2-0005" title="GanT , DanielsS , SinglaN , HamiltonD , CarrD . A novel injectable formulation of diclofenac compared with intravenous ketorolac or placebo for acute moderate-to-severe pain after abdominal or pelvic surgery: a multicenter, double-blind, randomized, multiple-dose study. Anesthesia and Analgesia2012;115(5):1212-20. ">Gan 2012</a>; <a href="./references#CD013263-bbs2-0007" title="MehlischD , DesjardinsP , DanielsS , HubbardR . Single doses of parecoxib sodium intravenously are as effective as ketorolac in reducing pain after oral surgery. Journal of Oral and Maxillofacial Surgery2003;61(9):1030-7. ">Mehlisch 2003</a>). Only one participant given ketorolac suffered an SAE (<a href="./references#CD013263-bbs2-0005" title="GanT , DanielsS , SinglaN , HamiltonD , CarrD . A novel injectable formulation of diclofenac compared with intravenous ketorolac or placebo for acute moderate-to-severe pain after abdominal or pelvic surgery: a multicenter, double-blind, randomized, multiple-dose study. Anesthesia and Analgesia2012;115(5):1212-20. ">Gan 2012</a>). The participant experienced an abdominal hematoma, which was considered to be possibly treatment‐related. No participants receiving another NSAID experienced an SAE. </p> </section> <section id="CD013263-sec-0084"> <h5 class="title">Specific adverse events</h5> <p>Methods of assessment and the reporting of specific AEs were inconsistent across studies, as was the time over which the information was collected. Our AEs of interest were NSAID‐related (renal dysfunction, cardiovascular events, gastrointestinal or operative‐site bleeding, and thrombophlebitis) or opioid‐related (nausea, vomiting, nausea and vomiting, pruritus, respiratory depression, sedation, urinary retention, and allergic reaction/rashes). These AEs occurred infrequently in all groups, with the exception of nausea, vomiting, itching and sedation amongst the opioid‐related AEs. Other than for these four outcomes, there were insufficient data for meta‐analysis. As with our analysis of SAEs, we assessed the certainty of evidence for the four meta‐analyses as low. Where there were so few events or studies that meta‐analysis was precluded, we assessed the certainty of evidence as very low. </p> <section id="CD013263-sec-0085"> <h6 class="title">Renal dysfunction</h6> <p>Only one study reported assessing renal dysfunction (<a href="./references#CD013263-bbs2-0005" title="GanT , DanielsS , SinglaN , HamiltonD , CarrD . A novel injectable formulation of diclofenac compared with intravenous ketorolac or placebo for acute moderate-to-severe pain after abdominal or pelvic surgery: a multicenter, double-blind, randomized, multiple-dose study. Anesthesia and Analgesia2012;115(5):1212-20. ">Gan 2012</a>). No participants in either of the intervention groups experienced this AE. </p> </section> <section id="CD013263-sec-0086"> <h6 class="title">Cardiovascular events</h6> <p>In the one study that reported cardiovascular events (<a href="./references#CD013263-bbs2-0005" title="GanT , DanielsS , SinglaN , HamiltonD , CarrD . A novel injectable formulation of diclofenac compared with intravenous ketorolac or placebo for acute moderate-to-severe pain after abdominal or pelvic surgery: a multicenter, double-blind, randomized, multiple-dose study. Anesthesia and Analgesia2012;115(5):1212-20. ">Gan 2012</a>), 6% (5/82) of participants receiving ketorolac experienced an event versus 5% (4/87) of those receiving another NSAID. None were considered to be treatment‐related. </p> </section> <section id="CD013263-sec-0087"> <h6 class="title">Gastrointestinal bleeding</h6> <p>In the one study that reported gastrointestinal bleeding, 1% of participants (1/82) receiving ketorolac experienced clinically significant bleeding versus none of those on another NSAID (<a href="./references#CD013263-bbs2-0005" title="GanT , DanielsS , SinglaN , HamiltonD , CarrD . A novel injectable formulation of diclofenac compared with intravenous ketorolac or placebo for acute moderate-to-severe pain after abdominal or pelvic surgery: a multicenter, double-blind, randomized, multiple-dose study. Anesthesia and Analgesia2012;115(5):1212-20. ">Gan 2012</a>). </p> </section> <section id="CD013263-sec-0088"> <h6 class="title">Operative‐site bleeding</h6> <p>One study reported operative‐site bleeding (<a href="./references#CD013263-bbs2-0005" title="GanT , DanielsS , SinglaN , HamiltonD , CarrD . A novel injectable formulation of diclofenac compared with intravenous ketorolac or placebo for acute moderate-to-severe pain after abdominal or pelvic surgery: a multicenter, double-blind, randomized, multiple-dose study. Anesthesia and Analgesia2012;115(5):1212-20. ">Gan 2012</a>). Two per cent (2/82) of those receiving ketorolac experienced this AE versus no participants (0/87) receiving another NSAID. </p> </section> <section id="CD013263-sec-0089"> <h6 class="title">Thrombophlebitis</h6> <p>Both studies that assessed thrombophlebitis used a six‐point scale (grade 0 = "no reaction" to grade 5 = "thrombosis with overt infection") and defined events as occurring in participants with a score of more than 1 (<a href="./references#CD013263-bbs2-0004" title="ChristensenK , DanielsS , BandyD , ErnstC , HamiltonD , MermelsteinF , et al. A double-blind placebo-controlled comparison of a novel formulation of intravenous diclofenac and ketorolac for postoperative third molar extraction pain. Anesthesia Progress2011;58(2):73-81. ">Christensen 2011</a>; <a href="./references#CD013263-bbs2-0005" title="GanT , DanielsS , SinglaN , HamiltonD , CarrD . A novel injectable formulation of diclofenac compared with intravenous ketorolac or placebo for acute moderate-to-severe pain after abdominal or pelvic surgery: a multicenter, double-blind, randomized, multiple-dose study. Anesthesia and Analgesia2012;115(5):1212-20. ">Gan 2012</a>). No events occurred in <a href="./references#CD013263-bbs2-0004" title="ChristensenK , DanielsS , BandyD , ErnstC , HamiltonD , MermelsteinF , et al. A double-blind placebo-controlled comparison of a novel formulation of intravenous diclofenac and ketorolac for postoperative third molar extraction pain. Anesthesia Progress2011;58(2):73-81. ">Christensen 2011</a>. In <a href="./references#CD013263-bbs2-0005" title="GanT , DanielsS , SinglaN , HamiltonD , CarrD . A novel injectable formulation of diclofenac compared with intravenous ketorolac or placebo for acute moderate-to-severe pain after abdominal or pelvic surgery: a multicenter, double-blind, randomized, multiple-dose study. Anesthesia and Analgesia2012;115(5):1212-20. ">Gan 2012</a> 7% (6/82) receiving ketorolac versus 3% (3/87) receiving another NSAID were assessed as experiencing this AE (<a href="./references#CD013263-fig-0030" title="">Analysis 2.9</a>). </p> </section> <section id="CD013263-sec-0090"> <h6 class="title">Nausea, vomiting or both</h6> <p>Five studies (516 participants) compared rates of nausea with another NSAID (<a href="./references#CD013263-bbs2-0002" title="BartonS , LangelandF , SnabesM , LeComteD , KussM , DhaddaS , et al. Efficacy and safety of intravenous parecoxib sodium in relieving acute postoperative pain following gynecologic laparotomy surgery. Anesthesiology2002;97(2):306-14. ">Barton 2002</a>; <a href="./references#CD013263-bbs2-0003" title="BikhaziG , SnabesM , BajwaZ , DavisD , LeComteD , TraylorL , et al. A clinical trial demonstrates the analgesic activity of intravenous parecoxib sodium compared with ketorolac or morphine after gynecologic surgery with laparotomy. American Journal of Obstetrics and Gynecology2004;191(4):1183-91. ">Bikhazi 2004</a>; <a href="./references#CD013263-bbs2-0005" title="GanT , DanielsS , SinglaN , HamiltonD , CarrD . A novel injectable formulation of diclofenac compared with intravenous ketorolac or placebo for acute moderate-to-severe pain after abdominal or pelvic surgery: a multicenter, double-blind, randomized, multiple-dose study. Anesthesia and Analgesia2012;115(5):1212-20. ">Gan 2012</a>; <a href="./references#CD013263-bbs2-0007" title="MehlischD , DesjardinsP , DanielsS , HubbardR . Single doses of parecoxib sodium intravenously are as effective as ketorolac in reducing pain after oral surgery. Journal of Oral and Maxillofacial Surgery2003;61(9):1030-7. ">Mehlisch 2003</a>; <a href="./references#CD013263-bbs2-0010" title="RasmussenG , StecknerK , HogueC , TorriS , HubbardR . Intravenous parecoxib sodium for acute pain after orthopedic knee surgery. American Journal of Orthopedics2002;31(6):336-43. ">Rasmussen 2002</a>) . </p> <p> <ul id="CD013263-list-0030"> <li> <p>The proportion of participants reporting nausea with ketorolac was 26% (68/257, range 19% to 41%). </p> </li> <li> <p>The proportion of participants reporting nausea with another NSAID was 23% (59/259, range 12% to 32%). </p> </li> <li> <p>The risk ratio of treatment compared with another NSAID was 1.16 (95% CI 0.86 to 1.56); there was no evidence of a difference (<a href="./references#CD013263-fig-0031" title="">Analysis 2.10</a>). </p> </li> </ul> </p> <p>Five studies (516 participants) compared rates of vomiting with another NSAID (<a href="./references#CD013263-bbs2-0002" title="BartonS , LangelandF , SnabesM , LeComteD , KussM , DhaddaS , et al. Efficacy and safety of intravenous parecoxib sodium in relieving acute postoperative pain following gynecologic laparotomy surgery. Anesthesiology2002;97(2):306-14. ">Barton 2002</a>; <a href="./references#CD013263-bbs2-0003" title="BikhaziG , SnabesM , BajwaZ , DavisD , LeComteD , TraylorL , et al. A clinical trial demonstrates the analgesic activity of intravenous parecoxib sodium compared with ketorolac or morphine after gynecologic surgery with laparotomy. American Journal of Obstetrics and Gynecology2004;191(4):1183-91. ">Bikhazi 2004</a>; <a href="./references#CD013263-bbs2-0005" title="GanT , DanielsS , SinglaN , HamiltonD , CarrD . A novel injectable formulation of diclofenac compared with intravenous ketorolac or placebo for acute moderate-to-severe pain after abdominal or pelvic surgery: a multicenter, double-blind, randomized, multiple-dose study. Anesthesia and Analgesia2012;115(5):1212-20. ">Gan 2012</a>; <a href="./references#CD013263-bbs2-0007" title="MehlischD , DesjardinsP , DanielsS , HubbardR . Single doses of parecoxib sodium intravenously are as effective as ketorolac in reducing pain after oral surgery. Journal of Oral and Maxillofacial Surgery2003;61(9):1030-7. ">Mehlisch 2003</a>; <a href="./references#CD013263-bbs2-0010" title="RasmussenG , StecknerK , HogueC , TorriS , HubbardR . Intravenous parecoxib sodium for acute pain after orthopedic knee surgery. American Journal of Orthopedics2002;31(6):336-43. ">Rasmussen 2002</a>) . </p> <p> <ul id="CD013263-list-0031"> <li> <p>The proportion of participants reporting vomiting with ketorolac was 11% (29/257, range 5% to 27%). </p> </li> <li> <p>The proportion of participants reporting vomiting with another NSAID was 8% (21/259, range 2% to 24%). </p> </li> <li> <p>The risk ratio of treatment compared with another NSAID was 1.36 (95% CI 0.81 to 2.28); there was no evidence of a difference (<a href="./references#CD013263-fig-0032" title="">Analysis 2.11</a>). </p> </li> </ul> </p> <p>No studies reported nausea and vomiting as a combined outcome.</p> </section> <section id="CD013263-sec-0091"> <h6 class="title">Pruritus</h6> <p>Four studies (415 participants) compared rates of pruritus with another NSAID (<a href="./references#CD013263-bbs2-0002" title="BartonS , LangelandF , SnabesM , LeComteD , KussM , DhaddaS , et al. Efficacy and safety of intravenous parecoxib sodium in relieving acute postoperative pain following gynecologic laparotomy surgery. Anesthesiology2002;97(2):306-14. ">Barton 2002</a>; <a href="./references#CD013263-bbs2-0003" title="BikhaziG , SnabesM , BajwaZ , DavisD , LeComteD , TraylorL , et al. A clinical trial demonstrates the analgesic activity of intravenous parecoxib sodium compared with ketorolac or morphine after gynecologic surgery with laparotomy. American Journal of Obstetrics and Gynecology2004;191(4):1183-91. ">Bikhazi 2004</a>; <a href="./references#CD013263-bbs2-0005" title="GanT , DanielsS , SinglaN , HamiltonD , CarrD . A novel injectable formulation of diclofenac compared with intravenous ketorolac or placebo for acute moderate-to-severe pain after abdominal or pelvic surgery: a multicenter, double-blind, randomized, multiple-dose study. Anesthesia and Analgesia2012;115(5):1212-20. ">Gan 2012</a>; <a href="./references#CD013263-bbs2-0010" title="RasmussenG , StecknerK , HogueC , TorriS , HubbardR . Intravenous parecoxib sodium for acute pain after orthopedic knee surgery. American Journal of Orthopedics2002;31(6):336-43. ">Rasmussen 2002</a>). </p> <p> <ul id="CD013263-list-0032"> <li> <p>The proportion of participants reporting pruritus with ketorolac was 5% (11/207, range 4% to 7%). </p> </li> <li> <p>The proportion of participants reporting pruritus with another NSAID was 6% (13/208, range 0 to 12%). </p> </li> <li> <p>The risk ratio of treatment compared with another NSAID was 0.85 (95% CI 0.40 to 1.84); there was no evidence of a difference (<a href="./references#CD013263-fig-0033" title="">Analysis 2.12</a>). </p> </li> </ul> </p> </section> <section id="CD013263-sec-0092"> <h6 class="title">Respiratory depression</h6> <p>Incidence of respiratory depression was only reported in one study (<a href="./references#CD013263-bbs2-0010" title="RasmussenG , StecknerK , HogueC , TorriS , HubbardR . Intravenous parecoxib sodium for acute pain after orthopedic knee surgery. American Journal of Orthopedics2002;31(6):336-43. ">Rasmussen 2002</a>). Two of 42 participants receiving ketorolac and two of 42 receiving another NSAID experienced this side effect. </p> </section> <section id="CD013263-sec-0093"> <h6 class="title">Sedation</h6> <p>Four studies (347 participants) compared rates of sedation with another NSAID (<a href="./references#CD013263-bbs2-0002" title="BartonS , LangelandF , SnabesM , LeComteD , KussM , DhaddaS , et al. Efficacy and safety of intravenous parecoxib sodium in relieving acute postoperative pain following gynecologic laparotomy surgery. Anesthesiology2002;97(2):306-14. ">Barton 2002</a>; <a href="./references#CD013263-bbs2-0003" title="BikhaziG , SnabesM , BajwaZ , DavisD , LeComteD , TraylorL , et al. A clinical trial demonstrates the analgesic activity of intravenous parecoxib sodium compared with ketorolac or morphine after gynecologic surgery with laparotomy. American Journal of Obstetrics and Gynecology2004;191(4):1183-91. ">Bikhazi 2004</a>; <a href="./references#CD013263-bbs2-0007" title="MehlischD , DesjardinsP , DanielsS , HubbardR . Single doses of parecoxib sodium intravenously are as effective as ketorolac in reducing pain after oral surgery. Journal of Oral and Maxillofacial Surgery2003;61(9):1030-7. ">Mehlisch 2003</a>; <a href="./references#CD013263-bbs2-0010" title="RasmussenG , StecknerK , HogueC , TorriS , HubbardR . Intravenous parecoxib sodium for acute pain after orthopedic knee surgery. American Journal of Orthopedics2002;31(6):336-43. ">Rasmussen 2002</a>) . </p> <p> <ul id="CD013263-list-0033"> <li> <p>The proportion of participants reporting sedation with ketorolac was 6% (11/175, range 4% to 7%). </p> </li> <li> <p>The proportion of participants reporting sedation with another NSAID was 2% (4/172, range 0 to 5%). </p> </li> <li> <p>The risk ratio of treatment compared with another NSAID was 2.51 (95% CI 0.86 to 7.35); there was no evidence of a difference (<a href="./references#CD013263-fig-0034" title="">Analysis 2.13</a>). </p> </li> </ul> </p> </section> <section id="CD013263-sec-0094"> <h6 class="title">Urinary retention</h6> <p>Only one study reported this safety outcome. <a href="./references#CD013263-bbs2-0003" title="BikhaziG , SnabesM , BajwaZ , DavisD , LeComteD , TraylorL , et al. A clinical trial demonstrates the analgesic activity of intravenous parecoxib sodium compared with ketorolac or morphine after gynecologic surgery with laparotomy. American Journal of Obstetrics and Gynecology2004;191(4):1183-91. ">Bikhazi 2004</a> reported that 2/42 participants receiving ketorolac and 0 of 41 receiving another NSAID experienced urinary retention. </p> </section> <section id="CD013263-sec-0095"> <h6 class="title">Allergic reaction/rashes</h6> <p>No study reported this outcome.</p> </section> </section> </section> <section id="CD013263-sec-0096"> <h4 class="title">3. Ketorolac versus an opioid</h4> <section id="CD013263-sec-0097"> <h5 class="title">Proportion of participants achieving at least 50% postoperative pain relief over a four‐hour period and over a six‐hour period </h5> <p>Three studies (243 participants) provided data for the comparison of IV ketorolac 30 mg with an opioid over four hours and six hours (<a href="./references#CD013263-bbs2-0002" title="BartonS , LangelandF , SnabesM , LeComteD , KussM , DhaddaS , et al. Efficacy and safety of intravenous parecoxib sodium in relieving acute postoperative pain following gynecologic laparotomy surgery. Anesthesiology2002;97(2):306-14. ">Barton 2002</a>; <a href="./references#CD013263-bbs2-0003" title="BikhaziG , SnabesM , BajwaZ , DavisD , LeComteD , TraylorL , et al. A clinical trial demonstrates the analgesic activity of intravenous parecoxib sodium compared with ketorolac or morphine after gynecologic surgery with laparotomy. American Journal of Obstetrics and Gynecology2004;191(4):1183-91. ">Bikhazi 2004</a>; <a href="./references#CD013263-bbs2-0010" title="RasmussenG , StecknerK , HogueC , TorriS , HubbardR . Intravenous parecoxib sodium for acute pain after orthopedic knee surgery. American Journal of Orthopedics2002;31(6):336-43. ">Rasmussen 2002</a>).<br/>Over four hours: </p> <p> <ul id="CD013263-list-0034"> <li> <p>The proportion of participants with at least 50% pain relief with ketorolac was 64% (79/124, range 51% to 76%). </p> </li> <li> <p>The proportion of participants with at least 50% pain relief with an opioid was 36% (43/119, range 26% to 55%). </p> </li> <li> <p>The relative benefit of treatment compared with an opioid was 1.75 (95% CI 1.34 to 2.28); the NNTB for one additional participant to benefit compared with an opioid was 3.7 (95% CI 2.6 to 6.7) (<a href="./references#CD013263-fig-0037" title="">Analysis 3.1</a>). </p> </li> </ul> </p> <p>Over six hours:</p> <p> <ul id="CD013263-list-0035"> <li> <p>The proportion of participants with at least 50% pain relief with ketorolac was 58% (72/124, range 46% to 71%). </p> </li> <li> <p>The proportion of participants with at least 50% pain relief with an opioid was 30% (36/119, range 19% to 50%). </p> </li> <li> <p>The relative benefit of treatment compared with an opioid was 1.90 (95% CI 1.40 to 2.56); the NNTB for one additional participant to benefit compared with an opioid was 3.7 (95% CI 2.6 to 6.3) <a href="./references#CD013263-fig-0038" title="">Analysis 3.2</a>). </p> </li> </ul> </p> <p>We assessed the certainty of evidence for this outcome as low over both four hours and six hours, based on unclear risk of bias for several domains among the included studies (study limitations) and the low total number of participants analyzed (imprecision). </p> </section> <section id="CD013263-sec-0098"> <h5 class="title">Time to use of rescue medication</h5> <p>Only two studies compared ketorolac 30 mg IV with an opioid (4 mg IV morphine) for this outcome. <a href="./references#CD013263-bbs2-0003" title="BikhaziG , SnabesM , BajwaZ , DavisD , LeComteD , TraylorL , et al. A clinical trial demonstrates the analgesic activity of intravenous parecoxib sodium compared with ketorolac or morphine after gynecologic surgery with laparotomy. American Journal of Obstetrics and Gynecology2004;191(4):1183-91. ">Bikhazi 2004</a> demonstrated that participants receiving IV ketorolac had a longer time to rescue than those participants receiving morphine (370 minutes versus 295 minutes, P &lt; 0.05, 80 participants). Similarly, <a href="./references#CD013263-bbs2-0010" title="RasmussenG , StecknerK , HogueC , TorriS , HubbardR . Intravenous parecoxib sodium for acute pain after orthopedic knee surgery. American Journal of Orthopedics2002;31(6):336-43. ">Rasmussen 2002</a> demonstrated that participants receiving ketorolac waited more than twice as long before requesting rescue (275 minutes versus 127 minutes, P &lt; 0.05). Due to study limitations and imprecision (lack of data), we assessed the certainty of evidence as low. </p> </section> <section id="CD013263-sec-0099"> <h5 class="title">Number of participants using rescue medication over a four‐ to six‐hour period</h5> <p>Only two studies provided usable data for ketorolac 30 mg versus an opioid (morphine 4 mg) (<a href="./references#CD013263-bbs2-0002" title="BartonS , LangelandF , SnabesM , LeComteD , KussM , DhaddaS , et al. Efficacy and safety of intravenous parecoxib sodium in relieving acute postoperative pain following gynecologic laparotomy surgery. Anesthesiology2002;97(2):306-14. ">Barton 2002</a>; <a href="./references#CD013263-bbs2-0003" title="BikhaziG , SnabesM , BajwaZ , DavisD , LeComteD , TraylorL , et al. A clinical trial demonstrates the analgesic activity of intravenous parecoxib sodium compared with ketorolac or morphine after gynecologic surgery with laparotomy. American Journal of Obstetrics and Gynecology2004;191(4):1183-91. ">Bikhazi 2004</a>). </p> <p> <ul id="CD013263-list-0036"> <li> <p>The proportion of participants using rescue medication with ketorolac was 61% (51/83).</p> </li> <li> <p>The proportion of participants using rescue medication with morphine was 79% (63/80).</p> </li> <li> <p>The risk ratio of ketorolac compared with an opioid was 0.72 (95% CI 0.25 to 2.04), that is, there is no evidence of a difference (<a href="./references#CD013263-fig-0039" title="">Analysis 3.3</a>). This meta‐analysis had substantial heterogeneity, as demonstrated by an I<sup>2</sup> score of 94%.  </p> </li> </ul> </p> <p>We judged the certainty of evidence for this outcome as very low, due to unclear risk of bias for several domains among the included studies (study limitations), unexplained heterogeneity (I<sup>2</sup> = 94%) and the low total number of events (imprecision).  </p> </section> <section id="CD013263-sec-0100"> <h5 class="title">Withdrawals due to adverse events, lack of efficacy, and for any cause</h5> <p>Numbers of participants withdrawing were generally low, and reasons for withdrawal were inconsistently reported. We therefore judged the certainty of evidence for these outcomes to be very low. </p> <p>There were only two studies that contributed data to each of these outcomes for this comparison. Number of events were low across all outcomes and similar between groups (<a href="./references#CD013263-fig-0040" title="">Analysis 3.4</a>; <a href="./references#CD013263-fig-0041" title="">Analysis 3.5</a>; <a href="./references#CD013263-fig-0042" title="">Analysis 3.6</a>). </p> </section> <section id="CD013263-sec-0101"> <h5 class="title">Participants experiencing any adverse event</h5> <p>Three studies reported the number of participants experiencing any AE (<a href="./references#CD013263-bbs2-0002" title="BartonS , LangelandF , SnabesM , LeComteD , KussM , DhaddaS , et al. Efficacy and safety of intravenous parecoxib sodium in relieving acute postoperative pain following gynecologic laparotomy surgery. Anesthesiology2002;97(2):306-14. ">Barton 2002</a>; <a href="./references#CD013263-bbs2-0003" title="BikhaziG , SnabesM , BajwaZ , DavisD , LeComteD , TraylorL , et al. A clinical trial demonstrates the analgesic activity of intravenous parecoxib sodium compared with ketorolac or morphine after gynecologic surgery with laparotomy. American Journal of Obstetrics and Gynecology2004;191(4):1183-91. ">Bikhazi 2004</a>; <a href="./references#CD013263-bbs2-0010" title="RasmussenG , StecknerK , HogueC , TorriS , HubbardR . Intravenous parecoxib sodium for acute pain after orthopedic knee surgery. American Journal of Orthopedics2002;31(6):336-43. ">Rasmussen 2002</a>). </p> <p> <ul id="CD013263-list-0037"> <li> <p>The proportion of participants reporting an AE with ketorolac was 74% (92/125).</p> </li> <li> <p>The proportion of participants reporting an AE with an opioid was 83% (103/124).</p> </li> <li> <p>The risk ratio of treatment compared with an opioid was 0.89 (95% CI 0.67 to 1.18); there was no evidence of a difference (<a href="./references#CD013263-fig-0043" title="">Analysis 3.7</a>). </p> </li> </ul> </p> <p>We assessed the certainty of evidence for comparisons with an opioid as low, based on unclear risk of bias in several domains for the included studies (study limitations), and also the low total number of events (imprecision). </p> </section> <section id="CD013263-sec-0102"> <h5 class="title">Participants experiencing any serious adverse event</h5> <p>In those studies that reported them, SAEs were very rare (<a href="./references#CD013263-fig-0044" title="">Analysis 3.8</a>). We assessed the certainty of evidence for this outcome as low, based on the very low event rates and unclear risk of bias for several domains in the included studies. </p> <p>Two studies (165 participants) did not demonstrate a difference in SAE rates between ketorolac and an opioid (RR 0.20, 95% CI 0.01 to 4.14) (<a href="./references#CD013263-bbs2-0002" title="BartonS , LangelandF , SnabesM , LeComteD , KussM , DhaddaS , et al. Efficacy and safety of intravenous parecoxib sodium in relieving acute postoperative pain following gynecologic laparotomy surgery. Anesthesiology2002;97(2):306-14. ">Barton 2002</a>; <a href="./references#CD013263-bbs2-0003" title="BikhaziG , SnabesM , BajwaZ , DavisD , LeComteD , TraylorL , et al. A clinical trial demonstrates the analgesic activity of intravenous parecoxib sodium compared with ketorolac or morphine after gynecologic surgery with laparotomy. American Journal of Obstetrics and Gynecology2004;191(4):1183-91. ">Bikhazi 2004</a>). No participants given ketorolac suffered an SAE. Two participants receiving an opioid suffered an SAE: pulmonary emboli and persistent nausea and vomiting, both of which were considered unrelated to treatment. </p> </section> <section id="CD013263-sec-0103"> <h5 class="title">Specific adverse events</h5> <p>Methods of assessment and the reporting of specific AEs were inconsistent across studies, as was the time over which the information was collected. Our AEs of interest were NSAID‐related (renal dysfunction, cardiovascular events, gastrointestinal or operative‐site bleeding, and thrombophlebitis) or opioid‐related (nausea, vomiting, nausea and vomiting, pruritus, respiratory depression, sedation, urinary retention, and allergic reaction/rashes). These AEs occurred infrequently in all groups, with the exception of nausea, vomiting, itching and sedation amongst the opioid‐related AEs. Other than for these four outcomes, there were insufficient data for meta‐analysis. As with our analysis of SAEs, we assessed the certainty of evidence for the four meta‐analyses as low. Where there were so few events or studies that meta‐analysis was precluded, we assessed the certainty of evidence as very low. </p> <section id="CD013263-sec-0104"> <h6 class="title">Nausea, vomiting or both</h6> <p>Four studies (369 participants) compared rates of nausea with an opioid (<a href="./references#CD013263-bbs2-0002" title="BartonS , LangelandF , SnabesM , LeComteD , KussM , DhaddaS , et al. Efficacy and safety of intravenous parecoxib sodium in relieving acute postoperative pain following gynecologic laparotomy surgery. Anesthesiology2002;97(2):306-14. ">Barton 2002</a>; <a href="./references#CD013263-bbs2-0003" title="BikhaziG , SnabesM , BajwaZ , DavisD , LeComteD , TraylorL , et al. A clinical trial demonstrates the analgesic activity of intravenous parecoxib sodium compared with ketorolac or morphine after gynecologic surgery with laparotomy. American Journal of Obstetrics and Gynecology2004;191(4):1183-91. ">Bikhazi 2004</a>; <a href="./references#CD013263-bbs2-0006" title="GonzalezC , MartinezJ , EsparzaV , MorenoL , CarreonJ . Comparison of intravenous ketorolac and butorphanol on ventilatory function and analgesia of pain after surgery. Proceedings of the Western Pharmacology Society1994;37:147-8. ">Gonzalez 1994</a>; <a href="./references#CD013263-bbs2-0010" title="RasmussenG , StecknerK , HogueC , TorriS , HubbardR . Intravenous parecoxib sodium for acute pain after orthopedic knee surgery. American Journal of Orthopedics2002;31(6):336-43. ">Rasmussen 2002</a>). </p> <p> <ul id="CD013263-list-0038"> <li> <p>The proportion of participants reporting nausea with ketorolac was 20% (37/185, range 7% to 41%). </p> </li> <li> <p>The proportion of participants reporting nausea with an opioid was 25% (46/184, range 17% to 31%). </p> </li> <li> <p>The risk ratio of treatment compared with an opioid was 0.80 (95% CI 0.55 to 1.17); there was no evidence of a difference (<a href="./references#CD013263-fig-0045" title="">Analysis 3.9</a>). </p> </li> </ul> </p> <p>Four studies (369 participants) compared rates of vomiting with an opioid (<a href="./references#CD013263-bbs2-0002" title="BartonS , LangelandF , SnabesM , LeComteD , KussM , DhaddaS , et al. Efficacy and safety of intravenous parecoxib sodium in relieving acute postoperative pain following gynecologic laparotomy surgery. Anesthesiology2002;97(2):306-14. ">Barton 2002</a>; <a href="./references#CD013263-bbs2-0003" title="BikhaziG , SnabesM , BajwaZ , DavisD , LeComteD , TraylorL , et al. A clinical trial demonstrates the analgesic activity of intravenous parecoxib sodium compared with ketorolac or morphine after gynecologic surgery with laparotomy. American Journal of Obstetrics and Gynecology2004;191(4):1183-91. ">Bikhazi 2004</a>; <a href="./references#CD013263-bbs2-0006" title="GonzalezC , MartinezJ , EsparzaV , MorenoL , CarreonJ . Comparison of intravenous ketorolac and butorphanol on ventilatory function and analgesia of pain after surgery. Proceedings of the Western Pharmacology Society1994;37:147-8. ">Gonzalez 1994</a>; <a href="./references#CD013263-bbs2-0010" title="RasmussenG , StecknerK , HogueC , TorriS , HubbardR . Intravenous parecoxib sodium for acute pain after orthopedic knee surgery. American Journal of Orthopedics2002;31(6):336-43. ">Rasmussen 2002</a>). </p> <p> <ul id="CD013263-list-0039"> <li> <p>The proportion of participants reporting vomiting with ketorolac was 11% (20/185, range 3% to 27%). </p> </li> <li> <p>The proportion of participants reporting vomiting with an opioid was 13% (24/184, range 8% to 24%). </p> </li> <li> <p>The risk ratio of treatment compared with an opioid was 0.84 (95% CI 0.48 to 1.44); there was no evidence of a difference (<a href="./references#CD013263-fig-0046" title="">Analysis 3.10</a>). </p> </li> </ul> </p> <p>No studies reported nausea and vomiting as a combined outcome.</p> </section> <section id="CD013263-sec-0105"> <h6 class="title">Pruritus</h6> <p>Three studies (249 participants) compared rates of pruritus with an opioid (<a href="./references#CD013263-bbs2-0002" title="BartonS , LangelandF , SnabesM , LeComteD , KussM , DhaddaS , et al. Efficacy and safety of intravenous parecoxib sodium in relieving acute postoperative pain following gynecologic laparotomy surgery. Anesthesiology2002;97(2):306-14. ">Barton 2002</a>; <a href="./references#CD013263-bbs2-0003" title="BikhaziG , SnabesM , BajwaZ , DavisD , LeComteD , TraylorL , et al. A clinical trial demonstrates the analgesic activity of intravenous parecoxib sodium compared with ketorolac or morphine after gynecologic surgery with laparotomy. American Journal of Obstetrics and Gynecology2004;191(4):1183-91. ">Bikhazi 2004</a>; <a href="./references#CD013263-bbs2-0010" title="RasmussenG , StecknerK , HogueC , TorriS , HubbardR . Intravenous parecoxib sodium for acute pain after orthopedic knee surgery. American Journal of Orthopedics2002;31(6):336-43. ">Rasmussen 2002</a>). </p> <p> <ul id="CD013263-list-0040"> <li> <p>The proportion of participants reporting pruritus with ketorolac was 6% (8/125, range 5% to 7%). </p> </li> <li> <p>The proportion of participants reporting pruritus with an opioid was 9% (11/124, range 7% to 12%). </p> </li> <li> <p>The risk ratio of treatment compared with an opioid was 0.73 (95% CI 0.30 to 1.74); there was no evidence of a difference (<a href="./references#CD013263-fig-0047" title="">Analysis 3.11</a>). </p> </li> </ul> </p> </section> <section id="CD013263-sec-0106"> <h6 class="title">Respiratory depression</h6> <p>Incidence of respiratory depression was only reported in one study (<a href="./references#CD013263-bbs2-0010" title="RasmussenG , StecknerK , HogueC , TorriS , HubbardR . Intravenous parecoxib sodium for acute pain after orthopedic knee surgery. American Journal of Orthopedics2002;31(6):336-43. ">Rasmussen 2002</a>). Two of 42 participants receiving ketorolac and five of 42 participants receiving an opioid experienced this side effect. </p> </section> <section id="CD013263-sec-0107"> <h6 class="title">Sedation</h6> <p>Three studies (249 participants) compared rates of sedation with an opioid (<a href="./references#CD013263-bbs2-0002" title="BartonS , LangelandF , SnabesM , LeComteD , KussM , DhaddaS , et al. Efficacy and safety of intravenous parecoxib sodium in relieving acute postoperative pain following gynecologic laparotomy surgery. Anesthesiology2002;97(2):306-14. ">Barton 2002</a>; <a href="./references#CD013263-bbs2-0003" title="BikhaziG , SnabesM , BajwaZ , DavisD , LeComteD , TraylorL , et al. A clinical trial demonstrates the analgesic activity of intravenous parecoxib sodium compared with ketorolac or morphine after gynecologic surgery with laparotomy. American Journal of Obstetrics and Gynecology2004;191(4):1183-91. ">Bikhazi 2004</a>; <a href="./references#CD013263-bbs2-0010" title="RasmussenG , StecknerK , HogueC , TorriS , HubbardR . Intravenous parecoxib sodium for acute pain after orthopedic knee surgery. American Journal of Orthopedics2002;31(6):336-43. ">Rasmussen 2002</a>). </p> <p> <ul id="CD013263-list-0041"> <li> <p>The proportion of participants reporting sedation with ketorolac was 7% (9/125, range all 7%). </p> </li> <li> <p>The proportion of participants reporting sedation with an opioid was 10% (13/124, range 5% to 17%). </p> </li> <li> <p>The risk ratio of treatment compared with an opioid was 0.69 (95% CI 0.31 to 1.55); there was no evidence of a difference (<a href="./references#CD013263-fig-0048" title="">Analysis 3.12</a>). </p> </li> </ul> </p> </section> <section id="CD013263-sec-0108"> <h6 class="title">Urinary retention</h6> <p>Only one study reported this safety outcome. <a href="./references#CD013263-bbs2-0003" title="BikhaziG , SnabesM , BajwaZ , DavisD , LeComteD , TraylorL , et al. A clinical trial demonstrates the analgesic activity of intravenous parecoxib sodium compared with ketorolac or morphine after gynecologic surgery with laparotomy. American Journal of Obstetrics and Gynecology2004;191(4):1183-91. ">Bikhazi 2004</a> reported that 2/42 participants receiving ketorolac and 2/40 participants receiving an opioid experienced urinary retention. </p> </section> <section id="CD013263-sec-0109"> <h6 class="title">Allergic reaction/rashes</h6> <p>No study reported this outcome.</p> </section> </section> </section> <section id="CD013263-sec-0110"> <h4 class="title">Subgroup analysis, sensitivity analysis, and investigation of heterogeneity</h4> <section id="CD013263-sec-0111"> <h5 class="title">Dosing</h5> <p>Where there were sufficient data, we planned to analyze the effect on our primary outcomes of different doses of ketorolac separately. Three different doses were used: 15 mg, 30 mg and 60 mg. Almost all studies administered 30 mg, so there were not enough data for a subgroup analysis. <a href="./references#CD013263-bbs2-0001" title="BalestrieriP , SimmonsG , HillD , BrownJ , JacksonA , Brull SJ , et al. The effect of intravenous ketorolac given intraoperatively versus postoperatively on outcome from gynecologic abdominal surgery. Journal of Clinical Anesthesia1997;9(5):358-64. ">Balestrieri 1997</a> administered only 60 mg (subsequent doses in this multiple‐dose study were 30 mg) and <a href="./references#CD013263-bbs2-0012" title="ZhouT , TangJ , WhiteP . Propacetamol versus ketorolac for treatment of acute postoperative pain after total hip or knee replacement. Anesthesia and Analgesia2001;92(6):1569-75. ">Zhou 2001</a> had both 15 mg and 30 mg arms. <a href="./references#CD013263-bbs2-0001" title="BalestrieriP , SimmonsG , HillD , BrownJ , JacksonA , Brull SJ , et al. The effect of intravenous ketorolac given intraoperatively versus postoperatively on outcome from gynecologic abdominal surgery. Journal of Clinical Anesthesia1997;9(5):358-64. ">Balestrieri 1997</a> compared ketorolac with placebo only. However, the RR versus placebo was not higher (better) in this study versus any of the other studies included over either four or six hours post‐interventions, in part because of the high placebo response in this study. In <a href="./references#CD013263-bbs2-0012" title="ZhouT , TangJ , WhiteP . Propacetamol versus ketorolac for treatment of acute postoperative pain after total hip or knee replacement. Anesthesia and Analgesia2001;92(6):1569-75. ">Zhou 2001</a>, there was no evidence of a difference in the number of participants achieving at least 50% pain relief with 15 mg versus 30 mg,  respectively over four hours (15/28 versus 16/27) or over six hours (14/28 versus 15/27). </p> </section> <section id="CD013263-sec-0112"> <h5 class="title">Type of surgery</h5> <p>We split the various surgeries that participants underwent into three subgroups: abdominal/pelvic; dental (third molar extraction); and orthopedic. For comparisons of ketorolac with placebo over four and six hours for our primary outcome, the z test demonstrated differences between subgroups (<a href="./references#CD013263-fig-0020" title="">Analysis 1.17</a>; <a href="./references#CD013263-fig-0021" title="">Analysis 1.18</a>). Ketorolac appeared to be most effective in dental surgery and least effective in abdominal surgery. For comparisons versus other NSAIDs, subgroup analysis (<a href="./references#CD013263-fig-0035" title="">Analysis 2.14</a>; <a href="./references#CD013263-fig-0036" title="">Analysis 2.15</a>) did not show differences between subgroups. There were insufficient data to perform a subgroup analysis for comparisons with an opioid. </p> </section> <section id="CD013263-sec-0113"> <h5 class="title">Heterogeneity</h5> <p>For our primary outcome analyses, studies generally enrolled similar numbers of participants. Substantial heterogeneity, as demonstrated by I<sup>2</sup> scores of greater than 50%, occurred only in comparisons of ketorolac versus placebo. <a href="./references#CD013263-fig-0004" title="">Analysis 1.1</a>, number of participants with at least 50% pain relief over four hours, had an I<sup>2</sup> of 65%. In this analysis, two studies, <a href="./references#CD013263-bbs2-0007" title="MehlischD , DesjardinsP , DanielsS , HubbardR . Single doses of parecoxib sodium intravenously are as effective as ketorolac in reducing pain after oral surgery. Journal of Oral and Maxillofacial Surgery2003;61(9):1030-7. ">Mehlisch 2003</a>; and <a href="./references#CD013263-bbs2-0011" title="RomundstadL , BreivikH , NiemiG , HelleA , StubhaugA . Methylprednisolone intravenously 1 day after surgery has sustained analgesic and opioid-sparing effects. Acta Anaesthesiologica Scandinavica2004;48(10):1223-31. ">Romundstad 2004</a>, had no participants in the placebo groups that achieved this outcome. Removal of these studies reduced the I<sup>2</sup> to32%. However, removal of these studies from the same comparison over six hours (<a href="./references#CD013263-fig-0005" title="">Analysis 1.2</a>) did not reduce the I<sup>2</sup> score. As noted above, subgroup analysis by surgery did show differences between subgroups. However, heterogeneity remained high (I<sup>2</sup> = 53%) in the orthopedic subgroup over four hours and in the abdominal/pelvic analysis over six hours (I<sup>2</sup> = 71%). Removal of the one study (<a href="./references#CD013263-bbs2-0001" title="BalestrieriP , SimmonsG , HillD , BrownJ , JacksonA , Brull SJ , et al. The effect of intravenous ketorolac given intraoperatively versus postoperatively on outcome from gynecologic abdominal surgery. Journal of Clinical Anesthesia1997;9(5):358-64. ">Balestrieri 1997</a>) that used a higher dose of ketorolac also did not reduce heterogeneity in <a href="./references#CD013263-fig-0004" title="">Analysis 1.1</a> or <a href="./references#CD013263-fig-0005" title="">Analysis 1.2</a>. </p> </section> <section id="CD013263-sec-0114"> <h5 class="title">Sensitivity analysis</h5> <p>For meta‐analyses with an I<sup>2</sup> score of greater than 50%, we re‐analyzed the data using a random‐effects model and presented these analyses preferentially. There were no large changes in the effect size when converting from fixed‐effect to random‐effects models; however, one analysis that had previously demonstrated superiority of ketorolac over placebo (<a href="./references#CD013263-fig-0006" title="">Analysis 1.3</a>), and one that demonstrated superiority of ketorolac versus an opioid (<a href="./references#CD013263-fig-0039" title="">Analysis 3.3</a>), no longer demonstrated a difference (P = 0.05 and P = 0.53, respectively). Both analyses were for the outcome of number of participants requiring rescue medication over four to six hours. For <a href="./references#CD013263-fig-0006" title="">Analysis 1.3</a>, comparing ketorolac with placebo, <a href="./references#CD013263-bbs2-0002" title="BartonS , LangelandF , SnabesM , LeComteD , KussM , DhaddaS , et al. Efficacy and safety of intravenous parecoxib sodium in relieving acute postoperative pain following gynecologic laparotomy surgery. Anesthesiology2002;97(2):306-14. ">Barton 2002</a>, had a very similar event rate in the ketorolac and placebo groups. The reasons for this similarity are unclear. Of note, the median <i>time</i> to rescue was longer in those receiving ketorolac in this study, as noted in <a href="#CD013263-sec-0057">Effects of interventions</a>. For <a href="./references#CD013263-fig-0039" title="">Analysis 3.3</a>, comparing ketorolac versus an opioid, there were only two studies and a low total number of participants, so this analysis was more susceptible to chance. </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD013263-sec-0115" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD013263-sec-0115"></div> <section id="CD013263-sec-0116"> <h3 class="title" id="CD013263-sec-0116">Summary of main results</h3> <p>We found 12 studies for inclusion in this review. Study designs were similar, in that most required participants to report moderate‐to‐severe pain postoperatively before being assigned to one of the planned intervention groups. Most were single‐dose studies that measured pain relief or pain intensity difference after an intervention was administered. Doses of ketorolac varied among studies, but in 11 studies a 30 mg dose was administered, which represents the dose typically used in clinical practice in patients under the age of 65 years (those over 65 years typically receive 15 mg). One study used a dose of 15 mg separately from a 30 mg dose arm, and one study used a 60 mg single dose. For studies assessing multiple‐dose regimens, we assessed outcomes based only on the first dose administered. The similarity of study designs, and the drugs administered in the comparator arms, was reflected in the fact that most analyses did not display substantial heterogeneity, which we defined as an I<sup>2</sup> score of greater than 50%. However, comparison of ketorolac and placebo for our primary outcomes displayed substantial heterogeneity over both four and six hours. In these analyses, there were no obvious explanations for the differences in event rates among studies, but subgroup analyses based on type of surgery suggest that event rates may be higher in dental surgery, specifically third molar extraction, and lowest in abdominal or pelvic surgeries. Although it has been suggested that NSAIDs are more effective in dental models, this has not been demonstrated conclusively (<a href="./references#CD013263-bbs2-0103" title="BardenJ , EdwardsJE , McQuayHJ , MooreRA . Pain and analgesic response after third molar extraction and other postsurgical pain. Pain2004;107(1-2):86-90.">Barden 2004</a>). Conversely, NSAIDs are thought to be less effective in treating visceral pain; presumably the latter would be a major component of abdominal and pelvic surgeries. Of note, pooled analyses of the outcome 'number of participants using rescue over 4 ‐ 6 hours post‐interventions' displayed heterogeneity in all three comparisons (placebo, NSAID and opioid). Informal subgroup analyses by type of surgery for this outcome did not suggest that this was the source of heterogeneity. Although not part of our planned analysis, subgroup analysis by specific NSAID did reduce heterogeneity for this outcome from an I<sup>2</sup> score of 65% to 0%. </p> <p>The results of the studies available for IV ketorolac versus placebo suggest that more participants achieved at least 50% pain relief with ketorolac. For the same outcome, ketorolac appears to be similar to other NSAIDs (parecoxib or diclofenac), and superior to an opioid (morphine 4 mg). Limited evidence suggests that ketorolac has a similar safety profile to all three comparator groups. </p> <section id="CD013263-sec-0117"> <h4 class="title">Efficacy</h4> <p>Analysis of our primary outcome, defined as participants achieving at least 50% maximum pain relief over both four and six hours, demonstrated that ketorolac was superior to placebo and the opioid morphine at a dose of 4 mg, and similar to other NSAIDs, specifically parecoxib and diclofenac. Limited analysis of the most commonly‐used dose, 30 mg, versus 15 mg or 60 mg arms, based on data from only two studies, did not suggest a dose‐response effect. The relative benefit of ketorolac compared with placebo over four hours was 2.81 (95% CI 1.80 to 4.37). Around three times as many participants achieved at least 50% pain relief in the ketorolac group compared with those receiving placebo. The NNTB for one additional participant to benefit compared with placebo was 2.4 (95% CI 1.8 to 3.7), which indirectly compares favorably with oral analgesics used in the same setting (<a href="./references#CD013263-bbs2-0156" title="MooreRA , DerryS , AldingtonD , WiffenPJ . Single dose oral analgesics for acute postoperative pain in adults - an overview of Cochrane reviews. Cochrane Database of Systematic Reviews2015, Issue 9. Art. No: CD008659. [DOI: 10.1002/14651858.CD008659.pub3]">Moore 2015a</a>), and similarly to other parenteral NSAIDs, which were 20 mg of parenteral parecoxib (<a href="./references#CD013263-bbs2-0140" title="LloydR , DerryS , MooreRA , McQuayHJ . Intravenous or intramuscular parecoxib for acute postoperative pain in adults. Cochrane Database of Systematic Reviews2009, Issue 2. Art. No: CD004771. [DOI: 10.1002/14651858.CD004771]">Lloyd 2009</a>) and 37.5 mg of parenteral diclofenac (<a href="./references#CD013263-bbs2-0143" title="McNicolED , FergusonMC , SchumannR . Single-dose intravenous diclofenac for acute postoperative pain in adults. Cochrane Database of Systematic Reviews2018, Issue 8. Art. No: CD012498. [DOI: 10.1002/14651858.CD012498]">McNicol 2018</a>). Of note, parecoxib is not available in the USA. A systematic review of the only other commercially‐available NSAID, ibuprofen, is ongoing (<a href="./references#CD013263-bbs2-0123" title="FergusonMC , McNicolED , SchumannR . Single-dose intravenous ibuprofen for acute postoperative pain in adults. Cochrane Database of Systematic Reviews2019, Issue 2. Art. No: CD013264. [DOI: 10.1002/14651858.CD013264]">Ferguson 2018</a>). The percentage of participants achieving at least 50% maximum pain relief with ketorolac was similar over six hours versus over four hours, suggesting that ketorolac has a relatively long duration of action. Parenteral ketorolac also demonstrated lower (that is, superior) NNTBs over four and six hours versus those found in a Cochrane Review of parenteral formulations of paracetamol (acetaminophen) for postoperative pain, where NNTBs were 5 and 6 over four and six hours, respectively (<a href="./references#CD013263-bbs2-0142" title="McNicolED , FergusonMC , HaroutounianS , CarrDB , SchumannR . Single dose intravenous paracetamol or intravenous propacetamol for postoperative pain. Cochrane Database of Systematic Reviews2016, Issue 5. Art. No: CD007126. [DOI: 10.1002/14651858.CD007126]">McNicol 2016</a>). Direct comparison of ketorolac with other NSAIDs within this review suggested similar efficacy over both four and six hours (RR 1.04, 95% CI 0.89 to 1.21 and RR 1.06, 95% CI 0.95 to 1.19, respectively). Limited evidence, based on three studies, demonstrated that ketorolac 30 mg was superior to morphine 4 mg over both four and six hours, with NNTs of 3.7 (95% CI 2.6 to 6.7) and 3.7 (95% CI 2.6 to 6.3), respectively. This is somewhat unexpected, in that opioids are generally considered to be more effective in reducing pain than NSAIDs, but could possibly be related to a relatively small comparison dose of morphine. </p> <p>For secondary efficacy outcomes, median time to rescue medication was longer in those receiving ketorolac versus those receiving placebo. Head‐to‐head comparisons with another NSAID for these outcomes showed similar efficacy. In comparisons with an opioid, very limited evidence from only two studies showed that participants waited longer for rescue medication. Lastly, there were an insufficient number of events to allow us to perform pooled analyses of the number of participants withdrawing from a trial due to lack of efficacy. </p> </section> <section id="CD013263-sec-0118"> <h4 class="title">Safety</h4> <p>Total AE rates were slightly higher in those receiving ketorolac versus placebo or another NSAID (although differences are unlikely to be clinically significant), but were similar when comparing ketorolac with an opioid. There was a lack of data for our planned analyses of specific AEs associated with NSAID use, comprising renal dysfunction, cardiovascular events, gastrointestinal bleeding, operative‐site bleeding, and thrombophlebitis. This likely reflects the relatively low frequency with which these events occur, particularly in studies of short duration and low participant enrollment. Probably because of the greater incidence of opioid‐related side effects in general, there were more data available for these outcomes for comparisons between ketorolac and placebo or other comparators. Opioid‐related outcomes were analyzed to assess whether a reduction in requirement for rescue opioid in turn resulted in a reduction in the rate of occurrence of opioid‐related events. However, ketorolac was only shown to be safer than placebo for one outcome, sedation, where fewer than half as many participants reported this AE versus placebo. There was no evidence that ketorolac had different event rates versus other NSAIDs or versus opioids for all of the opioid‐related AEs. It is unclear if this reflects a genuine lack of difference, or is simply due to a lack of data.<br/>Only one participant experienced an SAE (an abdominal hematoma) when administered ketorolac, which was assessed as possibly related to the intervention (<a href="./references#CD013263-bbs2-0005" title="GanT , DanielsS , SinglaN , HamiltonD , CarrD . A novel injectable formulation of diclofenac compared with intravenous ketorolac or placebo for acute moderate-to-severe pain after abdominal or pelvic surgery: a multicenter, double-blind, randomized, multiple-dose study. Anesthesia and Analgesia2012;115(5):1212-20. ">Gan 2012</a>). Lastly, withdrawals due to AEs were very rare in all groups, as these generally take more time to develop than the very short study period would permit. </p> </section> </section> <section id="CD013263-sec-0119"> <h3 class="title" id="CD013263-sec-0119">Overall completeness and applicability of evidence</h3> <p>There were a reasonable number of studies, participants and events for meta‐analyses of our primary outcomes when comparing ketorolac with placebo. The data were less robust for comparisons with other NSAIDs or with opioids. For secondary efficacy outcomes, there were fewer data available, with the exception of time to rescue medication, when comparing ketorolac with placebo. Safety outcomes generally had a small number of studies, participants, and events for most analyses. The limited data prevented us from interpreting safety data with any confidence. Adverse events, particularly those that occur rarely or develop after multiple doses, may be better captured in epidemiological studies. Such studies have assessed rates of renal dysfunction, bleeding, delayed bone healing and reduced spinal fusion with short‐term use of ketorolac (<a href="./references#CD013263-bbs2-0108" title="ChanDK , ParikhSR . Perioperative ketorolac increases post-tonsillectomy hemorrhage in adults but not children. Laryngoscope2014;124(8):1789-93.">Chan 2014</a>; <a href="./references#CD013263-bbs2-0122" title="FeldmanHI , KinmanJL , BerlinJA , HennessyS , KimmelSE , FarrarJ , et al. Parenteral ketorolac: the risk for acute renal failure. Annals of Internal Medicine1997;126(3):193-9.">Feldman 1997</a>; <a href="./references#CD013263-bbs2-0129" title="GobbleRM , HoangHL , KachniarzB , OrgillDP . Ketorolac does not increase perioperative bleeding: a meta-analysis of randomized controlled trials. Plastic and Reconstructive Surgery2014;133(3):741-55.">Gobble 2014</a>; <a href="./references#CD013263-bbs2-0128" title="GlassmanSD , RoseSM , DimarJR , PunoRM , CampbellMJ , JohnsonJR . The effect of postoperative nonsteroidal anti-inflammatory drug administration on spinal fusion. Spine1998;23(7):834-8.">Glassman 1998</a>; <a href="./references#CD013263-bbs2-0141" title="Marquez-LaraA , HutchinsonID , Nuñez F Jr, SmithTL , MillerAN . Nonsteroidal anti-inflammatory drugs and bone-healing: a systematic review of research quality. JBJS Reviews2016;4(3 e4):1-14. [PMID: 27500434]">Marquez‐Lara 2016</a>; <a href="./references#CD013263-bbs2-0160" title="RigginL , RamakrishnaJ , SommerDD , KorenG . A 2013 updated systematic review &amp; meta‐analysis of 36 randomized controlled trials; no apparent effects of non steroidal anti‐inflammatory agents on the risk of bleeding after tonsillectomy. Clinical Otolaryngology2013;38(2):115-29.">Riggin 2013</a>; <a href="./references#CD013263-bbs2-0166" title="StromBL , BerlinJA , KinmanJL , SpitzPW , HennessyS , FeldmanH , et al. Parenteral ketorolac and risk of gastrointestinal and operative site bleeding: a postmarketing surveillance study. JAMA1996;275(5):376-82.">Strom 1996</a>). </p> <p>Included studies reported data from comparisons of ketorolac with both placebo and with active controls administered at standard routine dosing to treat postoperative pain. The studies covered a range of commonly‐performed surgeries, but no studies were conducted in people undergoing cardiovascular surgeries, and only two studies described surgeries performed as 'major'. The lack of studies in major surgeries may explain the limited data for reduction in opioid consumption and, in turn, opioid‐induced AEs, as opioids would be expected to be a larger component of the postoperative regimen in more invasive procedures. While the use of opioids in the postoperative period has declined in recent years due to advances in multimodal analgesic regimens and awareness and concerns for the safety of opioids, most of the included studies were performed in the 1990s or early 2000s. Earlier studies may not fully reflect current practice, as opioid dosing may have been more liberal and multimodal analgesic regimens were less frequently administered. </p> <p>The lack of studies in cardiovascular surgeries is perhaps not surprising, given guidelines from regulatory organizations that recommend NSAIDs be contraindicated immediately postoperatively in people undergoing coronary artery bypass surgery (<a href="./references#CD013263-bbs2-0138" title="JenkinsJK , SeligmanPJ . Memorandum: analysis and recommendations for agency action regarding non-steroidal anti-inflammatory drugs and cardiovascular risk.. www.fda.gov/downloads/drugs/drugsafety/postmarketdrugsafetyinformationforpatientsandproviders/ucm106201.pdf (accessed 7 August 2020).">Jenkins 2005</a>). However, an ongoing study (<a href="./references#CD013263-bbs2-0098" title="Irct20180909040979N. Comparison of the effect of intravenous ketorolac and paracetamol on pain. www.who.int/trialsearch/Trial2.aspx?TrialID=IRCT20180909040979N4 (first received 12 September 2019). ">Irct20180909040979N 2019</a>) intends to assess outcomes in this population. </p> <p>The mean age of participants across studies was generally low, but three studies in orthopedic surgery (<a href="./references#CD013263-bbs2-0008" title="MoodieJ , BisleyE , HuangS , PickthornK , BellG . A single-center, randomized, double-blind, active, and placebo-controlled study of KAI-1678, a novel PKC-epsilon inhibitor, in the treatment of acute postoperative orthopedic pain. Pain Medicine2013;14(6):916-24. ">Moodie 2013</a>; <a href="./references#CD013263-bbs2-0010" title="RasmussenG , StecknerK , HogueC , TorriS , HubbardR . Intravenous parecoxib sodium for acute pain after orthopedic knee surgery. American Journal of Orthopedics2002;31(6):336-43. ">Rasmussen 2002</a>; <a href="./references#CD013263-bbs2-0012" title="ZhouT , TangJ , WhiteP . Propacetamol versus ketorolac for treatment of acute postoperative pain after total hip or knee replacement. Anesthesia and Analgesia2001;92(6):1569-75. ">Zhou 2001</a>) assessed participants with an average age of over 60 years. However, only one of these studies used the dose typically suggested for this population (<a href="./references#CD013263-bbs2-0012" title="ZhouT , TangJ , WhiteP . Propacetamol versus ketorolac for treatment of acute postoperative pain after total hip or knee replacement. Anesthesia and Analgesia2001;92(6):1569-75. ">Zhou 2001</a>). It has been recommended that ketorolac be avoided in elderly people due to safety concerns, specifically for renal and gastrointestinal AEs (<a href="./references#CD013263-bbs2-0104" title="2019 American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2019 updated AGS Beers criteria for potentially inappropriate medication use in older adults. Journal of the American Geriatrics Society2019;67(4):674-94.">Beers 2019</a>). </p> </section> <section id="CD013263-sec-0120"> <h3 class="title" id="CD013263-sec-0120">Quality of the evidence</h3> <p>When assessing the certainty of findings using GRADE, we ranked certainty as ranging from very low to moderate for efficacy outcomes, but generally ranked the certainty of the evidence as low across safety outcomes, as shown in <a href="./full#CD013263-tbl-0001">summary of findings Table 1</a> and <a href="./full#CD013263-tbl-0002">summary of findings Table 2</a>. 'Low certainty' means that our confidence in the effect estimate is limited, and the true effect may be substantially different from the estimate of the effect. Many individual studies had an unclear risk of bias for issues such as allocation concealment and blinding, and a high risk of bias for sample size, and none of the trials was unequivocally at low risk of bias for all criteria. The lack of clarity for many of the risks of bias may be due to the reporting standards or space limitations of journals rather than any fundamental flaws in the methodology of the studies. Where a study was also posted to a clinical trial website, we sought additional data to further inform assessments. For the outcomes for which we were able to perform pooled analysis, we further downgraded the certainty of evidence due to issues with imprecision (wide confidence intervals) or sparse data (low overall numbers of participants, events, or both) and important inconsistency (unexplained heterogeneity of results).  </p> </section> <section id="CD013263-sec-0121"> <h3 class="title" id="CD013263-sec-0121">Potential biases in the review process</h3> <p>We tried to minimize the potential for publication bias related to unpublished or unidentified studies by assessing clinical trial registries and multiple databases, respectively. We also assessed the impact publication bias may have on our findings. </p> <p>For analysis of our primary outcome of pain relief, we used the number of participants with 30% pain relief, rather than at least 50% pain relief, for one study (<a href="./references#CD013263-fig-0005" title="">Analysis 1.2</a>; <a href="./references#CD013263-fig-0023" title="">Analysis 2.2</a>) (<a href="./references#CD013263-bbs2-0005" title="GanT , DanielsS , SinglaN , HamiltonD , CarrD . A novel injectable formulation of diclofenac compared with intravenous ketorolac or placebo for acute moderate-to-severe pain after abdominal or pelvic surgery: a multicenter, double-blind, randomized, multiple-dose study. Anesthesia and Analgesia2012;115(5):1212-20. ">Gan 2012</a>), as these were the only data available for this study. Not surprisingly, more participants achieved at least 30% pain relief in this study than the proportion of those achieving at least 50% in the other studies included in these analyses. However, NNTBs for 30% and 50% pain relief have been shown to be similar over six hours when effective analgesics are compared with placebo (<a href="./references#CD013263-bbs2-0150" title="MooreRA , McQuayHJ . Single-patient data meta-analysis of 3453 postoperative patients: oral tramadol versus placebo, codeine and combination analgesics. Pain1997;69(3):287-94.">Moore 1997c</a>; <a href="./references#CD013263-bbs2-0152" title="MooreRA , EdwardsJE , McQuayHJ . Acute pain: individual patient meta-analysis shows the impact of different ways of analysing and presenting results. Pain2005;116(3):322-31. [DOI: 10.1016/j.pain.2005.05.001]">Moore 2005</a>), given that event rates tend to change proportionally in both groups when different cutpoints of pain relief are measured. </p> <p>We did not assess time to onset of analgesia as an efficacy outcome. This was not a frequently‐assessed outcome in our included studies. However, this may be an important outcome for patients. </p> <p>For some AEs we did not predefine assessment criteria for inclusion in a meta‐analysis. Instead we typically reported them as they were defined in the included studies. For example, <a href="./references#CD013263-bbs2-0001" title="BalestrieriP , SimmonsG , HillD , BrownJ , JacksonA , Brull SJ , et al. The effect of intravenous ketorolac given intraoperatively versus postoperatively on outcome from gynecologic abdominal surgery. Journal of Clinical Anesthesia1997;9(5):358-64. ">Balestrieri 1997</a> defined cardiovascular events as bradycardia, tachycardia, hypotension, and hypertension, whereas cardiovascular events would usually be defined as stroke, myocardial infarction, etc. This may have led to over‐ (or under‐) counting of events. Other AEs, such as vomiting, may be less vulnerable to assessor interpretation. </p> <p>We are not aware of additional potential biases.</p> </section> <section id="CD013263-sec-0122"> <h3 class="title" id="CD013263-sec-0122">Agreements and disagreements with other studies or reviews</h3> <p>We are aware of two other systematic reviews and meta‐analyses of ketorolac for postoperative pain, both of which compared ketorolac to placebo only (<a href="./references#CD013263-bbs2-0116" title="De OliveiraGS , AgarwalD , BenzonHT . Perioperative single dose ketorolac to prevent postoperative pain: a meta-analysis of randomized trials. Anesthesia &amp; Analgesia2012;114(2):424-33.">De Oliveira 2012</a>; <a href="./references#CD013263-bbs2-0164" title="SmithLA , CarrollD , EdwardsJE , MooreRA , McQuayHJ . Single-dose ketorolac and pethidine in acute postoperative pain: systematic review with meta-analysis. British Journal of Anaesthesia2000;84(1):48-58.">Smith 2000</a>). The former also included studies where ketorolac was administered before the end of surgery and assessed different efficacy outcomes, such as pain scores at four hours and opioid consumption in IV morphine equivalents. As with our analysis, reductions in opioid consumption were generally not accompanied by reductions in opioid‐related AEs. <a href="./references#CD013263-bbs2-0164" title="SmithLA , CarrollD , EdwardsJE , MooreRA , McQuayHJ . Single-dose ketorolac and pethidine in acute postoperative pain: systematic review with meta-analysis. British Journal of Anaesthesia2000;84(1):48-58.">Smith 2000</a> did not include any studies where ketorolac was administered intravenously; instead the eight included parenteral studies administered ketorolac intramuscularly. For the outcome of participants with at least 50% pain relief at four to six hours, the percentage of participants achieving this in the ketorolac and placebo groups was similar to our review, and the NNT was slightly higher compared to our findings (3.4 versus 2.6). Assessment of AE rates was similar to our findings. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD013263-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/urn:x-wiley:14651858:media:CD013263:CD013263-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD013263-fig-0001" src="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/image_n/nCD013263-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/image_t/tCD013263-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/full#CD013263-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/image_n/nCD013263-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013263-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/urn:x-wiley:14651858:media:CD013263:CD013263-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD013263-fig-0002" src="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/image_n/nCD013263-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/image_t/tCD013263-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/full#CD013263-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/image_n/nCD013263-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013263-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/urn:x-wiley:14651858:media:CD013263:CD013263-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD013263-fig-0003" src="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/image_n/nCD013263-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/image_t/tCD013263-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/full#CD013263-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/image_n/nCD013263-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013263-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/urn:x-wiley:14651858:media:CD013263:CD013263-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Ketorolac versus placebo, Outcome 1: Number of participants with at least 50% pain relief at 4 hours" data-id="CD013263-fig-0004" src="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/image_n/nCD013263-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/image_t/tCD013263-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Ketorolac versus placebo, Outcome 1: Number of participants with at least 50% pain relief at 4 hours </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/references#CD013263-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/image_n/nCD013263-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013263-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/urn:x-wiley:14651858:media:CD013263:CD013263-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Ketorolac versus placebo, Outcome 2: Number of participants with at least 50% pain relief at 6 hours" data-id="CD013263-fig-0005" src="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/image_n/nCD013263-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/image_t/tCD013263-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Ketorolac versus placebo, Outcome 2: Number of participants with at least 50% pain relief at 6 hours </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/references#CD013263-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/image_n/nCD013263-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013263-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/urn:x-wiley:14651858:media:CD013263:CD013263-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Ketorolac versus placebo, Outcome 3: Number of participants using rescue medication over 4 to 6 hours post interventions" data-id="CD013263-fig-0006" src="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/image_n/nCD013263-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/image_t/tCD013263-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Ketorolac versus placebo, Outcome 3: Number of participants using rescue medication over 4 to 6 hours post interventions </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/references#CD013263-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/image_n/nCD013263-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013263-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/urn:x-wiley:14651858:media:CD013263:CD013263-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Ketorolac versus placebo, Outcome 4: Number of participants withdrawing due to adverse events" data-id="CD013263-fig-0007" src="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/image_n/nCD013263-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/image_t/tCD013263-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: Ketorolac versus placebo, Outcome 4: Number of participants withdrawing due to adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/references#CD013263-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/image_n/nCD013263-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013263-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/urn:x-wiley:14651858:media:CD013263:CD013263-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Ketorolac versus placebo, Outcome 5: Number of participants withdrawing due to lack of efficacy" data-id="CD013263-fig-0008" src="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/image_n/nCD013263-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/image_t/tCD013263-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: Ketorolac versus placebo, Outcome 5: Number of participants withdrawing due to lack of efficacy </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/references#CD013263-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/image_n/nCD013263-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013263-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/urn:x-wiley:14651858:media:CD013263:CD013263-CMP-001.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Ketorolac versus placebo, Outcome 6: Number of participants withdrawing for any cause" data-id="CD013263-fig-0009" src="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/image_n/nCD013263-CMP-001.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/image_t/tCD013263-CMP-001.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1: Ketorolac versus placebo, Outcome 6: Number of participants withdrawing for any cause </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/references#CD013263-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/image_n/nCD013263-CMP-001.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013263-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/urn:x-wiley:14651858:media:CD013263:CD013263-CMP-001.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Ketorolac versus placebo, Outcome 7: Number of participants reporting any adverse event" data-id="CD013263-fig-0010" src="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/image_n/nCD013263-CMP-001.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/image_t/tCD013263-CMP-001.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1: Ketorolac versus placebo, Outcome 7: Number of participants reporting any adverse event </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/references#CD013263-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/image_n/nCD013263-CMP-001.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013263-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/urn:x-wiley:14651858:media:CD013263:CD013263-CMP-001.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Ketorolac versus placebo, Outcome 8: Number of participants reporting a serious adverse event" data-id="CD013263-fig-0011" src="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/image_n/nCD013263-CMP-001.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/image_t/tCD013263-CMP-001.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1: Ketorolac versus placebo, Outcome 8: Number of participants reporting a serious adverse event </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/references#CD013263-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/image_n/nCD013263-CMP-001.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013263-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/urn:x-wiley:14651858:media:CD013263:CD013263-CMP-001.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Ketorolac versus placebo, Outcome 9: Number of participants experiencing a cardiovascular event" data-id="CD013263-fig-0012" src="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/image_n/nCD013263-CMP-001.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/image_t/tCD013263-CMP-001.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1: Ketorolac versus placebo, Outcome 9: Number of participants experiencing a cardiovascular event </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/references#CD013263-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/image_n/nCD013263-CMP-001.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013263-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/urn:x-wiley:14651858:media:CD013263:CD013263-CMP-001.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Ketorolac versus placebo, Outcome 10: Number of participants experiencing operative site bleeding" data-id="CD013263-fig-0013" src="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/image_n/nCD013263-CMP-001.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/image_t/tCD013263-CMP-001.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1: Ketorolac versus placebo, Outcome 10: Number of participants experiencing operative site bleeding </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/references#CD013263-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/image_n/nCD013263-CMP-001.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013263-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/urn:x-wiley:14651858:media:CD013263:CD013263-CMP-001.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Ketorolac versus placebo, Outcome 11: Number of participants experiencing thrombophlebitis" data-id="CD013263-fig-0014" src="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/image_n/nCD013263-CMP-001.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/image_t/tCD013263-CMP-001.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1: Ketorolac versus placebo, Outcome 11: Number of participants experiencing thrombophlebitis </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/references#CD013263-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/image_n/nCD013263-CMP-001.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013263-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/urn:x-wiley:14651858:media:CD013263:CD013263-CMP-001.12" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Ketorolac versus placebo, Outcome 12: Number of participants reporting nausea" data-id="CD013263-fig-0015" src="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/image_n/nCD013263-CMP-001.12.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/image_t/tCD013263-CMP-001.12.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1: Ketorolac versus placebo, Outcome 12: Number of participants reporting nausea </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/references#CD013263-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/image_n/nCD013263-CMP-001.12.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013263-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/urn:x-wiley:14651858:media:CD013263:CD013263-CMP-001.13" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Ketorolac versus placebo, Outcome 13: Number of participants experiencing vomiting" data-id="CD013263-fig-0016" src="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/image_n/nCD013263-CMP-001.13.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/image_t/tCD013263-CMP-001.13.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.13</div> <div class="figure-caption"> <p>Comparison 1: Ketorolac versus placebo, Outcome 13: Number of participants experiencing vomiting </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/references#CD013263-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/image_n/nCD013263-CMP-001.13.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013263-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/urn:x-wiley:14651858:media:CD013263:CD013263-CMP-001.14" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Ketorolac versus placebo, Outcome 14: Number of participants reporting pruritus" data-id="CD013263-fig-0017" src="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/image_n/nCD013263-CMP-001.14.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/image_t/tCD013263-CMP-001.14.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.14</div> <div class="figure-caption"> <p>Comparison 1: Ketorolac versus placebo, Outcome 14: Number of participants reporting pruritus </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/references#CD013263-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/image_n/nCD013263-CMP-001.14.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013263-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/urn:x-wiley:14651858:media:CD013263:CD013263-CMP-001.15" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Ketorolac versus placebo, Outcome 15: Number of participants experiencing respiratory depression" data-id="CD013263-fig-0018" src="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/image_n/nCD013263-CMP-001.15.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/image_t/tCD013263-CMP-001.15.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.15</div> <div class="figure-caption"> <p>Comparison 1: Ketorolac versus placebo, Outcome 15: Number of participants experiencing respiratory depression </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/references#CD013263-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/image_n/nCD013263-CMP-001.15.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013263-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/urn:x-wiley:14651858:media:CD013263:CD013263-CMP-001.16" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Ketorolac versus placebo, Outcome 16: Number of participants experiencing sedation" data-id="CD013263-fig-0019" src="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/image_n/nCD013263-CMP-001.16.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/image_t/tCD013263-CMP-001.16.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.16</div> <div class="figure-caption"> <p>Comparison 1: Ketorolac versus placebo, Outcome 16: Number of participants experiencing sedation </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/references#CD013263-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/image_n/nCD013263-CMP-001.16.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013263-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/urn:x-wiley:14651858:media:CD013263:CD013263-CMP-001.17" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Ketorolac versus placebo, Outcome 17: Number of participants with at least 50% pain relief at 4 hours: subgroup analysis" data-id="CD013263-fig-0020" src="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/image_n/nCD013263-CMP-001.17.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/image_t/tCD013263-CMP-001.17.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.17</div> <div class="figure-caption"> <p>Comparison 1: Ketorolac versus placebo, Outcome 17: Number of participants with at least 50% pain relief at 4 hours: subgroup analysis </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/references#CD013263-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/image_n/nCD013263-CMP-001.17.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013263-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/urn:x-wiley:14651858:media:CD013263:CD013263-CMP-001.18" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Ketorolac versus placebo, Outcome 18: Number of participants with at least 50% pain relief at 6 hours: subgroup analysis" data-id="CD013263-fig-0021" src="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/image_n/nCD013263-CMP-001.18.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/image_t/tCD013263-CMP-001.18.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.18</div> <div class="figure-caption"> <p>Comparison 1: Ketorolac versus placebo, Outcome 18: Number of participants with at least 50% pain relief at 6 hours: subgroup analysis </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/references#CD013263-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/image_n/nCD013263-CMP-001.18.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013263-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/urn:x-wiley:14651858:media:CD013263:CD013263-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Ketorolac versus other NSAID, Outcome 1: Number of participants with at least 50% pain relief at 4 hours" data-id="CD013263-fig-0022" src="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/image_n/nCD013263-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/image_t/tCD013263-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: Ketorolac versus other NSAID, Outcome 1: Number of participants with at least 50% pain relief at 4 hours </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/references#CD013263-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/image_n/nCD013263-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013263-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/urn:x-wiley:14651858:media:CD013263:CD013263-CMP-002.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Ketorolac versus other NSAID, Outcome 2: Number of participants with at least 50% pain relief at 6 hours" data-id="CD013263-fig-0023" src="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/image_n/nCD013263-CMP-002.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/image_t/tCD013263-CMP-002.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2: Ketorolac versus other NSAID, Outcome 2: Number of participants with at least 50% pain relief at 6 hours </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/references#CD013263-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/image_n/nCD013263-CMP-002.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013263-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/urn:x-wiley:14651858:media:CD013263:CD013263-CMP-002.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Ketorolac versus other NSAID, Outcome 3: Number of participants using rescue medication over 4 to 6 hours post interventions" data-id="CD013263-fig-0024" src="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/image_n/nCD013263-CMP-002.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/image_t/tCD013263-CMP-002.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2: Ketorolac versus other NSAID, Outcome 3: Number of participants using rescue medication over 4 to 6 hours post interventions </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/references#CD013263-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/image_n/nCD013263-CMP-002.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013263-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/urn:x-wiley:14651858:media:CD013263:CD013263-CMP-002.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Ketorolac versus other NSAID, Outcome 4: Number of participants withdrawing due to adverse events" data-id="CD013263-fig-0025" src="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/image_n/nCD013263-CMP-002.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/image_t/tCD013263-CMP-002.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2: Ketorolac versus other NSAID, Outcome 4: Number of participants withdrawing due to adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/references#CD013263-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/image_n/nCD013263-CMP-002.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013263-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/urn:x-wiley:14651858:media:CD013263:CD013263-CMP-002.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Ketorolac versus other NSAID, Outcome 5: Number of participants withdrawing due to lack of efficacy" data-id="CD013263-fig-0026" src="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/image_n/nCD013263-CMP-002.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/image_t/tCD013263-CMP-002.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2: Ketorolac versus other NSAID, Outcome 5: Number of participants withdrawing due to lack of efficacy </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/references#CD013263-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/image_n/nCD013263-CMP-002.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013263-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/urn:x-wiley:14651858:media:CD013263:CD013263-CMP-002.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Ketorolac versus other NSAID, Outcome 6: Number of participants withdrawing for any cause" data-id="CD013263-fig-0027" src="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/image_n/nCD013263-CMP-002.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/image_t/tCD013263-CMP-002.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2: Ketorolac versus other NSAID, Outcome 6: Number of participants withdrawing for any cause </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/references#CD013263-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/image_n/nCD013263-CMP-002.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013263-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/urn:x-wiley:14651858:media:CD013263:CD013263-CMP-002.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Ketorolac versus other NSAID, Outcome 7: Number of participants reporting any adverse event" data-id="CD013263-fig-0028" src="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/image_n/nCD013263-CMP-002.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/image_t/tCD013263-CMP-002.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2: Ketorolac versus other NSAID, Outcome 7: Number of participants reporting any adverse event </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/references#CD013263-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/image_n/nCD013263-CMP-002.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013263-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/urn:x-wiley:14651858:media:CD013263:CD013263-CMP-002.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Ketorolac versus other NSAID, Outcome 8: Number of participants reporting a serious adverse event" data-id="CD013263-fig-0029" src="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/image_n/nCD013263-CMP-002.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/image_t/tCD013263-CMP-002.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.8</div> <div class="figure-caption"> <p>Comparison 2: Ketorolac versus other NSAID, Outcome 8: Number of participants reporting a serious adverse event </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/references#CD013263-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/image_n/nCD013263-CMP-002.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013263-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/urn:x-wiley:14651858:media:CD013263:CD013263-CMP-002.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Ketorolac versus other NSAID, Outcome 9: Number of participants experiencing thrombophlebitis" data-id="CD013263-fig-0030" src="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/image_n/nCD013263-CMP-002.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/image_t/tCD013263-CMP-002.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.9</div> <div class="figure-caption"> <p>Comparison 2: Ketorolac versus other NSAID, Outcome 9: Number of participants experiencing thrombophlebitis </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/references#CD013263-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/image_n/nCD013263-CMP-002.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013263-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/urn:x-wiley:14651858:media:CD013263:CD013263-CMP-002.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Ketorolac versus other NSAID, Outcome 10: Number of participants reporting nausea" data-id="CD013263-fig-0031" src="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/image_n/nCD013263-CMP-002.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/image_t/tCD013263-CMP-002.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.10</div> <div class="figure-caption"> <p>Comparison 2: Ketorolac versus other NSAID, Outcome 10: Number of participants reporting nausea </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/references#CD013263-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/image_n/nCD013263-CMP-002.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013263-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/urn:x-wiley:14651858:media:CD013263:CD013263-CMP-002.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Ketorolac versus other NSAID, Outcome 11: Number of participants experiencing vomiting" data-id="CD013263-fig-0032" src="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/image_n/nCD013263-CMP-002.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/image_t/tCD013263-CMP-002.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.11</div> <div class="figure-caption"> <p>Comparison 2: Ketorolac versus other NSAID, Outcome 11: Number of participants experiencing vomiting </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/references#CD013263-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/image_n/nCD013263-CMP-002.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013263-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/urn:x-wiley:14651858:media:CD013263:CD013263-CMP-002.12" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Ketorolac versus other NSAID, Outcome 12: Number of participants reporting pruritus" data-id="CD013263-fig-0033" src="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/image_n/nCD013263-CMP-002.12.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/image_t/tCD013263-CMP-002.12.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.12</div> <div class="figure-caption"> <p>Comparison 2: Ketorolac versus other NSAID, Outcome 12: Number of participants reporting pruritus </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/references#CD013263-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/image_n/nCD013263-CMP-002.12.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013263-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/urn:x-wiley:14651858:media:CD013263:CD013263-CMP-002.13" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Ketorolac versus other NSAID, Outcome 13: Number of participants experiencing sedation" data-id="CD013263-fig-0034" src="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/image_n/nCD013263-CMP-002.13.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/image_t/tCD013263-CMP-002.13.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.13</div> <div class="figure-caption"> <p>Comparison 2: Ketorolac versus other NSAID, Outcome 13: Number of participants experiencing sedation </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/references#CD013263-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/image_n/nCD013263-CMP-002.13.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013263-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/urn:x-wiley:14651858:media:CD013263:CD013263-CMP-002.14" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Ketorolac versus other NSAID, Outcome 14: Number of participants with at least 50% pain relief at 4 hours: subgroup analysis" data-id="CD013263-fig-0035" src="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/image_n/nCD013263-CMP-002.14.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/image_t/tCD013263-CMP-002.14.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.14</div> <div class="figure-caption"> <p>Comparison 2: Ketorolac versus other NSAID, Outcome 14: Number of participants with at least 50% pain relief at 4 hours: subgroup analysis </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/references#CD013263-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/image_n/nCD013263-CMP-002.14.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013263-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/urn:x-wiley:14651858:media:CD013263:CD013263-CMP-002.15" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Ketorolac versus other NSAID, Outcome 15: Number of participants with at least 50% pain relief at 6 hours: subgroup analysis" data-id="CD013263-fig-0036" src="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/image_n/nCD013263-CMP-002.15.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/image_t/tCD013263-CMP-002.15.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.15</div> <div class="figure-caption"> <p>Comparison 2: Ketorolac versus other NSAID, Outcome 15: Number of participants with at least 50% pain relief at 6 hours: subgroup analysis </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/references#CD013263-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/image_n/nCD013263-CMP-002.15.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013263-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/urn:x-wiley:14651858:media:CD013263:CD013263-CMP-003.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Ketorolac versus opioid, Outcome 1: Number of participants with at least 50% pain relief at 4 hours" data-id="CD013263-fig-0037" src="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/image_n/nCD013263-CMP-003.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/image_t/tCD013263-CMP-003.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3: Ketorolac versus opioid, Outcome 1: Number of participants with at least 50% pain relief at 4 hours </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/references#CD013263-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/image_n/nCD013263-CMP-003.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013263-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/urn:x-wiley:14651858:media:CD013263:CD013263-CMP-003.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Ketorolac versus opioid, Outcome 2: Number of participants with at least 50% pain relief at 6 hours" data-id="CD013263-fig-0038" src="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/image_n/nCD013263-CMP-003.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/image_t/tCD013263-CMP-003.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3: Ketorolac versus opioid, Outcome 2: Number of participants with at least 50% pain relief at 6 hours </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/references#CD013263-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/image_n/nCD013263-CMP-003.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013263-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/urn:x-wiley:14651858:media:CD013263:CD013263-CMP-003.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Ketorolac versus opioid, Outcome 3: Number of participants using rescue medication over 4 to 6 hours post interventions" data-id="CD013263-fig-0039" src="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/image_n/nCD013263-CMP-003.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/image_t/tCD013263-CMP-003.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3: Ketorolac versus opioid, Outcome 3: Number of participants using rescue medication over 4 to 6 hours post interventions </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/references#CD013263-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/image_n/nCD013263-CMP-003.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013263-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/urn:x-wiley:14651858:media:CD013263:CD013263-CMP-003.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Ketorolac versus opioid, Outcome 4: Number of participants withdrawing due to adverse events" data-id="CD013263-fig-0040" src="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/image_n/nCD013263-CMP-003.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/image_t/tCD013263-CMP-003.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3: Ketorolac versus opioid, Outcome 4: Number of participants withdrawing due to adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/references#CD013263-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/image_n/nCD013263-CMP-003.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013263-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/urn:x-wiley:14651858:media:CD013263:CD013263-CMP-003.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Ketorolac versus opioid, Outcome 5: Number of participants withdrawing due to lack of efficacy" data-id="CD013263-fig-0041" src="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/image_n/nCD013263-CMP-003.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/image_t/tCD013263-CMP-003.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3: Ketorolac versus opioid, Outcome 5: Number of participants withdrawing due to lack of efficacy </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/references#CD013263-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/image_n/nCD013263-CMP-003.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013263-fig-0042"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/urn:x-wiley:14651858:media:CD013263:CD013263-CMP-003.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Ketorolac versus opioid, Outcome 6: Number of participants withdrawing for any cause" data-id="CD013263-fig-0042" src="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/image_n/nCD013263-CMP-003.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/image_t/tCD013263-CMP-003.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.6</div> <div class="figure-caption"> <p>Comparison 3: Ketorolac versus opioid, Outcome 6: Number of participants withdrawing for any cause </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/references#CD013263-fig-0042">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/image_n/nCD013263-CMP-003.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013263-fig-0043"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/urn:x-wiley:14651858:media:CD013263:CD013263-CMP-003.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Ketorolac versus opioid, Outcome 7: Number of participants reporting any adverse event" data-id="CD013263-fig-0043" src="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/image_n/nCD013263-CMP-003.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/image_t/tCD013263-CMP-003.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.7</div> <div class="figure-caption"> <p>Comparison 3: Ketorolac versus opioid, Outcome 7: Number of participants reporting any adverse event </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/references#CD013263-fig-0043">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/image_n/nCD013263-CMP-003.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013263-fig-0044"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/urn:x-wiley:14651858:media:CD013263:CD013263-CMP-003.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Ketorolac versus opioid, Outcome 8: Number of participants reporting a serious adverse event" data-id="CD013263-fig-0044" src="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/image_n/nCD013263-CMP-003.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/image_t/tCD013263-CMP-003.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.8</div> <div class="figure-caption"> <p>Comparison 3: Ketorolac versus opioid, Outcome 8: Number of participants reporting a serious adverse event </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/references#CD013263-fig-0044">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/image_n/nCD013263-CMP-003.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013263-fig-0045"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/urn:x-wiley:14651858:media:CD013263:CD013263-CMP-003.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Ketorolac versus opioid, Outcome 9: Number of participants reporting nausea" data-id="CD013263-fig-0045" src="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/image_n/nCD013263-CMP-003.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/image_t/tCD013263-CMP-003.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.9</div> <div class="figure-caption"> <p>Comparison 3: Ketorolac versus opioid, Outcome 9: Number of participants reporting nausea </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/references#CD013263-fig-0045">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/image_n/nCD013263-CMP-003.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013263-fig-0046"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/urn:x-wiley:14651858:media:CD013263:CD013263-CMP-003.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Ketorolac versus opioid, Outcome 10: Number of participants experiencing vomiting" data-id="CD013263-fig-0046" src="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/image_n/nCD013263-CMP-003.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/image_t/tCD013263-CMP-003.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.10</div> <div class="figure-caption"> <p>Comparison 3: Ketorolac versus opioid, Outcome 10: Number of participants experiencing vomiting </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/references#CD013263-fig-0046">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/image_n/nCD013263-CMP-003.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013263-fig-0047"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/urn:x-wiley:14651858:media:CD013263:CD013263-CMP-003.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Ketorolac versus opioid, Outcome 11: Number of participants reporting pruritus" data-id="CD013263-fig-0047" src="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/image_n/nCD013263-CMP-003.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/image_t/tCD013263-CMP-003.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.11</div> <div class="figure-caption"> <p>Comparison 3: Ketorolac versus opioid, Outcome 11: Number of participants reporting pruritus </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/references#CD013263-fig-0047">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/image_n/nCD013263-CMP-003.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013263-fig-0048"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/urn:x-wiley:14651858:media:CD013263:CD013263-CMP-003.12" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Ketorolac versus opioid, Outcome 12: Number of participants experiencing sedation" data-id="CD013263-fig-0048" src="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/image_n/nCD013263-CMP-003.12.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/image_t/tCD013263-CMP-003.12.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.12</div> <div class="figure-caption"> <p>Comparison 3: Ketorolac versus opioid, Outcome 12: Number of participants experiencing sedation </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/references#CD013263-fig-0048">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/media/CDSR/CD013263/image_n/nCD013263-CMP-003.12.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD013263-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Intravenous ketorolac compared to placebo for adults with acute postoperative pain</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Intravenous ketorolac compared to placebo for adults with acute postoperative pain</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> adults (mean study ages 23 to 67 years) with acute postoperative pain after abdominal/pelvic, dental or orthopedic surgeries<br/><b>Settings:</b> hospital or community<br/><b>Intervention:</b> intravenous ketorolac (30 mg or 60 mg)<br/><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Probable outcome with:</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect and NNTB or NNTH (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>No of Participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Placebo</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Ketorolac</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants with at least 50% pain relief over 4 hours</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>192 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>586 per 1000</b><br/>(463 to 741) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 2.81</b><br/>(1.80 to 4.37) </p> <p><b>NNTB</b> 2.4 (1.8 to 3.7) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>658<br/>(8 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low</b><sup>a,b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants with at least 50% pain relief over 6 hours</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>231 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>592 per 1000</b><br/>(497 to 705) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 3.26</b><br/>(1.93 to 5.51) </p> <p><b>NNTB</b> 2.5 (1.9 to 3.7) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>914<br/>(10 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Median time to use of rescue medication</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>104 minutes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>271 minutes</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not applicable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>633<br/>(6 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>moderate</b><sup>a,d,e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants using rescue medication over 4 or 6 hours post‐interventions</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>830 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>531 per 1000</b><br/>(456 to 606) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.60</b> <br/>(0.36 to 1.00) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>417<br/>(5 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low</b><sup>a,b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants reporting any adverse event</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>647 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>705 per 1000</b><br/>(647 to 770) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.09</b> <br/>(1.00 to 1.19) </p> <p><b>NNTH</b> 16.7 (8.3 to infinite) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>810<br/>(8 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>moderate</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants experiencing a serious adverse event</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>11 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>7 per 1000</b><br/>(1 to 33) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.62</b> <br/>(0.13 to 3.03) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>703<br/>(8 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>a,f</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Studies underpowered to detect these events</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>CI:</b> confidence interval; <b>NNTB:</b> number needed to treat for an additional beneficial outcome; <b>NNTH:</b> number needed to treat for an additional harmful outcome; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""></td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded once for serious study limitations due to unclear risk of bias in several domains.<br/><sup>b</sup>Downgraded once for inconsistency due to unexplained heterogeneity (I<sup>2</sup> &gt; 50%).<br/><sup>c</sup>Downgraded once for imprecision due to total number of events &lt; 300.<br/><sup>d</sup>Downgraded once for imprecision due to being unable to estimate confidence intervals because of reporting of median data.<br/><sup>e</sup>Upgraded once for large magnitude of effect: time to rescue &gt; 3 times longer in ketorolac group.<br/><sup>f</sup>Downgraded once for imprecision due to very low event rate. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Intravenous ketorolac compared to placebo for adults with acute postoperative pain</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/full#CD013263-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD013263-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Intravenous ketorolac compared to another NSAID for adults with acute postoperative pain</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Intravenous ketorolac compared to another NSAID for adults with acute postoperative pain</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> adults (mean study ages 23 to 67 years) with acute postoperative pain after abdominal/pelvic, dental or orthopedic surgeries<br/><b>Settings:</b> hospital or community<br/><b>Intervention:</b> intravenous ketorolac (30 mg)<br/><b>Comparison:</b> another NSAID (parecoxib or diclofenac) </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Probable outcome with:</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect and NNTB or NNTH (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>No of Participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Other NSAID</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Ketorolac</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants with at least 50% pain relief over 4 hours</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>630 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>656 per 1000</b><br/>(561 to 763) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.04</b> <br/>(0.89 to 1.21) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>337<br/>(4 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants with at least 50% pain relief over 6 hours</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>626 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>663 per 1000</b><br/>(595 to 745) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.06</b> <br/>(0.95 to 1.19) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>603<br/>(6 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>moderate</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Median time to use of rescue medication</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>296 minutes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>331 minutes</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not applicable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>427<br/>(4 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>a,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants using rescue medication over 4 or 6 hours post interventions</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>515 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>474 per 1000</b><br/>(381 to 582) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.90</b> <br/>(0.58 to 1.40) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>260<br/>(3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low</b><sup>a,b,d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants reporting any adverse event</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>683 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>759 per 1000</b> <br/>(683 to 841) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.11</b> <br/>(1.00 to 1.23) </p> <p><b>NNTH</b> 12.5 (6.7 to infinite) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>516<br/>(5 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>moderate</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants experiencing a serious adverse event</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b><br/>(0 to 0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 3.18</b> <br/>(0.13 to 76.99) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>530<br/>(5 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>a,e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Studies underpowered to detect these events.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>CI:</b> confidence interval; <b>NNTB:</b> number needed to treat for an additional beneficial outcome; <b>NNTH:</b> number needed to treat for an additional harmful outcome; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded once for serious study limitations due to unclear risk of bias in several domains.<br/><sup>b</sup>Downgraded once for imprecision due to total number of events &lt; 300.<br/><sup>c</sup>Downgraded once for imprecision due to being unable to estimate confidence intervals because of reporting of median data.<br/><sup>d</sup>Downgraded once for inconsistency due to unexplained heterogeneity (I<sup>2</sup> &gt; 50%).<br/><sup>e</sup>Downgraded once for imprecision due to very low event rate. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Intravenous ketorolac compared to another NSAID for adults with acute postoperative pain</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/full#CD013263-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013263-tbl-0003"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Ketorolac versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Number of participants with at least 50% pain relief at 4 hours <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>658</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.81 [1.80, 4.37]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Number of participants with at least 50% pain relief at 6 hours <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>914</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.26 [1.93, 5.51]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Number of participants using rescue medication over 4 to 6 hours post interventions <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>417</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.60 [0.36, 1.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Number of participants withdrawing due to adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>945</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.31 [0.56, 3.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 Number of participants withdrawing due to lack of efficacy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>698</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.36, 1.78]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.6 Number of participants withdrawing for any cause <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>634</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.47, 1.36]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.7 Number of participants reporting any adverse event <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>810</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [1.00, 1.19]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.8 Number of participants reporting a serious adverse event <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>703</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.62 [0.13, 3.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.9 Number of participants experiencing a cardiovascular event <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>323</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.13 [0.63, 2.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.10 Number of participants experiencing operative site bleeding <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>241</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.78 [0.67, 21.26]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.11 Number of participants experiencing thrombophlebitis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.12 Number of participants reporting nausea <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>798</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.75, 1.04]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.13 Number of participants experiencing vomiting <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>724</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.59, 1.20]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.14 Number of participants reporting pruritus <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>574</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.49, 1.50]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.15 Number of participants experiencing respiratory depression <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>246</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.42 [0.14, 1.33]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.16 Number of participants experiencing sedation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>566</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.47 [0.25, 0.86]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.17 Number of participants with at least 50% pain relief at 4 hours: subgroup analysis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>658</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.81 [1.80, 4.37]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.17.1 Abdominal/pelvic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.13 [1.47, 3.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.17.2 Dental</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>98</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>69.73 [4.39, 1107.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.17.3 Orthopedic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>260</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.04 [1.67, 5.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.18 Number of participants with at least 50% pain relief at 6 hours: subgroup analysis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>914</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.26 [1.93, 5.51]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.18.1 Abdominal/pelvic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>458</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.81 [1.21, 2.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.18.2 Dental</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>196</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>22.72 [6.64, 77.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.18.3 Orthopedic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>260</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.22 [1.90, 5.46]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Ketorolac versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/references#CD013263-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013263-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Ketorolac versus other NSAID</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 Number of participants with at least 50% pain relief at 4 hours <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>337</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.89, 1.21]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.2 Number of participants with at least 50% pain relief at 6 hours <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>603</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.95, 1.19]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.3 Number of participants using rescue medication over 4 to 6 hours post interventions <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>260</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.58, 1.40]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.4 Number of participants withdrawing due to adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>531</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.35, 2.19]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.5 Number of participants withdrawing due to lack of efficacy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.6 Number of participants withdrawing for any cause <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>437</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.41, 1.26]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.7 Number of participants reporting any adverse event <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>516</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.11 [1.00, 1.23]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.8 Number of participants reporting a serious adverse event <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.9 Number of participants experiencing thrombophlebitis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.10 Number of participants reporting nausea <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>516</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.16 [0.86, 1.56]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.11 Number of participants experiencing vomiting <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>516</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.36 [0.81, 2.28]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.12 Number of participants reporting pruritus <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>415</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.40, 1.84]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.13 Number of participants experiencing sedation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>347</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.51 [0.86, 7.35]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.14 Number of participants with at least 50% pain relief at 4 hours: subgroup analysis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>337</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.89, 1.21]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.14.1 Abdominal/pelvic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>162</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.84, 1.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.14.2 Dental</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>98</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.19 [0.88, 1.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.14.3 Orthopedic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>77</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.58, 1.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.15 Number of participants with at least 50% pain relief at 6 hours: subgroup analysis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>603</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.95, 1.19]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.15.1 Abdominal/pelvic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>330</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.91, 1.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.15.2 Dental</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>196</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.15 [0.93, 1.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.15.3 Orthopedic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>77</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.56, 1.38]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Ketorolac versus other NSAID</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/references#CD013263-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013263-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Ketorolac versus opioid</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.1 Number of participants with at least 50% pain relief at 4 hours <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>243</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.75 [1.34, 2.28]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.2 Number of participants with at least 50% pain relief at 6 hours <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>243</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.90 [1.40, 2.56]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.3 Number of participants using rescue medication over 4 to 6 hours post interventions <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>163</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.25, 2.04]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.4 Number of participants withdrawing due to adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>167</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.47 [0.47, 4.64]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.5 Number of participants withdrawing due to lack of efficacy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.6 Number of participants withdrawing for any cause <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>166</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.20 [0.02, 1.65]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.7 Number of participants reporting any adverse event <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>249</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.67, 1.18]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.8 Number of participants reporting a serious adverse event <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.9 Number of participants reporting nausea <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>369</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.55, 1.17]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.10 Number of participants experiencing vomiting <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>369</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.48, 1.44]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.11 Number of participants reporting pruritus <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>249</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.30, 1.74]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.12 Number of participants experiencing sedation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>249</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.69 [0.31, 1.55]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Ketorolac versus opioid</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013263.pub2/references#CD013263-tbl-0005">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD013263.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD013263-note-0013">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD013263-note-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD013263-note-0012">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD013263-note-0010">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ko#CD013263-note-0007">한국어</a> </li> <li class="section-language"> <a class="" href="ms#CD013263-note-0009">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="th#CD013263-note-0008">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD013263-note-0006">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013263\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013263\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013263\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013263\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013263\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013263\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013263\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013263\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013263\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013263\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013263\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013263\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013263\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013263\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013263\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013263\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013263\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013263\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=8ranHhTh&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013263.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD013263.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD013263.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD013263.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013263.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740720146192"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD013263.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740720146197"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD013263.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918dfa0789e09377',t:'MTc0MDcyMDE0Ni4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 